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Senescence is defined as a permanent and irreversible cell cycle arrest. The 
initiating stimuli can be diverse, such as oncogene expression, reactive oxygen 
species and critically short telomeres. Irrespective of the nature of the trigger, 
p53-dependent DNA damage response (DDR) is initiated, leading to cell cycle 
arrest in G1. A prolonged DDR activation can further reinforce the arrest 
through the activation of the cyclin-dependent kinase inhibitor p16. The 
inability of the semi-conservative DNA replication machinery to completely 
copy the ends of linear eukaryotic chromosomes results in a gradual telomere 
shortening that is counteracted by telomerase, a ribonucleoprotein which can 
add telomeric repeats to the 3’ end of a chromosome. However, during human 
embryonic development, telomerase is downregulated through decreased 
expression of the telomerase catalytic subunit hTERT.  Consequently, human 
somatic cells undergo progressive telomere shortening that will ultimately lead 
to eroded telomeres being recognised by the DDR and induction of replicative 
senescence. Reconstitution of hTERT in several human somatic cells has 
been shown to prevent replicative senescence. During cancer development, 
cell immortalisation requires escaping senescence and telomerase 
reactivation is the prevalent route to this end. However, while it is clear that the 
presence of telomerase can counteract entry into the senescence, it is not 
known if, once senescence has been established, telomerase could drive cells 
out of the arrest. In this work, I address the reversibility of senescence 
triggered by critically short telomeres by: 1) reactivating telomerase expression 
in senescent cells; 2) reactivating expression and tethering telomerase to 
telomeres during senescence; and 3) reactivating telomerase expression 
together with transient DDR inhibition. By taking advantage of telomerase 
fused to a conditional degron, I have tested if telomerase stabilisation in 
senescent MRC5 human fibroblasts could bypass the arrest. My results show 
that the presence of telomerase was not sufficient to overcome senescence. 
Since it has been shown that yeast telomerase can only gain access to 
telomeres during DNA replication, one possibility is that telomerase reactivated 
in senescent cells was unable to localise to telomeres. To address this 
 vi 
possibility, I have expressed an hPOT1-hTERT fusion to tether telomerase to 
telomeres irrespective of the cell cycle stage. In a parallel approach, I have set 
up a system to allow senescent cells to enter the S-phase by transient 
inhibition of DDR, by IPTG-inducible knock-down of p53 and p16. This study 
contributes to improving our understanding of molecular mechanisms of 






Most human cells can divide for certain amount of times before indefinitely 
stopped dividing in a state called cellular senescence or the aging of cells. 
Senescence in human cells is known to be linked to the shortening of the 
telomeres, the physical ends of chromosomes. Throughout its lifetime, cells 
can accumulate damage which could result in the cells becoming cancer cells, 
if damage is not repaired. Senescence can prevent this by limiting the cell’s 
ability to divide when accumulation of damage is intolerable. On the other 
hand, the build-up of senescent cells is also known to be harmful, as it plays a 
role in the aging of tissues and the body of an organism. Furthermore, studies 
have shown that cancer cells may arise from cells that have escaped 
senescence. In this study, I am exploring how cells can escape senescence 
using human fibroblasts as a model, by introducing an enzyme that can 
elongate telomeres called telomerase to the cells. Furthermore, I have also 
attempted in modulating the senescence signalling in the cells, to study 
whether this can help cells escape senescence. The results of this study may 
have implications in our understanding of how senescent cells become cancer 
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Chapter 1 Introduction 
1.1 Organisation and maintenance of linear 
chromosomal ends 
Mammalian genomes are organised in linear chromosomes where each 
chromosome has two DNA ends, which are prone to end-to-end fusions and 
can potentially be a subject of DNA resection by endonucleases. As a 
countermeasure to avoid these detrimental processes, which could lead to 
genomic instability, linear chromosome ends are protected by DNA-protein 
complexes capping the DNA ends and called telomeres. Telomeres consist of 
repetitive non-coding DNA, which is bound by a set of proteins (shelterin) with 
the DNA binding specificity matching the telomeric repeat sequence. During 
normal cellular proliferation, the inability of the semi-conservative DNA 
replication machinery to copy linear DNA ends completely, colloquially termed 
the end-replication problem, could lead to a gradual shortening of telomeric 
DNA (Watson, 1972; Blackburn and Gall, 1978; Huffman et al., 2000; de 
Lange, 2002). When telomeres becomes critically short, they can no longer 
perform the capping function efficiently and the cell activates a DNA damage 
response (DDR) signalling at the telomeres which could initiate the 
senescence programme, if the DDR activation persists (de Lange, 2002; 
d’Adda di Fagagna et al., 2003). To overcome the end-replication problem, 
proliferating cells such as stem cells (embryonic and adult stem cells), male 
germ cells and activated lymphocytes, express telomerase, a 
ribonucleoprotein (RNP) which can elongate telomeres by adding telomeric 
repeats to the 3’ end of the telomeres (Greider and Blackburn, 1985; Wright et 
al., 1996; Weinrich et al., 1997). Telomerase mainly consists of an RNA 
component (hTR or hTERC in humans) and a protein with a reverse 
transcriptase enzymatic activity (hTERT in humans). In human somatic cells, 
telomerase is either not expressed or expressed at a non-detectable level 
(Wright et al., 1996). On the other hand, approximately 80% of all cancers are 
known to express telomerase in order to allow infinite cell proliferation, by 
abrogating replicative senescence (Kim et al., 1994). While hTR is known to 
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be expressed in somatic tissues (Feng et al., 1995; Avilion et al., 1996), hTERT 
is generally repressed in normal differentiated cells (Kim et al., 1994). Ectopic 
expression of hTERT is sufficient to activate telomerase and immortalise 
several types of somatic cells (Bodnar et al., 1998; Counter et al., 1998; Vaziri 
and Benchimol, 1998). Mutations in telomerase, telomerase accessory 
proteins, shelterin components or proteins associated with telomere 
replication/elongation lead to abnormally short telomeres resulting in limited 
proliferation potential and have been associated with various human diseases, 
such as dyskeratosis congenita, aplastic anaemia, pulmonary fibrosis and 
pancytopenia (Heiss et al., 1998; Armanios et al., 2007; Tsangaris et al., 2008). 
 
1.1.1 Structure and function of human telomeres 
The natural ends of linear chromosomes were first defined as telomeres, from 
the greek words telos (end) and meros (part), in the 1930s by Herman Muller 
and later by Barbara McClintock, who studied these chromosomal ends in flies 
and corn respectively (Muller, 1938; McClintock, 1941). Human telomeres 
comprise of three main components: single stranded telomeric repeats, double 
stranded telomeric repeats and the shelterin protein complex. In humans, 
telomeric DNA is made of the tandem repetitive sequence 5’-TTAGGG(n), with 
a length of approximately 5 – 15 kb (Samassekou et al., 2010). The single 
stranded G-rich component of the telomere extends out of the 3’-end of the 
telomeric dsDNA to a size of approximately 50 - 200 bp (Makarov, Hirose and 
Langmore, 1997; McElligott and Wellinger, 1997; Wright et al., 1997). This 
single strand overhang of the telomere invades back into the double-stranded 
DNA portion to form a telomere loop (T-loop) (Figure 1.1 A) (Griffith et al., 
1999; Cesare et al., 2003; Doksani et al., 2013). The shelterin complex 
consists of the six main protein components: TRF1, TRF2, TIN2, POT1, RAP1 
and TPP1 (Figure 1.1 B). Binding of the shelterin complex to telomeric DNA is 
mediated by three proteins: TRF1, TRF2 and POT1. TRF1 and TRF2 bind to 
the dsDNA telomeric repeats via their Myb/SANT domain, which recognises 
the sequence 5’-TAGGGTT (Broccoli et al., 1997; Bianchi et al., 1997; Court 
et al., 2005). TRF1 and TRF2 form homodimers via their TRFH domains. The 
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dimer formation is known to be required for their telomeric DNA binding activity 
(Broccoli et al., 1997; Li, Oestreich and de Lange, 2000; Fairall et al., 2001). 
POT1 binds ssDNA telomeric repeats. This binding is mediated by its two OB-
fold domains (OB1 & OB2) located at the N-terminus. POT1 recognises the 
sequence 5’-TTAGGGTTAG (Lei, Podell and Cech, 2004; Loayza et al., 2004). 
Unlike the three previously mentioned shelterin components, TIN2, TPP1 and 
RAP1 do not bind telomeric DNA directly. TIN2 is known to bind both TRF2 
and TRF1, forming a bridge which connects both proteins. TIN2 binds TRF2 
via its TRFH domain (Ye et al., 2004b). Furthermore, TIN2 also binds TRF1 
via a C-terminal TRF1-specific binding domain (Ye et al., 2004b). TPP1 binds 
TIN2 through its TIN2-specific binding domain (Liu et al., 2004). Furthermore, 
TPP1 also binds POT1 through its POT1 binding domain, located downstream 
of its OB domain (Ye et al., 2004a). Together, this allowed tethering of POT1 
to TIN2 via TPP1. Although RAP1 has a Myb domain similar to TRF1 and 
TRF2, it is understood that it is not capable of DNA binding but can play a role 
in protein-protein interactions and has been shown to be important for the 
binding of RAP1 to TRF2 (Hanaoka et al., 2001). However, another study 
suggests that human RAP1 can bind to telomeric DNA and that the binding of 
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Figure 1.1 Mammalian telomere cap structure.  
(A) The formation of the T-loop requires the invasion of the single-stranded 
DNA 3’-end of the telomere into its double-stranded DNA portion, which results 
in a displacement loop (D-loop). (B) Shelterin complex on telomeres. 
 
 
The T-loop structure and the individual components of the shelterin complex 
are proposed to be important for the capping and protective function of the 
telomeres (Griffith et al., 1999; M.Stansel, Lange and Griffith, 2001; Karlseder, 
Smogorzewska and Lange, 2002; Van Ly et al., 2018). TRF2 and RAP1 have 
been shown to prevent both classical and alternative non-homologous end 
joining (NHEJ) repair activity on telomeres (Bae and Baumann, 2007; Doksani 
et al., 2013; Sfeir and De Lange, 2012). Furthermore, studies in mouse cells 
implicated POT1 together with RAP1 in preventing homology-directed repair 
(HDR) at telomeres (Palm et al., 2009; Sfeir et al., 2010). Together with the T-
loop structure, these shelterin components prevent telomeric ends being 
(A) 
(B) 
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recognised as DSBs and processed by the DNA repair machineries resulting 
in telomeric end-to-end fusions.  Interestingly, recent data in mice suggest that 
DSB repair can still operate at telomeres during the S-phase in a PARP1- and 
a Lig3-dependent manner (Doksani and de Lange, 2016). Although mouse and 
human telomeres have a high degree of structural similarity, they have very 
different responses to DNA damage signalling activated at telomeres, 
necessitating very careful interpretation of the data in the mouse model when 
superimposing it to the human telomere biology (Smogorzewska and de 
Lange, 2002). 
 
1.1.2 DNA replication at telomeres 
Yeast telomeres have been shown to replicate late during the S-phase 
(McCarroll and Fangman, 1988). Heterochromatic regions are generally late-
replicating, and this was thought to be the reason for why telomeres replicate 
late. However, in human cells, replication of telomeres occurs sporadically 
throughout the cell cycle (Wright et al., 1999). A study using single molecule 
analysis of replicated DNA (SMARD) showed that the origins of replication 
exist at the sub-telomeric regions and that DNA replication could start from the 
sub-telomeric origins towards telomeres or originate from inside the telomeres 
themselves (Drosopoulos, Kosiyatrakul and Schildkraut, 2015).  
 
Owing to its high GC content, the formation of G-quadruplex structures is 
rampant at telomeres and could trigger stalling of the DNA replication 
machinery. Therefore, the DNA replication machinery requires assistance from 
the helicases which can unwind G-quadruplex structures, such as RTEL1 and 
BLM, which are recruited to telomeres by PCNA as part of the DNA replication 
machinery and by TRF1 respectively, in order to increase the accessibility of 
the telomeric DNA during DNA replication (Vannier et al., 2012, 2013; 
Zimmermann et al., 2014; Drosopoulos, Kosiyatrakul and Schildkraut, 2015). 
As previously mentioned, telomeres shorten with each replication cycle. The 
rate of telomere shortening in human cells not expressing telomerase is 
approximately 50 – 200 bp per population doubling (Harley, Futcher and 
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Greider, 1990). Thus, in actively proliferating human cells, telomerase 
expression is required to prevent the shortening of the telomeres.  
 
1.1.3 Telomerase structure and biogenesis 
As briefly mentioned above, to counteract the telomere shortening with each 
DNA replication cycle, several types of human cells express telomerase. The 
core components of this RNP complex in human cells are the catalytic subunit 
hTERT and the RNA component hTR or hTERC, which have been shown to 
be sufficient for telomerase activity in vitro (Weinrich et al., 1997; Masutomi et 
al., 2000). The hTERT protein belongs to the family of reverse transcriptases 
and contains four main protein domains: a reverse transcriptase (RT) domain, 
a telomerase essential N-terminal (TEN) domain, telomerase RNA binding 
(TRBD) domain and a C-terminal extension (CTE) domain (Figure 1.2) 
(Nguyen et al., 2018). The RT domain of hTERT is known to be conserved 
across different species (Nakamura et al., 1997). Binding of TERT to TR is 
known to be mediated by the TRBD domain, which binds to the CR4/CR5 
domain of TR (Lai, Mitchell and Collins, 2001). Other studies showed that the 
TRBD, RT and CTE domains form a ring-shaped structure (TERT ring) which 
is central to the catalytic activity of TERT (Gillis, Schuller and Skordalakes, 
2008; Mitchell et al., 2010; Robart and Collins, 2011). Previously, it has been 
shown that a small region in the TEN domain called the N-terminal Dissociates 
Activity of Telomerase (N-DAT) domain/region was implicated in trafficking of 
telomerase to telomeres (Armbruster et al., 2001, 2004). More recent studies 
have shown that N-DAT is part of a region in telomerase necessary for its 
binding to the TPP1-POT1 heterodimer, thereby providing the recruitment of 
telomerase to telomeres (Schmidt, Dalby and Cech, 2014; Sexton et al., 2014). 
hTR is a 451 base long non-polyadenylated RNA, which is transcribed by the 
RNA polymerase II from the telomerase RNA gene called TERC located at 
chromosome 3q26.2, and belongs to a family of H/ACA RNA (Figure 1.3) 
(Feng et al., 1995; Mitchell, Cheng and Collins, 1999). The 3’-terminus of hTR 
contains an H/ACA motif which is prevalent in small nucleolar RNAs (sno-
RNAs) and small Cajal body RNAs (Sca-RNAs) (Fu and Collins, 2003; Jády, 
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Bertrand and Kiss, 2004). During the hTR maturation process, the H/ACA motif 
is bound by the H/ACA pre-RNP complex, which consists of Dyskerin, NOP10, 
NHP2 and NAF1. This H/ACA motif is required for in-vivo accumulation and 
telomerase biogenesis (Mitchell, Cheng and Collins, 1999). The maturation of 
hTR occurs at nucleolus and is characterised by the substitution of NAF1 with 
GAR1 (Darzacq et al., 2006). hTERT is then bound to the pre-RNP complex 
to form a mature telomerase holoenzyme. The binding of hTERT to hTR is 
thought to be required for telomerase localisation to Cajal bodies (Tomlinson 
et al., 2008). A Cryo-EM structure of the human telomerase holoenzyme has 
been reported recently. It revealed a bi-lobal structure showing hTERT bound 
to one lobe and the telomerase accessory proteins at the other lobe (Nguyen 






Figure 1.2 Domains of the hTERT protein 
TEN domain at the N-terminus of hTERT is required for localisation of 
telomerase to telomeres. The TERT ring which encompasses the TRBD, RT 












TEN TRBD RT CTE 
TERT ring 
Investigating the reversibility of senescence 
  Introduction 











Figure 1.3 Domains of the hTR RNA 
hTR can be sub-divided into three separate domains. The 
pseudoknot/template is the region containing the telomeric template 3’-
CAAUCCCAAUC and is bound by hTERT, with its catalytic domain specifically 
located at the template. The CR4/CR5 also partially binds to the TRBD and 
CTE domains of hTERT. The H/ACA domain is bound by the telomerase 
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Figure 1.4 Structure of the human telomerase holoenzyme 
The mature telomerase holoenzyme forms a bi-lobal structure. One lobe is 
called the catalytic core and consists of hTERT and the hTR telomeric 
substrate (shown in green). The other lobe is called the H/ACA lobe (blue and 
yellow), which consists of two complexes of H/ACA proteins: Dyskerin, 
NOP10, NHP2, GAR1 and 1 single TCAB1 binding to the CAB box. (Adapted 
from Nguyen et al., 2018)  
 
 
1.1.4 Transcription regulation of hTERT 
The human TERT gene is located at chromosome 5 (Genomic coordinate: 
5p15.33), contains 16 exons and 15 introns which spans 40 kb in length (Cong, 
Wen and Bacchetti, 1999; Takakura et al., 1999; Wick, Zubov and Hagen, 
1999; Bryce et al., 2000; Leem et al., 2002). The transcription regulatory region 
of TERT contains a single promoter which extends from 330 bp upstream of 
the translation start site (ATG) to 228 bp downstream of it and is characterised 
by high GC content, absence of TATA and CAAT boxes and presence of 
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multiple transcription response elements such as E-box and GC-box (Cong, 
Wen and Bacchetti, 1999; Horikawa et al., 1999; Takakura et al., 1999; Wick, 
Zubov and Hagen, 1999). Removal of E-boxes and E2F consensus motif in 
did not significantly affect TERT transcription suggesting that transcription 
factors that bind to these transcriptional response elements are either not 
required for TERT transcription in these cells or suggest a possible functional 
redundancy with other transcription factors (Cheng et al., 2017). Transcription 
factors can activate or repress transcription of a gene. c-Myc, HIF-1, NF-κB 
and β-catenin are a few of the transcription factors found to bind to the TERT 
promoter and activate transcription (Wu et al., 1999; Yatabe et al., 2004; 
Gizard et al., 2011; Hoffmeyer et al., 2012). On the other hand,  WT1, Sp3 and 
CTCF were found to be repressors of TERT transcription (Oh et al., 1999; 
Wooten and Ogretmen, 2005; Renaud et al., 2007). TERT promoter mutations 
at position -146 (C228T) and -124 (C250T) have been reported in various 
cancers and were shown to form de novo binding sites for activator 
transcription factors ETS and GABPA respectively (Horn et al., 2013; Huang 
et al., 2013; Vinagre et al., 2013; Li et al., 2015; Stern et al., 2015). These 
mutations are implicated in de-repression of TERT in the majority of cancers 
which express telomerase (Huang et al., 2015). However, there are a subset 
of cancers such as Prostate cancer and Non-Hodgkin Lymphoma which 
express telomerase in the absence of these promoter mutations (Stoehr et al., 
2015; Lam et al., 2016), indicating an alternative TERT regulatory mechanism, 
proposed to be epigenetic in nature. The TERT promoter is located in a CpG 
island (-1800 to +2200 of ATG), which imply that DNA methylation may play a 
role in epigenetic regulation of TERT transcription (Cong, Wen and Bacchetti, 
1999). Methylation at CpG island promoters is generally thought to confer gene 
silencing (Aimee and Bird, 2011). Interestingly, a 433 bp region upstream of 
the transcription start site of the TERT promoter (–140 to –572, relative to the 
transcription start site) was discovered to be heavily methylated in cancer cells 
that express telomerase (Guilleret et al., 2002; Zinn et al., 2007; Castelo-
Branco et al., 2013; Lee et al., 2019). This region is called TERT 
Hypermethylated Oncological Region (THOR) and molecular manipulations to 
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demethylate CpGs in this region significantly downregulate TERT expression 
(Lee et al., 2019).  
 
1.1.5 Telomere length maintenance by telomerase 
The catalytic core hTERT and the RNA component hTR are sufficient for 
telomerase activity in vitro (Weinrich et al., 1997; Masutomi et al., 2000). 
However, telomere elongation in vivo (cells) is a more complex process 
involving several telomerase accessory proteins which are involved in 
telomerase maturation and recruitment to telomeres. It is known that the action 
of telomerase at telomeres is restricted to the S-phase (Zhu et al., 1996; Jády 
et al., 2006; Tomlinson et al., 2006). This was thought to be due to the coupling 
of telomerase action to the conventional DNA replication. A study in yeast 
showed that telomeres are elongated by telomerase at the end of the S-phase 
(Marcand et al., 2000) and that replication fork passage through a telomere is 
required for this telomere being subjected to telomerase-dependent 
lengthening (Dionne and Wellinger, 1998). In human cancer cells and 
fibroblasts, telomere extension by telomerase occurs throughout the S-phase 
(Zhao et al., 2009; Chow et al., 2012). This is in agreement with the idea that 
telomerase-dependent telomere lengthening is coupled with the DNA 
replication, as telomeres are replicated throughout the S-phase in human cells 
(Arnoult et al., 2010). Interestingly, the C-strand fill-in process and the 
subsequent processing of the telomere occur late in the S-phase, subsequent 
to DNA replication (Zhao et al., 2009; Chow et al., 2012). It is known that the 
recruitment of telomerase to telomeres requires the action of the TPP1-POT1 
heterodimer (Xin et al., 2007; Abreu et al., 2010). The Tel patch of the OB-fold 
domain of TPP1 is required for the binding to the TEN domain of hTERT 
(Nandakumar et al., 2012; Zhong et al., 2012). Furthermore, it has been 
reported that TPP1 undergoes an S-phase specific phosphorylation, which 
may indicate a potential telomerase restriction mechanism limiting it to the S-
phase (Zhang et al., 2013). The action of telomerase at telomeres have been 
suggested to require its localisation to Cajal bodies (Jády et al., 2006). It is 
known that this requires TCAB1 and that TCAB1 is known to bind to the CAB 
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box of hTR at the G1/S boundary (Vogan and Collins, 2015). Therefore, both 
of these mechanisms might be important for the S-phase restrictions of the 
telomerase action at telomeres in human cells.   
 
1.1.6 Role of TERRA in telomere length regulation 
Telomeres contain repetitive sequences which are abundant in the 
heterochromatic histone mark H3K9me3, HP1 proteins and DNA methylation 
and therefore believed to be transcriptionally inert (Gonzalo et al., 2006; 
Benetti, García-Cao and Blasco, 2007). This is supported by studies where 
reporter genes inserted at sub-telomeric regions resulted in these genes to be 
repressed or silenced (Baur et al., 2001; Koering et al., 2002). However, later 
studies have shown that transcription occurs at telomeres which resulted in 
the production of long non-coding RNAs called Telomeric Repeat containing 
RNA (TERRA) (Azzalin et al., 2007; Schoeftner and Blasco, 2008). TERRA 
contains UUAGGG repeats at its 3’-end and is transcribed mainly by RNA Pol 
II, although it may also be transcribed by RNA Pol I/RNA Pol III in mammals 
(Luke et al., 2008; Schoeftner and Blasco, 2008; Déjardin and Kingston, 2009). 
TERRA is transcribed from two cryptic transcription start site (TSS) located 
around 100 bp and 1 kb into the subtelomeric region (Nergadze et al., 2009; 
Porro et al., 2014). The presence of two different TSS for TERRA may partially 
account for its variable length, which range in length from 100 – 9000 bp 
(Azzalin et al., 2007). Furthermore, location of TERRA transcription 
termination sites at telomeres is not known and may also explain this variable 
length feature. Abundance of TERRA at telomeres have been shown to be 
regulated by the Nonsense mediated decay (NMD) machinery (Azzalin et al., 
2007). TERRA localisation studies showed that TERRA forms foci at telomeres 
which suggests that TERRA may play a role in telomere maintenance 
(Cusanelli, Romero and Chartrand, 2013).  
 
As previously mentioned, telomeres shorten through each replication cycle 
and that telomere shortening can be counteracted by the telomere elongating 
enzyme telomerase. TERRA have been implicated in the negative regulation 
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of telomerase via direct complementary binding to telomerase RNA and may 
also inhibit telomerase catalytic subunit directly, as shown by experiments 
using TERRA-mimetic oligonucleotides and co-immunoprecipitation 
respectively (Schoeftner and Blasco, 2008; Redon, Reichenbach and Lingner, 
2010). Contrastingly, TERRA does not seem to inhibit telomere elongation 
when overexpressed in a telomerase positive cancer cell line (Farnung et al., 
2012). In the same study, knockout of DNMT1 and DNMT3B DNA 
methyltransferase was able to increase TERRA production but unable to inhibit 
telomerase activity and prevent telomere elongation (Farnung et al., 2012). It 
is known that methylation status in the subtelomeric region can influence 
TERRA transcription (Deng et al., 2009; Nergadze et al., 2009; Ng et al., 2009). 
Furthermore, telomerase reactivated in iPS cells derived from fibroblasts of 
patients with Immunodeficiency, Centromeric region stability, and Facial 
anomalies (ICF) syndrome which overexpress TERRA due to a loss of function 
DNMT3B mutation, was not inhibited and exhibit telomere elongation (Sagie 
et al., 2014). Therefore, these data suggest that TERRA is insufficient to act 
as an inhibitor of telomerase activity. In spite of this, it is still possible that 
TERRA may act on telomerase at specific time in the cell cycle. Expression of 
TERRA is known to be cell cycle dependent and is higher in G1 and G2-phase 
compared to S-phase of the cell cycle (Porro et al., 2010). This coincides with 
telomerase activity at telomeres which is known to be restricted to S-phase. 
Together with its direct association with telomerase, TERRA may play a role 
as a negative regulator of telomerase at specific times in the cell cycle and 
needs to be investigated further. 
 
TERRA have also been shown to directly bind with telomeric repeats and form 
RNA:DNA hybrids or R-loops at telomeres (Luke et al., 2008; Xu, Kimura and 
Komiyama, 2008). Formation of RNA:DNA hybrid structure at telomeres may 
prevent telomerase access to telomeres. A study in the budding yeast 
Saccharomyces cerevisiae showed that TERRA can be degraded by the 
Rat1p 5’ – 3’ exonuclease which in turn promotes elongation of telomeres by 
telomerase (Luke et al., 2008). In the same study, a loss of function mutation 
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on Rat1p resulted in accumulation of TERRA at telomeres, formation of 
RNA:DNA hybrids and telomere shortening. This indicates that telomeric 
RNA:DNA hybrids may inhibit telomerase access to telomeres. Moreover, 
telomerase negative S. cerevisiae with short telomeres showed accumulation 
of R-loops at telomeres which promotes HR-based telomere elongation (Fallet 
et al., 2014; Yu, Kao and Lin, 2014). Whether this feature exist in human cells 
is not known, as homologous recombination is generally suppressed at 
telomeres of normal human cells (Wang, Smogorzewska and De Lange, 
2004). Furthermore, RNA:DNA hybrid or R-loops formation can result in 
replication fork stalling, DSBs and loss of DNA sequence (Tuduri et al., 2009; 
Gan et al., 2011). As telomeres are difficult to replicate regions, presence of 
R-loops may increase replication fork stalling and collapse at telomeres which 
can lead to DSBs and telomere loss. Studies in fibroblasts derived from ICF 
patients showed increased formation of R-loops compared to fibroblasts from 
healthy control, which is attributed to increased TERRA expression as a result 
of DNMT3B deregulation and DNA hypomethylation at subtelomeric regions 
(Yehezkel et al., 2008; Sagie et al., 2017). Furthermore, this increased R-loops 
significantly correlates with short telomeres in ICF patient cells compared to 
control (Yehezkel et al., 2008). Therefore, these data suggest that formation 
of telomeric R-loops by TERRA, promote telomere shortening possibly via 
telomerase access inhibition and stochastic telomere loss due to telomeric 
replication fork collapse.    
 
Although in general, TERRA is considered to be a negative regulator of 
telomerase and telomere length in the presence of telomerase, there are 
evidence in budding yeast which suggest the opposite. In S. cerevisiae, there 
is evidence that telomere shortening promote expression of TERRA 
(Cusanelli, Romero and Chartrand, 2013).  Furthermore, TERRA was shown 
to colocalize with budding yeast telomerase RNA TLC1 and was suggested to 
act as a scaffold for the formation of telomerase recruitment clusters (T-recs), 
which recruit telomerase to the short telomere at early S-phase, from which 
TERRA was transcribed from (Gallardo et al., 2011; Cusanelli, Romero and 
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Chartrand, 2013). It is known that in budding yeast, there is a preference for 
telomerase to elongate the shortest telomere, which occur late in S-phase 
(Teixeira et al., 2004). This telomere elongation coincides with a reduction in 
TERRA molecules localisation at telomeres late in S-phase (Gallardo et al., 
2011). In conclusion, these data suggest that in budding yeast, TERRA may 
act as a positive regulator of telomerase and may also suggest that TERRA 
have species specific telomeric functions.  
 
1.1.7 Telomeropathies 
Telomeropathies are genetic disorders of premature aging which is associated 
with abnormally short telomeres and/or telomere dysfunction (Armanios and 
Blackburn, 2012; Holohan, Wright and Shay, 2014). It is primarily caused by 
mutations in protein components of telomerase, shelterin and telomere 
maintenance pathway, which causes misregulation of the telomere 
maintenance mechanism and subsequently accelerated telomere shortening 
(Holohan, Wright and Shay, 2014). One of the earliest telomeropathy 
discovered was Dyskeratosis congenita (DKC), which was characterised by 
multiple phenotypes such as nail dystrophy, skin hyperpigmentation and oral 
leukoplakia, commonly called the “diagnostic triad” for DKC (Heiss et al., 1998; 
Mitchell, Cheng and Collins, 1999). DKC was initially found to be caused by 
mutations in the DKC1 gene which encodes for Dyskerin, an H/ACA SnoRNP 
which binds to the H/ACA motif of hTR and is important for hTR processing 
and maturation (Mitchell, Cheng and Collins, 1999; Ballarino et al., 2005; 
Tseng et al., 2018; MacNeil, Lambert-Lanteigne and Autexier, 2019). Further 
studies showed that manifestations of DKC is very heterogenous, includes 
other symptoms not part of the diagnostic triad such as bone marrow failure, 
and have phenotype overlaps with other telomeropathies such as Hoyeraal-
Hreidersson syndrome (HHS), Revesz syndrome and Coats plus syndrome 
(Tsangaris et al., 2008; Dokal, 2011; Young, 2012). 
 
Mutation in TINF2 gene which codes for the shelterin component TIN2 have 
been shown to be associated with HHS and Revesz syndrome (Savage et al., 
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2008; Sasa et al., 2012; Vulliamy et al., 2012). Both HHS and Revesz 
syndrome have similar symptoms to DKC but with a more severe manifestation 
which includes prenatal growth retardation and cerebellar hypoplasia (Aalfs et 
al., 1995). Exudative retinopathy is a symptom which is observed only in 
Revesz syndrome and distinguishes it from HHS (Kajtar and Mehes, 1994). 
Symptoms of HHS have also been discovered in patients with mutations in 
RTEL1 gene, which encodes for the helicase RTEL1, important for DNA 
replication through G4 structure rich telomeres and T-loop disassembly 
(Vannier et al., 2012, 2013; LeGuen et al., 2013). Furthermore, Mutation on 
TPP1 TEL-patch, which play a role in telomerase recruitment to telomere, have 
also been associated with HHS (Nandakumar et al., 2012; Kocak et al., 2014). 
Mutations in CTC1 gene, which encodes for CTC1, a member of the CST 
complex which play a role in telomere replication and end processing, have 
also been found in Patients with Coats plus syndrome (Anderson et al., 2012; 
Polvi et al., 2012; Walne et al., 2013). Mutations in hTR or hTERT can cause 
one of the following symptoms such as idiopathic pulmonary fibrosis, aplastic 
anemia and liver cirrhosis, particularly in adult patients (Fogarty et al., 2003; 
Armanios et al., 2007; Tsakiri et al., 2007). Other telomeropathy-associated 
mutations have also been found in NOP10, NHP2, TCAB1 and POT1 (Walne 
et al., 2007; Vulliamy et al., 2008; Zhong et al., 2011; Takai et al., 2016). 
Although telomeropathies have a very wide range of symptoms, many seems 
to overlap between distinct telomere disorders. Furthermore, compromised 
telomere maintenance seems to be the common fundamental mechanism 
between distinct telomere disorders. Thus, telomeropathies are currently 
considered to be a single spectrum of disorder caused by mutations in 
telomere maintenance associated genes, which manifests as cellular 
proliferation defect in various tissues (Dokal, 2011; Armanios and Blackburn, 
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1.2 Cellular Senescence 
1.2.1 Types of cellular senescence 
In 1961, Hayflick and Moorhead described the finite proliferation capabilities of 
human fibroblasts in culture, which resulted in the onset of cellular senescence 
(Hayflick and Moorhead, 1961; Hayflick, 1965). The later studies in human 
fibroblasts have shown that cellular senescence is associated with telomere 
shortening and the telomeres have been proposed to act as a biological clock 
for cellular ageing (Harley, Futcher and Greider, 1990; Vaziri et al., 1994). 
However, other studies revealed that senescence can also be activated by 
other type of stress-inducing agents such as oncogene activation, reactive 
oxygen species (ROS) and DNA damaging agents (Reviewed in (Kuilman et 
al., 2010)). Therefore, cellular senescence was later classified into replicative 
senescence (RS) and premature senescence (PS), which were associated 
with telomere shortening and cell dysfunction/cellular ageing and cellular 
stress response, respectively. RS is activated by critically short telomeres, 
caused by the failure of the semi-conservative DNA replication machinery to 
replicate extreme ends of linear DNA, leading to DNA attrition every DNA 
replication cycle. Although the earlier discoveries suggest that short telomeres 
correlate with the onset of cellular senescence, it is not clearly understood how 
these short telomeres activate the senescence program. It has been proposed 
that short telomeres may have lost its T-loop conformation, presumably via 
loss of the 3’ overhang, which in turn activates the DDR signalling required for 
the senescence program (Li et al., 2003; Stewart et al., 2003). However, in 
another report which uses a new overhang protection assay (Chai, Shay and 
Wright, 2005) in comparison to the telomere oligonucleotide ligation assay (T-
OLA) used in previous reports (Cimino-Reale et al., 2001), showed that the 
size of the telomeric 3’-overhangs in senescent cells were similar to those in 
proliferating cells and the cells that bypassed the senescence via the 
expression of the HPV E6 and E7 oncoproteins, necessitating a re-think to this 
theory (Chai, Shay and Wright, 2005). Furthermore, the unfolding of the T-loop 
does not completely explain why the telomeres in senescent cells do not 
exhibit end-to-end fusions as observed in the cells undergoing crisis. It has 
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been suggested that the components of the shelterin complex, in particular 
TRF2, might still be bound to these short telomeres: this could be sufficient to 
prevent any end-to-end fusion (Reviewed in (Cesare and Karlseder, 2012)). 
TRF2 is known to be important for the formation of the T-loop (Doksani et al., 
2013). A depletion of TRF2 is suggested to be the trigger of T-loop unfolding 
in senescent cells and this was supported by a study using a dominant 
negative TRF2 in mouse and human fibroblasts, which sequestrate TRF2 from 
binding to telomeres and activates a DDR response with similar characteristics 
to RS (Smogorzewska and de Lange, 2002). Therefore, although short 
telomeres are associated with RS, the RS might be activated by a state of a 
telomere in which the t-loop is unfolded resulting in an open telomere 
conformation, in the presence of limited amount of TRF2, rather than by 
telomere length per se.  
 
On the other hand, as mentioned above PS could be triggered by various 
cellular stressors such as ROS and activation of oncogenes. Although RS and 
PS differ in the type of stimuli that activate them, there are some commonalities 
in terms of the maintenance of the senescence program and the biomarkers 
in both types of senescence (Figure 1.5). PS triggered by ROS have been 
implicated in accelerated shortening of telomeres (Richter and Zglinicki, 2007). 
Both RS and PS have been shown to require irreparable DNA damage which 
triggers a prolonged activation of the DDR (d’Adda di Fagagna et al., 2003; 
Fumagalli et al., 2012; Suram et al., 2012; Fumagalli et al., 2014). Interestingly, 
continuous DDR activation exists at telomeres in both types of senescence 
(Fumagalli et al., 2012; Suram et al., 2012). This suggests that DNA damage 
that occur at telomeres is maintained and required for the activation and 
maintenance of senescence (Fumagalli et al., 2014). Indeed, the presence of 
TRF2-RAP1 and POT1 at telomeres have been shown to prevent NHEJ and 
HDR respectively at telomeres, at least in human cells (Van Steensel, 
Smogorzewska and De Lange, 1998; Bae and Baumann, 2007; Denchi and 
de Lange, 2007; Palm et al., 2009; Sfeir and De Lange, 2012). Studying 
senescence reversal would possibly improve our understanding whether 
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damage at telomeres is required to maintain the senescence program or acts 
















Figure 1.5 The senescence signalling pathway 
Diagram showing pathways activating and maintaining senescence. The main 
pathways of senescence can be generally divided into the p53-p21 and p16-
pRb pathways. It is also possible that these two pathways converge at pRb 
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1.2.2 Stress-induced premature senescence and the role for 
telomeres 
As previously mentioned, acute form of senescence not associated with 
chronological age of cells or telomere shortening is called premature 
senescence, which is triggered by various types of stressors. It can be 
activated in cells at early population doublings in vitro, hence the word 
premature (Brack et al., 2000). Premature senescence can be classified 
further into OIS which is triggered by the activation of oncogenes and stress 
induced premature senescence (SIPS), which is triggered by a diverse cell 
stress signals (Serrano et al., 1997; Brack et al., 2000). In general, depending 
on the level of cellular damage caused, cells can respond to cellular stress by 
either repairing the damage, commit to death via necrosis or apoptosis 
pathways or undergo senescence. It is now generally accepted that SIPS 
occur when cell stress is insufficient to induce cell death (sublethal), but 
sufficient to cause irreparable damage to the cell (Dumont et al., 2000; 
Toussaint, Medrano and Von Zglinicki, 2000). Fibroblasts undergoing SIPS 
exhibit similar features to RS cells such as a large and flattened morphology, 
increased SA-β-Galactosidase activity and upregulation of p16 (Toussaint, 
Medrano and Von Zglinicki, 2000).   There is a great number of oxidative and 
DNA damaging cellular stressors that have been discovered in in vitro cell 
culture studies which can trigger SIPS such as hyperoxia, UVB, H2O2, tert-
Butyl hydroperoxide (t-BHP), ionising radiation and antineoplastic agents 
(Bleomycin, Doxorubicin and Mitomycin C)(Rodemann, 1989; von Zglinicki et 
al., 1995; Von Zglinicki, Pilger and Sitte, 2000; Dumont et al., 2000; Chainiaux 
et al., 2002; Liu and Hornsby, 2007; Rodier et al., 2009; Bielak-Zmijewska et 
al., 2014). However, there are discrepancies surrounding the role of telomeres 
in SIPS. 
 
Although SIPS, unlike RS, is thought to be independent of telomere length, 
studies on human fibroblasts undergoing hyperoxia (40% oxygen partial 
pressure) showed accelerated telomere shortening, due to oxidative DNA 
damage and formation of single strand breaks at telomeres (von Zglinicki et 
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al., 1995; Von Zglinicki, Pilger and Sitte, 2000). On the other hand, other 
oxidative damage inducer such as H2O2 showed contradicting result, where it 
showed significant accelerated telomere shortening in   MRC-5 (Von Zglinicki, 
Pilger and Sitte, 2000) and 2BS (Duan et al., 2005) cells but not in IMR90 cells 
(Chen et al., 2001). Intriguingly, although accelerated telomere shortening was 
observed in WI-38 (von Zglinicki et al., 1995) and MRC-5 (Von Zglinicki, Pilger 
and Sitte, 2000) cells cultured under hyperoxic conditions, it was not the case 
with BJ (Lorenz et al., 2001) cells cultured under the similar conditions. 
Therefore, it is possible that there are cell specific differences which affect how 
these different SIPS-inducers stimulate telomere shortening. It is proposed 
that this may be due to the distinct antioxidative defence capacity of each cell 
type (Von Zglinicki, 2002). Furthermore, the dose (high vs low) and protocol 
(acute vs chronic) used to induce SIPS may also play a role in accelerated 
telomere shortening, as it may account for the difference in stress levels and 
possibly activate SIPS in a dose-dependent manner (Duan et al., 2005). The 
H2O2-induced SIPS study in IMR90 cells (Chen et al., 2001) utilised a more 
acute and higher dose protocol compared to a similar study in 2BS cells (Duan 
et al., 2005), which instead used a more chronic and lower dose protocol. An 
acute and high dose protocol may result in a faster growth arrest, which may 
prevent observation requiring cellular proliferation such as telomere 
shortening. Hence, aside from cell type specific antioxidative defence capacity, 
this difference between low and high stress induction may discriminate 
between telomere shortening dependent and independent SIPS, respectively. 
Interestingly, a more recent study showed that induction of SIPS by X-ray 
ionising radiation resulted in irreparable DNA damage and persistent DDR 
activation at telomeres in MRC-5 fibroblasts and MEFs regardless of 
telomerase expression, leading to telomere dysfunction and senescence, 
suggesting a different role for telomeres in SIPS (Hewitt et al., 2012). This 
persistent DDR activation at telomeres was also observed in oncogenic Ras-
induced OIS in human BJ fibroblasts, irrespective of the presence of 
telomerase expression (Suram et al., 2012). It is possible that acute higher 
level of sublethal stress induced double strand breaks at telomeres rather than 
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single strand breaks as observed in chronic low-level stress. Thus, in chronic 
low stress SIPS, telomere shortening may play a role in its activation, while 
telomere dysfunction, but not telomere shortening is more important in acute 
high stress SIPS. 
 
1.2.3 Cellular and molecular markers that define senescence 
There are various morphological and molecular markers that could 
differentiate senescence from other cell cycle exit phenomena, such as 
quiescence and terminal differentiation. However, the variability of senescence 
stimuli and cellular responses in different types of cells have resulted in a lack 
of a universal cellular and molecular marker that could define senescence. 
Compared to its proliferating counterpart, a senescent cell exhibits a flattened, 
enlarged, vacuolated morphology and commonly shows multiple nuclei 
(Bowman, Meek and Daniel, 1975; Angello et al., 1987; Chen and Ames, 1994; 
Serrano et al., 1997; Denoyelle et al., 2006). Although not necessarily specific 
to senescent cells, the molecular markers for cell proliferation, such as Ki-67 
expression and thymidine analogue (BrdU/EdU) incorporation, are also 
frequently used to characterise senescent cells. A particular staining method 
that could be considered as a gold standard for detecting almost all types of 
senescent cell, regardless of the  activating stimuli, is the senescence-
associated β-galactosidase staining/assay (SA-β-gal) (Dimri et al., 1995). 
Senescent cells are known to express high levels of lysosomal β-
galactosidase, hence, specific staining of senescent cells could be achieved 
using X-gal as a chromogenic substrate for β-galactosidase at the sub-optimal 
detection pH of 6.0 (Lee et al., 2006). In contrast, the level of β-galactosidase 
enzyme activity in non-senescent cells is undetectable at this pH. Upregulation 
of the proteins involved in the molecular pathways associated with the 
activation and maintenance of the cell cycle arrest in senescence, such as p53, 
p16 and p21, have also been detected in multiple cell types during senescence 
(Serrano et al., 1997; Stein et al., 1999; Beauséjour et al., 2003). In addition, 
DDR foci formation, particularly at telomeres, which are associated with 
senescence have been previously detected utilising antibodies against ɣh2ax 
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or 53BP1 (d’Adda di Fagagna et al., 2003; Sedelnikova et al., 2004; Fumagalli 
et al., 2014). The downregulation of Lamin B1 have been implicated in IR-
induced and oncogenic RAS-induced senescence (Freund et al., 2012). 
Telomere length is a marker ubiquitously employed in many replicative 
senescence studies. However, caution is required as sub-optimal culture 
conditions have been shown to induce senescence irrespective of telomere 
length (Ramirez et al., 2001). Formation of densely heterochromatic regions 
which could be detected via staining with a dsDNA-specific stain such as DAPI 
and an antibody to H3K9me3 and called senescence-associated 
heterochromatic foci (SAHF) have also been observed in senescent cells 
(Narita et al., 2003; Kosar et al., 2011). SAHF formation is thought to mediate 
gene silencing of proliferation genes via upregulation of H3K9me3 and HP1 
(Narita et al., 2003). However, the use of SAHF is very limited as only specific 
senescence stimuli and type of cells, exhibit this feature (Kosar et al., 2011). 
Most importantly, senescent cells are known to secrete various cytokines, 
chemokines, growth factors and other factors highly associated with 
inflammation and cancer which is a phenomenon called Senescence-
associated Secretory Phenotype (SASP) (Coppé et al., 2008).  
 
1.2.4 Nuclear changes in senescence 
During interphase of the cell cycle, chromatins are observed as loose bundles 
with a non-random and distinct separation between chromosomes called 
chromosomal territories (Cremer et al., 1982). High throughput whole genome 
conformation capture (Hi-C) studies have confirmed the idea of chromosome 
territories, in which intra-chromatin interactions tend to be stronger than inter-
chromatin interactions, which the latter is also confirmed to be non-random 
(van Berkum et al., 2010; Sarnataro et al., 2017). It is thought that locality of a 
chromosome or chromosome neighbourhood may affect expression genes in 
that particular chromosome (Zhao et al., 2009). Furthermore, in normal cells, 
interphase chromatin are organised into specific compartments, in such a way 
that transcriptionally repressed heterochromatins are mostly associated with 
the nuclear lamina and nucleolus which are called Lamin-associated domains 
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(LADs) and Nucleolus-associated domains (NADs) respectively, while 
euchromatins fill the 3D space between these domains (Guelen et al., 2008; 
Németh et al., 2010). LADs have been shown to be a gene-poor region and 
largely transcriptionally silent (Guelen et al., 2008). Artificial tethering of 
transcriptionally active genes to the nuclear lamina have been shown to result 
in transcriptional downregulation, suggesting that the nuclear lamina is a 
transcriptionally repressive compartment (Finlan et al., 2008; Reddy et al., 
2008). Together, it is clear that nuclear architecture can affect gene expression 
in a more global manner. Multiple studies have shown that senescent cells 
undergo various alterations to its nuclear architecture and morphology in the 
form of nuclear lamina depletion and deformation, senescence-associated 
heterochromatin foci (SAHF), and senescence associated distension of 
satellites (SADS), and these alterations may contribute to regulation of gene 
expression in senescent cells (Narita et al., 2003; Raz et al., 2008; Shimi et 
al., 2008; Swanson et al., 2013). 
 
The nuclear lamina is located at the surface of the inner nuclear membrane 
and consists of A-type lamins (lamin A and C), B-type lamins (lamin B1 and 
B2) and lamin associated proteins (Gruenbaum and Foisner, 2015). The 
nuclear lamina provides mechanical support for the nuclear envelope and is 
known to be involved in chromatin organisation, DNA replication and cell 
division (Ottaviano and Gerace, 1985; Lammerding et al., 2004; Guelen et al., 
2008; Shimi et al., 2008; Shumaker et al., 2008). As previously mentioned, the 
nuclear lamina interacts with heterochromatic regions of chromosomes called 
LADs. Downregulation of the components of the nuclear lamina, LMNA and 
Lamin B1 have been observed in cells undergoing RS or OIS (Shimi et al., 
2011; Freund et al., 2012; Dou et al., 2015; Lenain et al., 2015). Furthermore, 
Ras oncogene activation was shown to trigger autophagy-mediated 
degradation of Lamin B1 via its binding with LC3 to induce nuclear export to 
cytoplasm for lysosomal protein degradation (Dou et al., 2015; Lenain et al., 
2015). Induction of gene silencing to LMNB1 resulted in premature 
senescence and formation of Lamin A/C blebs characteristic of senescent and 
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progeroid cells (Goldman et al., 2004; Shimi et al., 2008, 2011; Shah et al., 
2013; Adams et al., 2013). Furthermore, p53-induced Lamin A/C stabilisation 
have recently been shown to be the link between p53 and p16 induction during 
activation of cellular senescence through Lamin A/C mediated degradation of 
BMI-1 and MEL-18 (Yoon et al., 2019). Loss of Lamin B1 from the nuclear 
lamina was further showed to be responsible for the formation of SAHF, as it 
detaches heterochromatic LADs from the nuclear lamina (Sadaie et al., 2013). 
Lastly, Lamin B1 depletion significantly correlates with pericentromeric satellite 
DNA distention, suggesting for a role for Lamin B1 in SADS formation 
(Swanson et al., 2013). 
 
As previously mentioned, certain senescent cells exhibit SAHF, a highly 
compacted chromatin domain observable by DAPI staining and is enriched in 
H3K27me3 and H3K9me3 marks, which are histone tail marks associated with 
facultative and constitutive heterochromatin respectively (Narita et al., 2003; 
Kosar et al., 2011; Chandra et al., 2012). It was one of the earliest known 
higher-order chromatin changes observed in senescent cells and is thought to 
mediate silencing of proliferation genes such as E2F target genes in a p16-
pRb pathway-dependent manner, in order to enforce the permanent growth 
arrest of senescence (Narita et al., 2003). HP1, High mobility group A proteins 
(HMGA1 and HMGA2) and macroH2A histones are also known to be part of 
the SAHF structure (Zhang et al., 2005; Narita et al., 2006). Each SAHF focus 
is formed from a single chromosome, driven by the histone chaperones 
Histone Repressor A (HIRA) and Anti-silencing Function 1a (ASF1a) (Zhang 
et al., 2005; Ye et al., 2007; Zhang, Chen and Adams, 2007). Activity from both 
p53 and pRb senescence pathways are also required for SAHF formation, in 
parallel to HIRA and ASF1a (Narita et al., 2003; Zhang et al., 2005; Ye et al., 
2007; Zhang, Chen and Adams, 2007). Later studies showed that the structure 
of SAHF is structured as H3K27me3-enriched outer layer which encapsulates 
an H3K9me3-enriched core (Chandra and Narita, 2013). SAHF have also 
been shown to be derived from LADs that have underwent spatial 
reorganisation, due to loss of heterochromatin attachment to the nuclear 
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lamina triggered by depletion of Lamin B1, a component of the nuclear lamina 
during senescence (Shimi et al., 2011; Freund et al., 2012; Sadaie et al., 
2013). Hi-C analysis of OIS in WI-38 fibroblasts showed reduced local 
interactions of topologically associating domains associated with 
heterochromatin and increased long range interactions which represent the 
formation of SAHF by spatial clustering of heterochromatins (Chandra et al., 
2015). Interestingly, formation of SAHF is consistently observed in OIS but not 
in RS or other SIPS in multiple fibroblastic cell lines (Narita et al., 2003; Di 
Micco et al., 2011). Furthermore, SAHF formation is cell type specific 
suggesting that SAHF may not be a universal feature of senescence (Kosar et 
al., 2011). 
 
It is known that large arrays of tandem repeats called satellite DNA, prevalent 
in centromeres, form the bulk of the heterochromatin (Saksouk, Simboeck and 
Déjardin, 2015). Centromeric and Pericentromeric satellite DNA are normally 
constitutively repressed to maintain genomic stability. H3K18 deacetylation by 
SIRT6 have been shown to be required for satellite DNA transcriptional 
repression (Tasselli et al., 2016). It has been shown that centromeric and 
pericentromeric satellite DNA undergo decompaction shown as a distension of 
these satellites when observed by FISH and also DNA hypomethylation, in 
cells undergoing RS and OIS, in the absence of changes in heterochromatic 
marks H3K9me3 and H3K27me3 (Cruickshanks et al., 2013; De Cecco et al., 
2013; Swanson et al., 2013; Criscione et al., 2016). This senescence-
associated nuclear phenomenon is called senescence associated distension 
of satellites (SADS) and can be observed by 3D FISH (Swanson et al., 2013). 
Lamin B1 depletion, a marker of senescence, is proposed to be required for 
the formation of SADS. Interestingly, SADS was also present in fibroblasts 
derived from HGPS, suggesting a role for SADS in progeroid syndromes 
(Swanson et al., 2013). As a relatively recent discovery, it is currently unclear 
what role SADS play in the maintenance of senescence. It is proposed that 
SADS is an early event in the global chromatin alteration observed in 
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senescence and due to its location in the centromeres, it may also play a role 
in preventing cell division in senescent cells (Swanson et al., 2013).  
 
1.2.5 Senescence in postmitotic cells 
Postmitotic cells are cells that have exited the cell cycle and permanently 
cease cell division such as terminally differentiated cells. Postmitotic terminally 
differentiated cells are refractory to cellular proliferation stimuli and this was 
thought to be conferred by the action of pRb (Lipinski and Jacks, 1999). 
However, although most terminally differentiated cells are postmitotic, in 
exceptional cases such as during liver injury, terminally differentiated mature 
hepatocytes cells can re-enter the cell cycle and undergo cellular division for 
liver regeneration (Bisteau, Caldez and Kaldis, 2014). Senescence is 
traditionally associated with loss of proliferative capacity and therefore 
associated with actively cycling cells. Conversely, it is now generally accepted 
that cellular senescence is a stress response and a driver of organismal aging 
which hypothetically can affect all cells regardless of whether they are dividing 
or non-dividing. Most human cells that make up tissues of the human body are 
postmitotic and therefore it is interesting to observe whether these postmitotic 
cells can senesce in relation to the chronological age. Recent studies showed 
that terminally differentiated postmitotic cells, such as neurons, can undergo a 
senescent-like phenotype in mice, which correlate with old age (Jurk et al., 
2012). Classical senescence markers such as persistent DDR activation, 
Elevated ROS production, SASP-associated IL-6 upregulation, positive SA-β-
gal staining and SAHF-associated macroH2A histones accumulation have 
been observed in neurons from old mice, which was not observed in neurons 
of young mice (Jurk et al., 2012). As these cells are not cycling, cellular 
proliferation markers such as Ki-67 expression, PCNA expression and 
thymidine analogue incorporation are generally ineffective as a biomarker for 
senescence. Moreover, postmitotic cell senescence have also been shown to 
involve similar tumour suppressive pathway to cellular senescence in mitotic 
cells such as the p53-p21 and p16-pRb pathways (Farr et al., 2016; Oubaha 
et al., 2016; Musi et al., 2018). Several of these classical senescence markers 
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have also been observed in postmitotic cells of other tissues such as 
osteocytes, retinal cells, skeletal myofibers and cardiomyocytes, and 
osteocytes (Farr et al., 2016; Oubaha et al., 2016; Anderson et al., 2019). It is 
hypothesised that in the presence of debilitating cellular stressors, postmitotic 
cells may prefer senescence instead of apoptosis in order to maintain 
structural integrity of tissues (Sapieha and Mallette, 2018). Indeed, attempts at 
cell cycle re-entry in postmitotic cells have been shown to induce apoptosis 
instead of proliferation in neurons (Giovanni et al., 1999; Ino and Chiba, 2001). 
Ironically, senescent postmitotic cells also produce SASP which is implicated 
in the harmful aspects of senescence such as paracrine senescence and 
protumourigenic/ proinflammatory microenvironment (Coppé et al., 2008, 
2010; Jurk et al., 2012; Oubaha et al., 2016; da Silva et al., 2019). Research 
into senescence of postmitotic cells is relatively new, therefore, further studies 
are required to help understand whether senescence in postmitotic cells are 
beneficial or detrimental for tissue integrity and function.   
 
1.2.6 Mitochondria and senescence 
Mitochondria, the cellular respiration organelles, play an essential role in 
producing chemical energy in the form of ATP for the cell and are present in 
most eukaryotic cells. However, mitochondria also emit hazardous by-products 
during molecular aerobic metabolism in the form of reactive oxygen species 
(ROS) (Boveris and Chance, 1973; Loschen et al., 1974; Turrens et al., 1982), 
which can induce oxidative stress damage to proteins, lipids and both 
mitochondrial and nuclear DNA (Richter, Park and Ames, 1988; Starke-Reed 
and Oliver, 1989; Rubbo et al., 1994). In vitro culture of mammalian cells is 
frequently carried out under atmospheric oxygen levels (~21% O2) and have 
been shown to result in elevated ROS production and increased oxidative DNA 
damage (Turrens et al., 1982; Chen et al., 1995; Parrinello et al., 2003; Rai et 
al., 2009). Moreover, this increased ROS production can induce single strand 
DNA breaks to telomeric DNA (Petersen, Saretzki and Von Zglinicki, 1998; 
Von Zglinicki, Pilger and Sitte, 2000). G-rich telomeric DNA is prone to 
oxidative DNA damage and can also form 8-oxo-7,8-dihydro- 2′-
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deoxyguanosine (8-oxodG) lesions (Kawanishi and Oikawa, 2004). ROS-
induced single strand break formation at telomeres is difficult to repair which 
result in loss of telomeric sequence during subsequent DNA replication and is 
proposed to be the mechanism of ROS-induced accelerated telomere 
shortening, which increases the propensity for cells to undergo telomere 
dysfunction and senescence (von Zglinicki et al., 1995; Petersen, Saretzki and 
Von Zglinicki, 1998; Von Zglinicki, Pilger and Sitte, 2000; Coluzzi et al., 2014).  
 
Thus, inhibiting ROS should theoretically prevent ROS-induced telomere 
shortening and possibly delay senescence. Indeed, treatment with the 
mitochondria targeted antioxidant MitoQ prevents accelerated telomere 
shortening in fibroblasts cultured in 40% oxygen partial pressure (Saretzki, 
Murphy and von Zglinicki, 2003). Furthermore, treatment of pre-senescent 
human endothelial cells with N-acetylcysteine antioxidant treatment was 
shown to decrease ROS formation and delay the onset of senescence 
(Haendeler et al., 2004). Similarly, uncoupling of mitochondria with 2,4-
Dinitrophenol in MRC-5 fibroblasts also decreased telomere shortening rate 
and improved in vitro lifespan of the cells (Passos et al., 2007). Therefore, this 
reinforces the view that mitochondrial ROS overproduction is a major 
contributor of cellular senescence. The CDK inhibitor p21 is implicated in 
senescence-associated cell cycle arrest and overexpression of p21 have been 
shown to upregulate ROS, suggesting a link between senescence activation 
and ROS production (Macip et al., 2002). Moreover, chronic activation of p21 
was also shown to activate a signalling cascade of GADD45 - p38MAPK - 
GRB2 - TGFBR2 - TGFβ which induce mitochondrial dysfunction and ROS 
production, resulting in a vicious cycle of ROS production and induction of 
persistent DDR activation, in order to maintain senescence in human 
fibroblasts (Passos et al., 2010). Together, these suggest that mitochondria 
play an important role in the activation and maintenance of cellular senescence 
through the production of ROS.  
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Aside from its role in ROS-dependent cellular senescence, mitochondria are 
also thought to play a role in SASP production, which the latter is thought to 
be activated by a persistent DNA damage associated with the activation and 
maintenance of senescence (Rodier et al., 2009). The transcription factors 
C/EBPβ and NF-κB have been shown to be involved in upregulation of 
proinflammatory cytokines IL-6 and IL-8 respectively during SASP (Kuilman et 
al., 2008; Acosta et al., 2013). In addition, the inflammasome is also implicated 
in the regulation of C/EBPβ and NF-κB during SASP production via IL-1 
signalling upstream of these transcription factors, in a Caspase-1 dependent 
manner (Acosta et al., 2013). Mitochondria of senescent cells frequently 
exhibit increased mass, inefficient metabolism and elevated ROS production, 
suggesting impaired mitochondrial function (Lee et al., 2002; Passos et al., 
2007; Moiseeva et al., 2009).  In addition, retrograde signalling, a cellular 
response observed in dysfunctional mitochondria characterised by decreased 
membrane potential,  Ca2+ signalling deregulation, metabolic readjustment, 
upregulation of antiapoptotic signalling and activation of mitochondrial 
biogenesis is also observed in senescent human fibroblast (Biswas et al., 
1999; Butow and Avadhani, 2004; Passos et al., 2007). Mitochondria ablation 
in senescent fibroblasts showed reduction in multiple senescence markers 
including p21, p16 and SASP pro-inflammatory cytokines IL-6 and IL-8, 
suggesting that mitochondria play a role as a driver of the senescent 
phenotype (Correia‐Melo et al., 2016). In the same study, DDR activation leads 
to a signalling cascade of ATM-Akt-mTORC1-PGC1β which increase 
mitochondrial mass. Moreover, inhibition of ATM or mTORC1 with an ATM 
inhibitor KU55933 or Rapamycin respectively, showed reduction in 
mitochondrial mass. This suggest that the DDR play a direct role in SASP 
maintenance via PGC1β-dependent mitochondrial biogenesis. 
 
1.2.7 Irreversibility of senescence 
In the 1960s, Leonard Hayflick and Patrick Moorhead discovered that following 
a certain number of population doublings, human diploid fibroblasts enter a 
state of cell cycle arrest  called phase III growth phase, later termed as cellular 
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senescence, which can persist for a long time in culture and seems to be 
refractory to growth factor stimulation present in serum used in cell culture 
(Hayflick and Moorhead, 1961; Hayflick, 1965). This suggest that cellular 
senescence is a permanent endpoint to a cell’s life cycle and possibly 
irreversible. It is thought that although p53-p21 pathway plays a role in 
activation of senescence in human fibroblasts, p16-pRb pathway seems to be 
the pathway associated with the persistent growth arrest phenotype, in a cell 
type dependent manner (Beauséjour et al., 2003). Furthermore, nuclear 
alterations observed in senescence such as SAHF and SADS, have been 
proposed to play a role in conferring the permanent growth arrest observed in 
senescent cells, by silencing of E2F gene targets and blocking cell division 
respectively (Narita et al., 2003; Swanson et al., 2013).  However, there are 
evidence which suggest that reversal or escape from cellular senescence is 
possible under certain conditions. BJ fibroblasts which express low levels of 
p16 during senescence showed cellular proliferation following inhibition of p53 
(Beauséjour et al., 2003). p53 inhibition was also sufficient to induce 
proliferation in senescent MEFs which maintains senescence in ARF and p53-
dependent manner (Dirac and Bernards, 2003). This suggest that, escape or 
reversal from senescence is possible in cells where senescence is maintained 
by p53.  
 
Findings in antineoplastic drug-induced cellular senescence suggest that it is 
a mechanism in which cancer survive from drug-induced cell death and may 
be reversed in certain conditions. Expression of senescence associated 
markers was observed in p16-negative HCT116 colorectal cancer cell line 
following low dose doxorubicin treatment (Sliwinska et al., 2009). A few cells 
were found to have escaped senescence growth arrest and exhibit aneuploidy 
(Sliwinska et al., 2009). However, it is possible that the absence of p16 may 
have resulted in a p53-dependent senescence maintenance, which was 
previously shown to be reversible following p53 inhibition (Beauséjour et al., 
2003). Upregulation of CDK1 and its downstream target Survivin have also 
been observed in cells that have escaped ATM/ATR-dependent senescence 
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of H1299 cells induced with Camptotechin  (Roberson et al., 2005; Wang et 
al., 2011). However, H1299 is a double p53 and p16 negative human lung 
cancer cell line, suggesting that other conditions may function as a prerequisite 
for senescence reversal. As previously mentioned, E2F targets required for 
cellular proliferation, is possibly silenced through heterochromatinization to 
maintain permanent cell cycle arrest of senescence. A recent report showed 
that depletion of Suv39h1 histone methyltransferase is sufficient to reverse the 
growth arrest phenotype of doxorubicin induced senescence in Eµ-Myc mouse 
cells with conditional Suv39h1 allele (Milanovic et al., 2018). It is also 
suggested that the constitutive heterochromatin mark H3K9me3 is constantly 
replenished in senescent cells by Suv39h1 histone methyltransferase to 
maintain silencing of E2F targets, suggesting a more dynamic nature of 
senescence (Braig et al., 2005; Milanovic et al., 2018).  
 
Another aspect that confounds the study of the irreversibility of cellular 
senescence is its heterogenous nature. In a population of cultured cells, there 
are large differences in lifespan between individual cells, which could possibly 
be attributed to stochastic culture stress events, in particular oxidative stress 
(Smith and Whitney, 1980). In a report which studies single cell expression of 
SASP in IMR90 cells undergoing SIPS by bleomycin treatment, differing SASP 
expression was observed between cells (Wiley et al., 2017). Furthermore, RS 
cells have been shown to be more heterogenous in terms of cell to cell gene 
expression pattern than SIPS cells induced by IR damage (Tang et al., 2019). 
It is possible that the acute nature of SIPS may account for the observed 
relatively homogenous gene expression compared to RS cells where the 
senescence phenotype is developed over a long time in culture. Cellular 
senescence studies are often carried out using population of cells. This cell to 
cell variability in senescent phenotype may complicate analysis when trying to 
look for cellular alterations required for senescence reversal, as there is a 
possibility that these heterogeneity may reflect a subpopulation of cells which 
are arrested but not senescent or cells that are not fully senescent or cells are 
never senescent due to underlying genetic alteration which result in bypass of 
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senescence. Distinguishing between these technically non-senescent cells in 
a population of senescent cells would be crucial to specifically determine the 
genetic and epigenetic regulators which govern senescence. 
 
1.2.8 Role of cellular senescence in organismal ageing 
It has been long disputed whether cellular senescence contributes to 
organismal ageing. It has been previously suggested that cellular senescence 
is a process that only occurs during ex-vivo culturing of mammalian cells and 
consequently an artefact of cell culture (Rubin, 1997). However, observations 
in ageing mice and primate tissues showed significant correlation between old 
age and the build-up of senescent cells in the tissues (Jeyapalan et al., 2007; 
Lawless et al., 2010; Wang et al., 2009; Krishnamurthy et al., 2004). 
Furthermore, the importance of the accumulation of senescent cells during 
ageing is further highlighted in the studies which utilise biological or 
pharmacological (senolytics) approach to selectively deplete senescent cells. 
Targeting of senescent cells that express p16 for cell death in mice via an 
engineered construct called INK-ATTAC showed improvement of organ 
function and organismal fitness of these ageing mice, suggesting that the 
removal of senescent cells rescues these mice from the detrimental effects of 
ageing (Baker et al., 2011, 2016). Others have also seen similar effects using 
a class of small molecule inhibitors called senolytics which can specifically 
induce cell death in senescent cells (Chang et al., 2016; Yosef et al., 2016). 
Senolytics commonly target anti-apoptotic Bcl-2 family proteins such as Bcl-W 
and Bcl-XL and the inhibitors of p53 such as MDM2, which are upregulated in 
senescent cells (Reviewed in (van Deursen, 2019)). Overall, these reports 
suggest that cellular senescence plays an important role in organismal ageing 
and that the therapies targeting senescent cells could potentially increase the 
quality of life in humans during the old age.  
 
1.2.9 Cellular senescence disorders: Progeroid syndromes  
Progeroid syndromes is a terminology which corresponds to a group of genetic 
disorders associated with accelerated or premature aging. Progeroid 
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syndromes can be classified into lamina-associated and DNA repair-
associated progeroid syndromes based on the affected molecular pathway 
(Carrero, Soria-Valles and López-Otín, 2016). Examples of lamina associated 
progeroid syndromes are Hutchinson-Gilford progeria syndrome (HGPS), 
progeria syndrome (NGPS) and atypical progeria syndromes (APS). While, 
Werner syndrome, Cockayne syndrome and Bloom syndrome are examples 
of DNA repair-associated progeroid syndromes which are caused by mutations 
in WRN, ERCC6/8 and BLM genes, respectively. One of the most extensively 
studied progeroid syndrome is HGPS which is the disease synonymous with 
the name Progeria. HGPS is caused by a C>T point mutation at position 1824 
of the LMNA gene, which encodes for the precursor of Lamin A, one of the 
structural proteins of nuclear lamina (De Sandre-Giovannoli et al., 2003; 
Eriksson et al., 2003). This point mutation results in de novo formation of a 
spice site at exon 11 of the LMNA gene, which results in the production of a 
shorter mRNA transcript and translated pathologic protein called progerin (De 
Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). Accumulation of 
progerin at the nuclear lamina can cause deformation of the nuclear envelope 
and this has been shown to cause DNA replication defects in HGPS cells 
(Gonzalo and Kreienkamp, 2015). Furthermore, a persistent activation of the 
DDR thought to be due to DNA repair problems on DNA damage sites have 
also been observed in HGPS cells suggesting a link between HGPS and SIPS 
(Liu et al., 2005, 2006). Indeed, p53 pathway activation is implicated in HGPS 
and was found to be triggered by progerin-induced replication fork stalling 
(Wheaton et al., 2017). Expression of progerin have been discovered in 
fibroblasts from old patients with age ranging from 81 – 96 years old, 
suggesting a role for Lamin A/progerin in normal aging (Scaffidi and Misteli, 
2006). A study in cultured fibroblast from HGPS patients showed that 
treatment with the mTOR inhibitor rapamycin induced removal of progerin and 
restored nuclear membrane morphology and proper cellular functions, 
suggesting that the mTOR pathway is responsible in HGPS (Cao et al., 2011). 
Interestingly, mTOR has been recently shown to be involved in maintenance 
of DDR signalling in cellular senescence through mitochondrial biogenesis, 
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suggesting another feature cellular senescence that is replicated in premature 
aging syndromes (Correia‐Melo et al., 2016).  
 
The Werner syndrome, a DNA repair-associated progeroid syndrome, have 
also been extensively studied, as it showed similar accelerated aging features 
to HGPS but with a later onset which made it frequently called as adult 
progeria. It is caused by a spectrum of mutations on the WRN gene located at 
chromosome position 8p12, which encodes for a RecQ family helicase 
important in unwinding DNA during repair of DSBs by NHEJ or HR (Goto et 
al., 1992; Yu et al., 1996; Gray et al., 1997; Chen et al., 2003; Huang et al., 
2006). Somatic cells derived from Werner syndrome patients exhibit various 
chromosomal aberrations such as translocations, inversions and large 
deletions in the genome suggesting genomic instability (Salk et al., 1981; 
Fukuchi et al., 1985; Fukuchi, Martin and Monnat, 1989). A study using DNA 
methylation markers as “epigenetic clocks”, showed that white blood cells of 
Werner syndrome patients displayed accelerated epigenetic aging as shown 
from increased DNA methylation at specific CpG sites (Maierhofer et al., 
2017). Moreover, a gene expression microarray study showed similarity 
between gene expression pattern of fibroblasts of Werner syndrome patients 
and from old people, confirming the premature aging phenotype of patients 
with Werner syndrome (Kyng et al., 2003). The WRN helicase have also been 
implicated in telomere replication (Crabbe et al., 2004). Werner syndrome 
fibroblast showed reduced in vitro lifespan compared to normal fibroblasts, 
which can be rescued by telomerase expression, suggesting a role for 
telomere dysfunction in Werner syndrome (Martin, Sprague and Epstein, 1970; 
Wyllie et al., 2000).  Loss of telomeric sequence from telomeres replicated by 
lagging strand synthesis was observed in fibroblasts lacking WRN, linking this 
progeroid syndrome to telomeropathies (Crabbe et al., 2004, 2007). 
Importantly, cellular feature overlaps are observed between telomeropathies 
and progeroid syndromes as both, in some of cases, prematurely activates the 
cellular senescence program (Davis et al., 2006, 2007; Deng et al., 2013; Lin, 
Mobasher and Alawi, 2014; Stockklausner et al., 2015; Wheaton et al., 2017).  
Investigating the reversibility of senescence 
  Introduction 
36   
1.3 Cellular senescence and cancer: Tumour 
suppression vs Tumour promotion 
 
1.3.1 Structure and function of the tumour suppressor p53 
The tumour suppressor protein p53 is a transcription factor which play multiple 
roles in cancer suppression such as DDR, DNA repair, apoptosis and 
senescence among others and due to these roles it is also known as the 
guardian of the genome (Yonish-Rouach et al., 1991; Shaw et al., 1992; Lane, 
1992; el-Deiry et al., 1993; Waldman, Kinzler and Vogelstein, 1995; Offer et 
al., 1999; Saintigny et al., 1999; Lin et al., 2000; Amundson et al., 2002; 
Kortlever, Higgins and Bernards, 2006). p53 is frequently mutated in cancer 
and in Li Fraumeni syndrome which is characterised by early onset and 
increased susceptibility to multiple cancer formation (Baker et al., 1990; Malkin 
et al., 1990; Srivastava et al., 1990; Hussain and Harris, 1998). In humans, 
p53 is transcribed from the gene TP53, located at the genomic locus 17p13.1, 
which has 11+2 (β & γ) exons (2005). The gene has three known promoters; 
one located upstream of the first exon which is also a non-coding exon (P1) , 
a second one located at the first intron (P1’) and a third one located at intron 4 
(P2) (Reisman, Greenberg and Rotter, 1988; Bourdon et al., 2005). The full-
length mRNA of the canonical p53 is transcribed from the P1 promoter, 
resulted in a 53 kDa protein following translation when analysed by SDS-
PAGE, hence its name (Lane and Crawford, 1979; Linzer and Levine, 1979). 
mRNA transcription from the P2 promoter and multiple alternative splicing 
event can result in the formation of p53 isoforms (Joruiz and Bourdon, 2016). 
12 different isoforms of human p53 have been discovered so far which include 
p53α (canonical p53), p53β, p53γ, ∆40p53α, ∆40p53β, ∆40p53γ, ∆133p53α, 
∆133p53β, ∆133p53γ, ∆160p53α, ∆160p53β, ∆160p53γ. Although the function 
of these isoforms are mostly not known, p53β, Δ40p53 and Δ133p53α have 
been shown to be implicated in the regulation of cellular senescence (Fujita et 
al., 2009; Fujita, 2019). The main wild-type p53 gene product consist of 393 
amino acids and has two N-terminal Transactivation domains (TAD1 & TAD2) 
followed by a Proline rich region (PRD), a core DNA binding domain (DBD), a 
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nuclear localisation signal domain (NLS), a tetramerization domain (TET) and 
a C-terminal basic domain (BD) (Figure 1.6). Residues encompassing TADI, 
TADII and PRD are known to be natively unfolded and undergoes folding when 
binding to another protein such as MDM2 (Dawson et al., 2003).  
 
The p53 protein can only exert its function by binding to p53-response element 
as a tetramer to regulate expression of target genes (Halazonetis and Kandil, 
1993; Warnock et al., 2008). The canonical p53 response element contains 
two repeats the motif "RRRCWWGYYY", where R represents Guanine / 
Adenine (purine) , W represents Adenine / Thymine and Y represents Cytosine 
/ Thymine (pyrimidine), separated by a spacer of up to 13 nucleotides (El-Deiry 
et al., 1992; Funk et al., 1992; Farmer et al., 1992). The p53 tetramer is 
organised as a symmetric dimer of dimers and requires the tetramerization 
domain (TET) located at amino acid positions 325 – 356 (Jeffrey, Gorina and 
Pavletich, 1995). p53 tetramerization is also known to be required for effective 
ubiquitination of p53 by MDM2, p53 phosphorylation at S20 by Chk1/Chk2 and 
acetylation of p53 C-terminal lysine residues by p300 histone/lysine 
acetyltransferase (Maki, 1999; Shieh, 1999; Shieh et al., 2000; Mak, 2000; 
Itahana, Ke and Zhang, 2009). p53 is known to regulate expression of various 
genes such as CDKN1A (p21) and BBC3 (PUMA) which play a role in cell 
cycle arrest and apoptosis respectively (El-Deiry et al., 1992; Shaw et al., 
1992). Regulation of p53 activity mainly involves a negative feedback loop with 
the proteins MDM2 and MDM4/MDMX (Kubbutat, Jones and Vousden, 1997; 
Freedman, Wu and Levine, 1999; Stommel and Wahl, 2004). MDM2 is known 
to directly bind to the N-terminal transactivation domain of p53 and can also 
act as an E3 ubiquitin ligase for p53 and export p53 to the cytosol for 
degradation by the proteasome (Lin et al., 1994; Kussie et al., 1996; Honda, 
Tanaka and Yasuda, 1997; O’Keefe, Li and Zhang, 2003). Phosphorylation at 
Threonine residue 18 (Thr18) by Casein Kinase 1 (CK1) can release binding 
of MDM2 to p53 and this requires prior phosphorylation at Serine residue 15 
(Ser15) (Dumaz, Milne and Meek, 1999; Lai et al., 2000; Sakaguchi et al., 
2000; Schon et al., 2002). Ser15 residue is known to be phosphorylated by the 
Investigating the reversibility of senescence 
  Introduction 
38   
PI3K family kinases ATM and ATR in response to cellular stress such as DSB 
DNA damage (Nakagawa et al., 1999; Tibbetts et al., 1999). p53 Ser15 
phosphorylation is required for p53 transactivation of p53 target genes and is 
known to precede any other phosphorylation at the transactivation domain 
(Sakaguchi et al., 1998; Dumaz, 1999; Dumaz, Milne and Meek, 1999; Saito 
et al., 2003). Therefore, this suggest that phosphorylation at Ser15 is the 
primary event in the activation and stabilisation of p53 and may be used as a 
general marker for p53 activation. Phosphorylation at Ser15 also play a role in 
the recruitment of the p53 coactivators p300/CBP to mediate acetylation of p53 
at lysine sites in the DNA binding domain (DBD) and C-terminal basic domain 
(BD) which enhances p53 transactivation of target genes and increase stability 
of p53 by inhibiting MDM2-mediated ubiquitination of p53 (Lambert et al., 
1998; Sakaguchi et al., 1998; Dumaz, 1999; Ito et al., 2001, 2002). Another 
transactivation domain phosphorylation site, Serine residue 20 (Ser20), is 
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1.3.2 Differences between tumour suppressor pathways in 
humans and mice 
Mouse models have been used for a very long time to study cancer biology, 
owing to its ease in genetic manipulations and similarities to humans in terms 
of physiology, anatomy, and genetics. Thus, it is an indispensable tool in the 
quest to further understand cancer biology and discover future cancer 
therapies. However, it is also known that there are differences in tumour 
suppressor pathways between humans and mice (Wadhwa et al., 2002; 
Horvath et al., 2007; Jegga et al., 2008). Therefore, a cautious interpretation 
is required in order to be able to use data from mice to explain scientific 
findings in humans. This section will briefly describe these differences in order 
to understand how to interpret data taken from studies using mouse cells and 
animal models prior to extrapolating it to human cancer and senescence 
biology. This is important particularly as cellular senescence which is the main 
topic of this study, is a tumour suppressive mechanism and the tumour 
suppressor gene regulatory network plays an important role in the regulation 
of the senescence program (Alexander and Hinds, 2001; Beauséjour et al., 
2003).  
 
In 1977, Richard Peto  postulated that bigger animals that live longer and have 
higher cell counts should have higher cancer incidence compared to smaller 
animals, due to increased risks of formation of oncogenic mutations from each 
cell division (Peto, 2015). However, he discovered that this was not the case 
as cancer incidence does not seem to correlate with the number of cells in an 
organism. For example, humans have 1000x more cells and live 30x longer 
than mice (Peto, Hiatt and Watson, 1977). However, probability of 
carcinogenesis induction in mice and humans by the end of the organism’s life 
is similar at roughly 30% (Rangarajan and Weinberg, 2003). This simple 
observation is dubbed Peto’s paradox and this spurred more research into how 
bigger animals can suppress cancer even with a very large number of cells 
and longer life expectancy. One factor that is thought to be able to explain this 
paradox is the difference in the components or regulation of tumour suppressor 
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pathway between species. Comparative cell culture studies in mice and 
humans have elucidated several distinctions in the molecular signalling of 
tumour suppressors which contribute to tumorigenic capacity in vitro. The first 
cell culture evidence which suggest that distinction was from a study which 
showed that spontaneous immortalisation, which is a hallmark of cancer, was 
observed in cultured murine but not human fibroblasts (Newbold, Overell and 
Connell, 1982). Further studies showed that p53-inactivating mutations were 
found in spontaneously immortalised mouse embryonic fibroblasts (MEF), 
suggesting a role for p53 in preventing immortalisation and activating 
senescence (Harvey and Levine, 1991). As telomerase is readily expressed in 
mice, it is thought that murine cells are readily immortalised, as long as the 
senescence pathway is inhibited via p53 inactivation. This idea was reinforced 
by experiments which showed that MEFs can bypass senescence and become 
immortal following p53 inactivation (Harvey et al., 1993; Dirac and Bernards, 
2003). On the other hand, p53 alone is insufficient to bypass replicative 
senescence in human fibroblast which do not express telomerase (Shay, 
Pereira-Smith and Wright, 1991). In the same study, although cells can bypass 
senescence via ectopic expression of SV40 LT antigen or HPV E6/E7 viral 
oncoprotein which inhibit both p53 and pRb, this was not sufficient to induce 
immortalisation as the cells underwent crisis in the absence of telomerase 
expression. This suggest that, unlike in mice, both inactivation of p53 and pRb 
is required for cellular immortalisation in human cells. Lastly, a study which 
compared the requirement for cancer formation in both humans and mice 
showed that transformation of murine fibroblasts requires alteration in only two 
signalling pathways involving Raf and p53,  compared to at least six in human 
fibroblasts, which involves p53, pRb, PI3K, telomerase, PP2A, Raf, and Ral-
GEFs (Rangarajan et al., 2004). Overall, these data suggest an underlying 
difference in the regulation of tumour suppressor between the two species and 
could also explain the robustness of cancer suppression in humans.  
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1.3.3 Replicative senescence and crisis 
It has been proposed that replicative senescence is a tumour-suppressive 
mechanism. p53, a principal component of the DDR and a tumour suppressor 
protein, is known to be inactivated in many cancer cells (Rivlin et al., 2011). 
Experimentally, inactivation of p53 and pRb via the expression of the SV40 LT 
antigen or the HPV E6-E7 oncoproteins results in a bypass of senescence 
which allows cells to continue proliferating until the cells reach a second 
proliferative barrier called crisis (Shay, Pereira-Smith and Wright, 1991). 
Unlike senescence, crisis is characterised by the end-to-end chromosomal 
fusions and genomic instability, which might be caused by the absence of all 
of the shelterin components required for telomere protection against the DNA 
repair machineries (Sfeir and De Lange, 2012). It is thought that genomic 
instability, arising from the breakage-fusion-bridge cycle and observed in the 
cells undergoing crisis may be sufficient to select for rare mutations which 
allow further uncontrollable proliferation (Shay and Wright, 1989; Wright, 
Pereira-Smith and Shay, 1989). Escape from the crisis may be accomplished 
by either reactivation of hTERT expression or by alternative lengthening of 
telomeres (ALT), which is a recombination-based telomere lengthening 
mechanism. Both routes lead to immortality and are a characteristic of cancer 
cells. Therefore, this suggests that senescence is a barrier that prevents 
carcinogenesis.   
 
The idea that telomerase promotes cancer, came from studies showing that 
telomerase is expressed in the majority of cancers (Kim et al., 1994). However, 
this does not confirm whether telomerase is necessary early in oncogenesis. 
Indeed, telomerase expression alone does not confer phenotypical similarities 
to cancer in culture (Jiang et al., 1999; Morales et al., 1999). Studies in ageing 
mice have also shown that the over-expression of mouse TERT resulted in 
increased life expectancy without the tumour-inducing side effects (Bernardes 
de Jesus et al., 2012). Interestingly, although mice do express telomerase and 
have very long telomeres, this treatment surprisingly showed a decrease in 
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short telomeres suggesting that telomerase canonical function in telomere 
lengthening is required. 
 
1.3.4 Reversal of senescence 
Epigenetic evidence of the similarities between pre-cancer cells and senescent 
cells such as global hypomethylation and focal hypermethylation at promoters 
of genes linked to cancer, suggests that cancer cells may be derived from 
senescent cells that have escaped/reversed senescence (De Cecco et al., 
2013; Cruickshanks et al., 2013; Sidler et al., 2014; Lowe et al., 2015). 
Although senescence is an important tumour suppressive mechanism, by 
limiting proliferation of old cells which have accumulated pathological 
mutations (RS) or cells which activated oncogenes (OIS – oncogene-induced 
senescence), it may paradoxically give rise to tumour-promoting cellular 
processes. Indeed, SASP have been proposed to produce a tumour-promoting 
microenvironment which could stimulate cell proliferation, epithelial to 
mesenchymal transition and invasion/metastasis capacity (Coppé et al., 2008). 
On the other hand, although some epigenetic changes and cellular processes 
of senescent cells are associated with cancer, it is unclear whether 
senescence escape/reversal is possible. Senescence bypass studies in 
human cells have shown that inhibition of both the p53-p21 and p16-pRb 
pathways is required to prevent cells from undergoing senescence, but 
insufficient to prevent cells from undergoing crisis (Shay, Pereira-Smith and 
Wright, 1991). Abrogation of senescence, once it has been established, has 
been shown possible in mice and certain human cells via the inhibition of p53 
(Beauséjour et al., 2003; Dirac and Bernards, 2003). However, in human cells 
that upregulate p16, inhibition of both pathways is sufficient to abrogate cell 
cycle arrest but insufficient to allow cell division (Beauséjour et al., 2003). This 
suggests that senescence, at least RS, is irreversible in human cells 
expressing high levels of p16.  
 
Activation of a single oncogene is generally insufficient to drive cancer 
formation. Furthermore, increased mutagenic signal from activated oncogenes 
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has been experimentally shown to trigger OIS, a subcategory of PS in various 
mouse and human cells, inhibiting the proliferation of pre-cancerous cells 
(Serrano et al., 1997; Suram et al., 2012). However, a study in BJ fibroblasts 
undergoing OIS showed a spontaneous escape from senescence associated 
with the upregulation of telomerase, thereby questioning the irreversibility of 
senescence (Patel et al., 2016). Interestingly, inhibition of p53 in BJ fibroblasts 
with RS was sufficient to reverse senescence (Beauséjour et al., 2003). 
Therefore, regardless of the senescence trigger, it is possible that irreversibility 
of senescence requires expression of p16. 
 
1.4 Project aims 
Cellular senescence is an important tumour suppressive mechanism and it has 
been suggested that cancer cells may be derived from the cells that escaped 
senescence. Therefore, this raises the question of whether senescence is truly 
permanent and therefore irreversible. This project aims to unravel potential 
ways in how RS cells might abrogate the proliferative arrests that governs their 
senescence by using telomerase. This project also aims to discover the 
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Chapter 2 Materials and methods 
2.1 Cell culture conditions 
MRC-5 Wild-Type (WT), hTERT and DD-hTERT cells were cultured in Gibco  
minimum essential medium (MEM) (Thermo Fisher Scientific, Waltham, MA, 
USA) supplemented with 10% HyClone foetal bovine serum (FBS) (GE 
Healthcare Life Sciences, Chicago, IL, USA), 1X Gibco penicillin-streptomycin-
glutamine (PSG) solution (Thermo Fisher Scientific, Waltham, MA, USA), 1X 
Gibco non-essential amino acids (Thermo Fisher Scientific, Waltham, MA, 
USA), 1 mM Gibco sodium pyruvate (Thermo Fisher Scientific, Waltham, MA, 
USA). Shield-1 (Generon, Slough, UK) was added to the MRC-5 DD-hTERT 
cells at the concentration of 700 nM and replaced every four days. HEK293T 
packaging cells were cultured in Gibco Dulbecco’s modified Eagle medium 
(DMEM) containing 3.7 g/l glucose, 4 mM glutamine, 1 mM sodium pyruvate 
(Thermo Fisher Scientific, Waltham, MA, USA) and supplemented with 10% 
HyClone FBS and 1X Gibco PSG solution. All cells were cultured in a 37 °C 
incubator with 5% CO2. Proliferating cells were passaged every four days and 
re-seeded at 2.5 x 105, 7.5 x 105 or 1.75 x 106 cells per CELLSTAR 25 cm2 
(T25), 75 cm2 (T75) or 175 cm2 (T25) culture flasks (Greiner Bio-One, 
Kremsmünster, Austria) respectively.   
 
2.2 Calculation of population doubling 
Cells were manually counted using an improved Neubauer haemocytometer 
and the number of population doublings was calculated using the following 
formula: 3.32 (log UCY – log I) + X. Ultimate Cell Yield (UCY) corresponds to 
the cell number in the current passage, while Inoculum (I) is the number of the 
cells seeded in the previous passage and X is the population doubling number 
established at the previous passage (Patterson, 1979). 
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2.3 Genomic DNA extraction and quantification 
Adherent cells were trypsinised and harvested by centrifuging at 300 RCF for 
5 minutes. The supernatant was discarded, and the pellet was dissolved in 1 
ml 1X PBS and transferred into a 2 ml microcentrifuge tube. This was followed 
by centrifugation at 300 RCF for 5 minutes. The resulting pellet was dissolved 
in 1 ml Tris-EDTA (TE) containing 0.1% SDS and 150 µg/ml Proteinase K, to 
lyse the cells overnight at 55 °C. 500 μl of Phenol:Chloroform:Isoamyl alcohol 
(25:24:1) solution was mixed with the lysed cells, followed by centrifugation for 
5 minutes at 13,000 RPM, room temperature. The upper phase was then 
transferred into a fresh 2 ml microcentrifuge tube and 500 μl of chloroform was 
mixed with the upper phase solution. This was followed by centrifugation for 5 
minutes at 13,000 RPM, room temperature. The Upper phase was transferred 
into a fresh 2 ml microcentrifuge tube. 100 μl of 3M sodium acetate and 1 ml 
of isopropanol were added to the upper phase solution. Genomic DNA was 
allowed to precipitate at -20 °C for at least 1 hour and as long as overnight. 
Following this, the genomic DNA was pelleted by centrifugation for 15 minutes 
at 13,000 RPM, 4 °C. The pellet was washed with ice-cold 70% ethanol and 
centrifuged for 5 minutes at 13,000 RPM, 4 °C. The DNA pellet was air-dried 
for 2 - 4 minutes and dissolved in 100 – 300 μl of the TE buffer, pH 8.0. 1 μl of 
RNAseA was added to the genomic DNA solution and the sample was 
incubated at 37 °C for 30 minutes to degrade contaminating RNA. 
 
2.4 Western blotting 
2.4.1 Protein extraction and quantification 
1X RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM EDTA, either 
1% NP-40 or 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS) 
supplemented with 1X cOmplete EDTA-free protease inhibitor cocktail (Roche 
Applied Science, Penzberg, Germany) and 1X Sigma phosphatase inhibitor 
cocktail 3 (Merck-Millipore, Burlington, MA, USA) was used to lyse mammalian 
cells that have been trypsinised and harvested by centrifugation. Following the 
cell resuspension in the RIPA buffer, the cell lysate was incubated on ice for 
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30 minutes and centrifuged at 8,000 RCF for 10 minutes at 4 °C, to pellet cell 
debris and clear up the lysate. Sigma bicinchoninic acid protein assay kit 
(Merck-Millipore, Burlington, MA, USA), was used to quantify proteins in the 
whole cell lysate according to the manufacturer’s instructions, with 1 mg/ml 
BSA used for making a standard curve. Another method was also used in 
several western blots, where proteins were extracted from trypsinised cells by 
dissolving cell pellet in 2X Laemmli sample buffer at 1x104 cells/µl of the 
sample buffer and boiling for 10 minutes at 100 °C on a heat block. 2X Laemmli 
sample buffer was prepared by diluting 4X Laemmli sample buffer containing 
200 mM Tris-HCl pH 6.8, 8% SDS, 40 % glycerol, 0.04% Bromophenol blue 
and 400 mM DTT. The boiled whole cell lysate was passed through a 30G 
syringe needle 10 times to shear genomic DNA and reduce sample viscosity.  
 
2.4.2 SDS-PAGE and protein transfer onto blotting 
membranes 
For the cells lysed with the RIPA buffer, 30 to 50 µg of proteins were mixed 
with the 4X Laemmli sample buffer to a final concentration of 1X Laemmli, 
boiled for 5 minutes at 95 °C and then loaded into an SDS-PAGE gel in a 
vertical electrophoresis mini tank (Bio-Rad, Hercules, CA, USA) filled with 1X 
SDS-PAGE running buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS) and 
run at 100 V for 2 hours or 180 V for 1 hour to separate the proteins by size. 
For cells directly lysed with 2X Laemmli buffer, 10 to 50 µl of whole cell extract 
(corresponding to 1x105 to 5x105 cells) was loaded into an SDS-PAGE gel and 
followed a similar electrophoresis setting as above. Following the SDS-PAGE, 
the proteins were transferred from the gel onto a Protran 0.45 µm NC 
nitrocellulose membrane (GE Healthcare Life Sciences, Chicago, IL, USA). 
The gel and the membrane were sandwiched between four blotting paper 
pieces (two on either side) and two fibre pads, which were all held together by 
a blotting cassette. The blotting sandwich was submerged completely in 1X 
transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol) in a mini 
blotting tank (Bio-Rad, Hercules, CA, USA) and protein transfer was run at 400 
mA, 4°C for 1 hour or at 30 V, 4°C overnight. 
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2.4.3 Antibody probing and detection 
Prior to antibody probing, western blot membranes were blocked in 4% skim 
milk dissolved in 1X TBS for 1 hour at room temperature. The membranes 
were then probed with primary antibodies diluted in 4% skim milk in 1X TBS 
and 0.1% Tween-20 (1X TBST) at the appropriate concentrations (Table 2.3). 
The incubations were carried out overnight at 4 °C. Following the primary 
antibody incubations, the membranes were washed with 1X TBST and probed 
for 1 hour at room temperature with a secondary antibody conjugated to either 
IRDye 680RD or IRDye 800CW (LI-COR, Lincoln, NE, USA) diluted at 
1:15,000 in 4% skim milk in 1X TBST. The membranes were washed again 
with 1X TBST before detection of the proteins using a LI-COR Odyssey Imager 
(LI-COR, Lincoln, NE, USA) using either the 700 nm channel for IRDye 680RD 
secondary antibodies or the 800 nm channel for the IRDye 800CW secondary 
antibodies. 
 
2.5 Telomere Repeat Amplification Protocol (TRAP) 
Whole cell lysates for TRAP assays were made by re-suspending cell pellets 
in the NP-40 lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM MgCl2, 1 mM EDTA, 
1% NP-40, 0.25 mM sodium deoxycholate, 10% glycerol, 150 mM NaCl, 5 mM 
β-mercaptoethanol, 1X Sigma P8340 protease inhibitor cocktail (Merck-
Millipore, Burlington, MA, USA)). 1 µl of the buffer was used per 1,000 cells to 
lyse and the cell lysis samples were incubated on ice for 30 minutes. The cell 
lysates were diluted accordingly, using NP-40 lysis buffer and fluorescence-
based TRAP assay was performed as described by Mender and Shay, with 
some modifications (Mender and Shay, 2015). MRC-5 WT and MRC-5 hTERT 
cells were used as negative and positive controls, respectively. The 5’-DY-782-
labelled oligo TRAP-TS-IR was used as a synthetic template for telomerase. 
A mixture of 3 primers: ACX, TSNT and NT was also used in the TRAP reaction 
to function as a reverse primer for telomerase product, an internal control for 
the PCR reaction and a reverse primer for the internal control, respectively. 
The TRAP PCR reactions were setup in 50 µl reaction volumes, containing 1X 
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TRAP buffer (200 mM Tris-HCl pH 8.3, 15 mM MgCl2, 630 mM KCl, 0.5% v/v 
Tween-20 and 10 mM EGTA), 200 µM dNTPs, 0.2 mg/ml BSA, 2 ng/μl TRAP-
TS-IR primer, 1X TRAP primer mix (0.1 µg/µl ACX primer 0.1 µg/µl NT primer 
and 0.01 pM TSNT primer), 2.5 U Taq polymerase and 1 µl of a tested sample 
or a cell lysate. The TRAP PCR reaction was initiated with a telomerase 
extension step at 30 °C for 40 minutes followed by an initial denaturation step 
at 95 °C for 5 minutes and 26 cycles of Denaturation, Annealing and Extension 
for 30 seconds at 95 °C, 30 seconds at 52 °C and 45 seconds at 72 °C 
respectively, before ending the PCR with a final extension step at 72 °C for 10 
minutes. 10 µl of 6X Orange G DNA loading dye was added to 50 µl of the 
TRAP PCR products and 30 µl of the mixture was loaded into a pre-chilled 
10% native polyacrylamide gel in 0.5 % TBE running buffer. The gel was run 
in a Biometra Model V.15.17 vertical electrophoresis apparatus (Analytik Jena, 
Jena, Germany) at 250 V, 4 °C for 2.5 hours.  The whole gel was scanned 
using a LI-COR Odyssey Imager (LI-COR, Lincoln, NE, USA) using the IR800 
channel. DNA markers were imaged separately by staining the gel with 0.5 
µg/ml ethidium bromide (EtBr) for 15 minutes, followed by washing with 
distilled water for 15 minutes and scanning using a gel imaging system 
equipped with a UV transilluminator. 
2.6 Telomere Restriction Fragment (TRF) Southern 
blotting (Teloblots) 
2.6.1 Genomic DNA restriction digests 
30 µg of genomic DNA was digested with the HinfI restriction enzyme (Thermo 
Fisher Scientific, Waltham, MA, USA) at 5 U/µg DNA in 1X buffer R at 37 °C 
in a water bath overnight. Following inactivation of HinfI at 65 °C for 20 
minutes, HinfI-digested DNA was precipitated using either one volume of 
100% isopropanol or three volumes of 100% ethanol, 1/10 volume of 3 M 
sodium acetate pH 5.2 and 100 µg/ml glycogen at -20 °C overnight. The 
precipitated DNA was pelleted by centrifugation at 17,000 g, 4 °C for 15 
minutes. The DNA pellet was washed with 100 % ethanol, one volume of the 
initial genomic DNA digest, and centrifuged again as above for 5 minutes. The 
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supernatant was removed, and the pellet was allowed to dry before being 
resuspended in 100 µl of dH2O. The HinfI-digested genomic DNA was further 
digested with the RsaI restriction enzyme (Thermo Fisher Scientific, Waltham, 
MA, USA) at 5 U/µg DNA in 1X Tango buffer at 37 °C in a water bath overnight. 
RsaI was inactivated by incubation at 80 °C (heatblock) for 20 minutes. HinfI-
RsaI digested genomic DNA was precipitated, centrifuged, and washed 
according to the procedure described above for the HinfI-digested DNA. Air-
dried HinfI-RsaI digested genomic DNA was dissolved in 20 µl of dH2O and 
the DNA quantity was measured using Nanodrop 2000 (Thermo Fisher 
Scientific, Waltham, MA, USA). 
 
2.6.2 DNA electrophoresis 
20 µg  of HinfI-RsaI digested genomic DNA was mixed with 1X Orange G DNA 
loading dye and loaded into the wells of a 0.8% agarose gel in 1X TAE buffer 
supplemented with 0.5 µg/ml EtBr. Agarose gel electrophoresis was run at 30 
V for 1 hour and at 45 V for 16 hours using a Bio-Rad Sub-Cell GT tank (Inter-
electrode distance = 29.5) (Bio-Rad, Hercules, CA, USA). Following the 
electrophoresis, the agarose gel was incubated sequentially in depurination 
solution (0.25 M HCl) for 30 minutes, in denaturing solution (1.5 M NaCl and 
0.5 M NaOH) for 30 minutes and in neutralising solution (1.5 M NaCl, 0.5 M 
Tris-HCl pH 7.2 and 1 mM EDTA) for 40 minutes, with a single tap water rinse 
in between the incubations with the solutions above. 
 
2.6.3 DNA transfer onto a membrane 
3 mm filter paper and Hybond N+ charged nylon membrane (GE Healthcare 
Life Sciences, Chicago, IL, USA) were cut to the size of the gel and soaked in 
20X SSC buffer (3M NaCl and 0.3 M Na citrate). The DNA was transferred 
from gel on to the membrane by capillary action through a Southern blot 
sandwich, for 8 hours at room temperature with 20X SSC buffer (Figure 2.1). 
Following the transfer, the nylon membrane was air dried and the DNA was 
cross-linked to the membrane using a 254 nm UV cross-linker at 120 
mJoules/cm2. 
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Figure 2.1 Southern blot sandwich. 
 
 
2.6.4 TRF probe hybridization 
The membrane was placed into a hybridization bottle containing ~17.5 ml of 
pre-warmed (50 °C) fresh hybridization solution (5X Denhardt’s solution [0.1% 
w/v BSA Fraction V, 0.1% w/v Ficoll 400, 0.1% w/v Polyvinylpyrrolidone], 6X 
SSPE buffer [0.9 M NaCl, 60 mM NaH2PO4 pH 7.4 and 6 mM EDTA ] and 
0.5% SDS). The membrane was pre-hybridized for 1 hour at 50 °C in a 
hybridization oven. 2 μl of 0.5 μg/μl DY-782-conjugated TRF probe (5’-DY-782-
TTAGGGTTAGGGTTAGGG) was diluted with 100 μl of dH2O, denatured for 2 
minutes at 95 °C in a thermal cycler and cold shocked on ice. The denatured 
TRF probe was added to ~7.5 ml of pre-warmed (50 °C) hybridization solution. 
The pre-hybridization solution was replaced with the TRF probe solution and 
the membrane was hybridized overnight at 50 °C in the dark. Following the 
hybridization, the membrane was washed with 30 ml of pre-warmed washing 
buffer (1X SSPE and 0.1% SDS) at 50 °C, twice for 20 minutes and 15 minutes, 
respectively. The membrane was transferred to a clean container, rinsed with 
1X SSPE buffer and stored in 1X SSPE buffer, dark until scanning. 
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2.6.5 Blot scanning 
The membrane was placed on the glass scanning surface of a Li-COR 
Odyssey infrared imager, the DNA side down, and any bubbles formed were 
removed using a roller. The membrane was scanned at 800 nm, 169 μm 
resolution and medium image quality. 
 
2.7 Senescence-associated β-galactosidase staining 
Cells cultured in either 6-well or 24-well plate were washed with 1X PBS and 
fixed with 4% formaldehyde solution for 5 minutes at room temperature. 
Following the fixation, the cells were washed again with 1X PBS and then 
immersed in the SA-β-Gal staining solution (1 mg/ml X-gal, 40 mM citrate-
phosphate buffer pH 6.0, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 150 mM NaCl, 2 mM MgCl2). Cells were then incubated at 37 °C 
in the dark for 16 hours. Following the incubation, the cells were washed 
sequentially with 1X PBS for 5 minutes, dH2O for 5 minutes and 100% 
methanol for 30 seconds at room temperature and left to dry in the dark before 
taking images of the cells using a bright-field microscope.  
 
2.8 Immunofluorescence microscopy 
Cells were cultured on acid-washed, poly-L-lysine coated coverslips and fixed 
for 10 minutes using 4% formaldehyde solution made fresh by dissolving 
paraformaldehyde in 1X PBS. The fixed cells were permeabilised by 
incubating in 0.2% Triton-X100 in 1X PBS at 37 °C for 10 minutes. 4% BSA in 
1X PBS was used for blocking and diluting primary and secondary antibodies 
(See Table 2.3. for list of antibodies used in this study). After blocking and the 
incubations with primary and secondary antibodies, the cells were 
counterstained with DAPI di-lactate solution (5 mg/ml) diluted at 1:5,000 in 1X 
PBS for 10 minutes. Prolong Gold antifade mountant (Thermo Fisher 
Scientific, Waltham, MA, USA) was used to mount coverslips on superfrost 
microscope slides. The slides were imaged using a Zeiss AxioImager 
fluorescence microscope (Carl Zeiss Microscopy, Jena, Germany) and 
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µManager open source microscopy software (Open-Imaging, UCSF, San 
Francisco, CA, USA). 
 
2.9 Quantification of Immunofluorescence signals  
NIH ImageJ 1.51r software (Schneider, Rasband and Eliceiri, 2012) was used 
for semi-automatic quantification analysis of immunofluorescence microscopy 
images. Initially, 16-bit image stacks consisting of a DAPI channel image and 
a target protein channel image (defined by the secondary antibody fluorescent 
conjugate) were size calibrated and split into single images and converted into 
8-bit grayscale images. These images were processed using the “Auto-
threshold” function with the default setting, in order to highlight the cells. The 
images were then converted into the binary format, which allowed 
quantification of cells as particles of a certain size. The “watershed” function 
was used to cut cells that were merged together. False positives were removed 
by subtracting the target channel image with the DAPI channel image using 
the “Image Calculator” function. The “Analyze Particles” function was used to 
quantify cells in both DAPI channel and target protein channel, which 
corresponded to the total cell count and the positively stained cell count, 
respectively.  
 
2.10 Cell proliferation assayed by EdU incorporation 
followed by flow cytometry 
Cells were grown in a 10 cm culture dish to approximately 60% confluency. 
EdU was added dropwise to the cells at the final concentration of 10 µM and 
the cells were incubated for 24 hours in a 37 °C, 5% CO2 incubator. Following 
the incubation, culture media were removed, cells were washed with 5 ml of 
cold 1X PBS and incubated with 2 ml Gibco 1X Trypsin-EDTA  (Made from 
10X Trypsin-EDTA containing no phenol red and diluted to 1X with 1X 
PBS)(Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C to dislodge 
adherent cells. Trypsin-EDTA was quenched with 4 ml of media containing 
10% FBS and the cells were dissociated by pipetting up and down. The cells 
were then pelleted by centrifugation at 300 RCF for 5 minutes and the pellet 
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was resuspended in 2.5 ml of ice-cold 1% FBS in 1X PBS. The cells were 
counted using Invitrogen Countess cell counter (Thermo Fisher Scientific, 
Waltham, MA, USA) and fixed by adding 7.5 ml of ice cold 100% ethanol, drop 
by drop while gently vortexing. 7.5 x 105 cells were transferred into a 2 ml 
microcentrifuge tube and centrifuged for 5 minutes at 500 RCF, 4 °C. The 
ethanol-fixed cells (as a pellet) were washed with 900 μl of 1X PBS and 
centrifuged for 5 minutes at 500 RCF, 4 °C. Click reaction cocktail was 
prepared by combining the following ingredients in the following order, for 1 
reaction: 873 μl 1X PBS, 9 μl of 1 M sodium ascorbate, 0.45 μl of Alexa Fluor 
647 Azide and 18 μl of 0.1 M CuSO4. The cell pellet was resuspended in 900 
μl of either the Click reaction cocktail (for protein staining) or 900 μl 1X PBS 
(for DAPI only and no staining controls) and incubated at room 
temperature/dark on a rotator for 30 minutes. Following the Click reaction, cells 
were centrifuged for 5 minutes at 500 g, room temperature. The cell pellet was 
then resuspended in 900 μl of 1% FBS and 0.5% Tween-20 in 1X PBS and 
incubated for 10 minutes at room temperature to permeabilise the cells. 
Following the cell permeabilisation, cells were centrifuged for 5 minutes at 500 
RCF at room temperature and the pellet was resuspended in 300 μl of 1% FBS 
+ 2.5 μg/ml DAPI in 1X PBS or 900 μl of 1% FBS in 1X PBS for Alexa 647 only 
and no staining controls, followed by incubation at room temperature for 1 
hour. Cells were passed through a 40 µm cell strainer and analysed using an 
LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were 
analysed using FlowJo software (FlowJo LLC., Ashland Oregon, USA) or 
Flowing software (Perttu Terho, University of Turku, Finland). 
 
2.11 Cell proliferation assayed by EdU incorporation 
followed by immunofluorescence microscopy 
Cells were seeded on coverslips overnight. Next day, EdU solution was added 
directly to the culture media to the final concentration of 10 μM. The EdU 
treated cells were incubated for 30 minutes in a 37 °C, 5% CO2 incubator. 
Following the EdU treatment, cells were fixed with 4% formaldehyde solution 
in 1X PBS for 10 minutes in the dark at room temperature. The fixed cells were 
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washed with 1X PBS three times for 5 minutes each wash. Cells were then 
permeabilised by incubating in 0.5% Triton-X100 in 1X PBS for 10 minutes at 
37 °C. The permeabilised cells were washed with 1X PBS twice for 1 minute 
each wash followed by a wash with 3% BSA in 1X PBS for 2 minutes. 
Invitrogen Click-iT EdU cell proliferation kit (Thermo Fisher Scientific, 
Waltham, MA, USA) was used to stain EdU positive cells. 500 µl of the Click 
Reaction cocktail (430 µl of 1X Click-iT reaction buffer, 20 µl of CuSO4, 1.2 µl 
Alexa Fluor 647 azide and 50 µl of 1X reaction buffer additive) was added onto 
the coverslips containing the fixed and permeabilised cells and incubated for 
30 minutes in the dark at room temperature. This was followed by a 2-minute 
wash with 3% BSA in 1X PBS. Cells were then counterstained with 2 µg/ml 
DAPI in 1XPBS for 20 minutes in the dark at room temperature. Following two 
5-minute washes with 1X PBS remove excess DAPI, cells on the coverslips 
were mounted on Superfrost microscope slides using Prolong Gold antifade 
mountant. Slides were imaged and quantified according to the 
immunofluorescence microscopy method described in the sections 2.8 and 
2.9.  
 
2.12 Lentiviral transduction 
2.12.1 p53 and p16 shRNA constructs 
p53 and p16 shRNA sequences (shp53 and shp16 respectively) were acquired 
from several publications and the RNAi consortium database (Table 2.4). An 
shRNA sequence to luciferase (shLuc) was used as a non-targeting shRNA 
control. Based on these sequences, custom DNA oligos corresponding to the 
shRNA sequences were designed; a 5’ AgeI overhang (CCGG) and a 3’ 
termination sequence (TTTTT) were added to the top oligo and a 5’ EcoRI 
overhang (AATT) preceding the complementary sequence of the termination 
sequence (AAAAA) was included into the bottom oligo. These DNA oligos 
were custom made by Sigma-Aldrich and reconstituted in dH2O. 11.25 µl of 
the top and bottom oligos were mixed with 2.5 µl of 10X annealing buffer (1 M 
NaCl and 100 mM Tris-HCl pH 7.4) and annealed using a thermal cycler by 
heating the mixture to 95 °C for 5 minutes, cooling to 25 °C at 0.1 °C/s  followed 
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by 10 minute incubation at 25 °C. This produced a double stranded DNA ready 
for ligation into a vector digested with AgeI and EcoRI. These shRNA-
corresponding sequences were diluted 1:400 in 0.5X annealing buffer and 
ligated with either a pLKO-IPTG-3XLacO or pLKO.1-hygro plasmids digested 
with  AgeI and EcoRI before subsequent lentiviral packaging and transduction 
into target cells. 
 
2.12.2 Cloning of the hPOT1-hTERT fusion into a lentiviral 
vector 
The insert of the pBABE-Puro-hPOT1-hTERT plasmid, a gift from Christopher 
M. Counter (Armbruster et al., 2004), was PCR amplified using the primers 
with AttB1/B2 overhangs (Table 2.2) and Q5 high-fidelity DNA polymerase 
(New England Biolabs, Ipswich, MA, USA) to create the hPOT1-hTERT fusion 
sequence flanked by the AttB1 and AttB2 sites for cloning into a Gateway 
cloning-compatible plasmid according to the manufacturer’s instructions 
(Table 2.1). The amplified fragment was run on a 0.8% agarose gel to confirm 
the size (5455 bp), excised from the gel and purified with a Qiaquick gel 
extraction kit according to the manufacturer’s instructions (QIAGEN, Hilden, 
Germany). The amplified AttB1-hPOT1-hTERT-AttB2 insert was cloned into 
pDONR211 Gateway entry plasmid using the Gateway BP clonase II enzyme 
mix (Thermo Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s instructions, converting the pDONR211 into a pENTR-hPOT1-
hTERT. The insert of the pENTR-hPOT1-hTERT plasmid was cloned into a 
pLENTI6/V5-DEST Gateway destination plasmid using Gateway LR clonase II 
enzyme mix (Thermo Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s instructions, converting the pDONR211 into a pLENTI6-
hPOT1-hTERT plasmid ready for lentiviral packaging. The integrity of the 
inserts in pBABE-Puro-hPOT1-hTERT, pENTR-hPOT1-hTERT and pLENTI6-
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Table 2.1 PCR conditions for AttB1-hPOT1-hTERT-AttB2 amplification 
Step Temperature Time Cycles 
Initial denaturation 98 °C 1 minute 1 
Denaturation 98 °C 10 seconds 
30 Annealing 66 °C 20 seconds 
Extension 72 °C 1 minute and 30 seconds 
Final Extension 72 °C 2 minutes 1 
 
 
2.12.3 Viral packaging and delivery of lentiviral constructs 
2.5 x 106 HEK293T cells were seeded into 10 ml of the DMEM media in a 10-
cm dish. 2-days after the seeding, the following plasmids were transfected into 
the HEK293T cells via the calcium phosphate method: 1 µg of pMD-HIV1-
Gag/Pol plasmid, 1 µg of pRSV-Rev plasmid, 2 µg of pMD2.G-VSVG plasmid 
and 20 μg lentivector plasmid (e.g., pLKO-puro-shp53-1, pLENTI6-hPOT1-
hTERT etc.). Following an overnight incubation, the medium containing the 
transfection reagent was replaced with a fresh medium and cells were 
incubated for another 24 hours for viral production. Virus-containing media 
were harvested and centrifuged at 300 RCF for 3 minutes at room temperature 
to remove any dislodged cells. The supernatant with the virus was filtered 
through a 0.45 µm polyethersulfone (PES) syringe filter, supplemented with 8 
µg/ml Polybrene and directly transferred to a T75 culture flask containing the 
target cells which had its media removed. Fresh DMEM media were added 
back to HEK293T cells following the harvesting of the lentiviral supernatant. 
After the incubation for another 24 hours, the harvesting process and lentiviral 
transduction of the target cells was repeated one more time. Selection of the 
positive cells was performed by a treatment with either 2 µg/ml Puromycin,       
5 µg/ml Blasticidin or 100 µg/ml Hygromycin, according to the mammalian 
antibiotic resistance marker of the lentivector plasmid used. 
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2.13 DNA oligonucletides 
All DNA oligonucleotides were synthesized by Sigma-Genosys, Haverhill, 
United Kingdom unless otherwise stated. 
Table 2.2 DNA oligonucleotides used in this study as primers 
Primer Description Sequence 5' → 3' Source 
attB1-hPOT1-
hTERT-F2 Primers with attB 














For sequencing of 
hPOT1-hTERT  
AAGTGGACGGAGCATCATTTC This study 
hPOT1-Seq-1-R TTTGTAGCCGATGGATGTGAC This study 
hPOT1-Seq-2-F TCAGTCTGTTAAACTTCATTGCCC This study 
hPOT1-Seq-2-R ATGTGGAACTTCTTGCAGCAAATG This study 
hPOT1-Seq-3-F AAATTGATGCATATCCGTGGTTGG This study 
hPOT1-Seq-3-R ATGACTTGATGAAGCATTCCAACC This study 
hTERT-Seq-1-F TGCAGAGCGACTACTCCAGCTATG This study 
hTERT-Seq-1-R AGGCTGTTCACCTGCAAATC This study 
hTERT-Seq-2-F CTGAGCTGTACTTTGTCAAGGTGG This study 
hTERT-Seq-2-R CTGGAGGTCTGTCAAGGTAGAG This study 
hTERT-Seq-3-F GCTTCCTCAGGAACACCAAG This study 
hTERT-Seq-3-R TTTGAAACGTGGTCTCCGTGAC This study 
hTERT-Seq-4-F CTCCTTCCTACTCAGCTCTC This study 
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hTERT-Seq-4-R GCCTGGAACCCAGAAAGATG This study 
pLKO-shRNA-
Seq-1 











ACCCAGAGAGGGCCTATTTC This study 
pLKO-shRNA-
Seq-3 
CTCTGCTGTCCCTGTAATAAAC This study 
pLKO-shRNA-
Seq-4 
GGACTATCATATGCTTACCGTAAC This study 
pLKO-shRNA-
Seq-5 
TGGATGAATACTGCCATTTGTCTC This study 
pBABE-Seq-F 













M13 (-21) M13 Forward primer  TGTAAAACGACGGCCAGT 
Applied 
Biosystems 





TGGACCTTTCAGCACCATTTCT This study 
hPOT1-hTERT-
R1 





GCCAAGCCTTTGTCTCAAGAAG This study 
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Table 2.3 DNA oligonucleotides used in this study to make the 
constructs for shRNA expression 
shRNA 
Oligo 
Description Target Sequence 5' → 3' Source 
shp53-1-
TOP 
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Table 2.4 Primary antibodies used in this study 
Antigen Host Clone Application Dilution Supplier 
Catalog 
number 
β-Tubulin Mouse TUB 2.1 WB 1:3000 Sigma-Aldrich T4026 




FLAG Mouse M2 WB 1:1000 Agilent 200472-21 
GAPDH Rabbit Polyclonal WB 1:3000 Abcam  ab9485 
ɣH2AX (S139) Mouse JBW301 IF 1:1000 Millipore 05-636 








Lamin B1 Rabbit Polyclonal WB 1:1000 Abcam  ab16048 
















TRF-2 Rabbit Polyclonal IF 1:250 
Novus 
Biologicals NB110-57130 
TERT Rabbit Y182 WB 1:1000 Abcam ab32020 
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2.15 Plasmid vectors 
Table 2.5 Plasmid vectors 
Plasmid name Description Source 
pBABE-hPOT1-hTERT Retroviral expression of hPOT1-hTERT 
(Armbruster et al., 2004) 
(Christopher Counter) 
pDONR221 Gateway™ donor plasmid Invitrogen/Thermo-Fisher 
pENTR-hPOT hPOT1-hTERT Gateway™ entry plasmid This study 
pLENTI6/V5-DEST 
Lentiviral expression vector Gateway™ 
destination plasmid 
Invitrogen/Thermo-Fisher 
pLENTI6-hPOT1-hTERT Lentiviral expression of hPOT1-hTERT This study 
pLKO-puro-IPTG-3xLacO 




IPTG-inducible expression of shRNA to 
knockdown p53 (type 1) 
This study 
pLKO-IPTG-shp53-2 
IPTG-inducible expression of shRNA to 
knockdown p53 (type 2) 
This study 
pLKO-IPTG-shp16-1 
IPTG-inducible expression of shRNA to 
knockdown p16 (type 1) 
This study 
pLKO-IPTG-shp16-2 
IPTG-inducible expression of shRNA to 
knockdown p16 (type 2) 
This study 
pLKO-IPTG-shp16-3 
IPTG-inducible expression of shRNA to 
knockdown p16 (type 3) 
This study 
pLKO-IPTG-shp16-4 
IPTG-inducible expression of shRNA to 
knockdown p16 (type 4) 
This study 
pLKO.1 hygro Constitutive shRNA expression plasmid Bob Weinberg 
pLKO.1-hygro-shp16-1 
Constitutive shRNA expression to 
knockdown p16 (type 1) 
This study 
pLKO.1-hygro-shp16-2 
Constitutive shRNA expression to 
knockdown p16 (type 2) 
This study 
pLKO.1-hygro-shp16-3 
Constitutive shRNA expression to 
knockdown p16 (type 3) 
This study 
pLKO.1-hygro-shp16-4 
Constitutive shRNA expression to 
knockdown p16 (type 4) 
This study 
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pMDLg/pRRE 
Lentiviral packaging plasmid for Gag, Pol 
and RRE expression 
(Dull et al., 1998)    
(Didier Trono) 
pMD2.G VSV-G expressing envelope plasmid Didier Trono 
pRSV-Rev Rev cDNA expressing plasmid 
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Chapter 3 Results - A cellular model of 
inducible-degradation of telomerase 
3.1 Introduction 
Telomerase plays an essential role during embryonic development and 
adulthood by maintaining the proliferative capacity of embryonic stem cells and 
adult/somatic stem cells respectively (Hiyama et al., 1996; Morrison et al., 
1996; Wright et al., 1996; Amit et al., 2000; Xu et al., 2001; Wright et al., 2001). 
However, telomerase activity is significantly higher in embryonic stem cells 
compared to adult/somatic stem cells, resulting in a more limited proliferative 
capacity in the latter (Reviewed in (Hiyama and Hiyama, 2007)). On the other 
hand, somatic cells (not stem cells) do not express telomerase or have no 
detectable telomerase activity (Kim et al., 1994; Wright et al., 1996). These 
observations suggest a fine-tuning mechanism of telomerase expression 
regulation and suggest a linear relationship to proliferative capacity/self-
renewal. Furthermore, although telomerase is expressed in ~90% of cancers, 
telomere length of primary cancer cells is shorter compared to the adjacent 
normal somatic cells (Shay and Bacchetti, 1997; Barthel et al., 2017). This 
suggests that telomerase expression in cancer cells is sufficient to counter but 
inadequate to overcome telomere shortening and therefore, maintain 
telomeres at a short length. In contrast, somatic stem and progenitor cells 
cannot maintain telomere lengths during cellular division despite having 
detectable levels of telomerase activity, eventually reaching to senescence as 
reported in cell culture studies (Harley, Futcher and Greider, 1990; Vaziri et 
al., 1994; Hiyama et al., 1996). Therefore, a cell model allowing precise tuning 
of telomerase levels would be very useful for studying the role of telomerase 
in various developmental and pathological disorders, involving variable 
telomerase protein levels. The following chapter will describe the 
characterisation of a human fibroblast cell line expressing telomerase whose 
protein levels can be controlled by fusing a destabilising domain to hTERT 
coding sequence. This cell line was used in this study to investigate the role of 
telomerase in senescence reversal, once senescence is established.  
Investigating the reversibility of senescence 
 Results – A cellular model of inducible degradation of telomerase 
64   
3.2 Establishment of MRC-5 cells expressing hTERT 
fused to a destabilising domain 
To allow a tuneable and reversible control of hTERT protein, a destabilising 
domain (DD) tag derived from a F36V/L106P mutated FKBP12 protein 
(Banaszynski et al., 2006) was utilised by fusing the DD-tag to the N-terminus 
of hTERT. The DD-tag is inherently unstable due to protein misfolding and, 
when fused to another protein, can target it for degradation via the ubiquitin-
proteasome pathway (Egeler et al., 2011). A small molecule ligand called 
Shield-1 could prevent the degradation of the DD-fusion protein by specifically 
binding to the DD-domain, allowing proper folding, and resulting in the 
stabilisation of the tagged protein (Figure 3.1). This process can be reversed 
by addition or removal of Shield-1. The cDNA encoding for the fusion protein 
DD-hTERT was cloned into a pBABE-Neo retroviral vector (pBABE-
DDΔpthTERTNeo) and MRC-5 lung fibroblasts were transduced with the 













Figure 3.1 hTERT fused to a destabilising domain (DD).  
Fusing hTERT to a DD-tag allows reversible stabilisation of hTERT in the 
presence of a Shield-1 ligand. 
 
 
                                                 Investigating the reversibility of senescence 
Results – A cellular model of inducible degradation of telomerase 
  65 
To measure if, in the cellular context, Shield-1 addition could stabilise enough 
DD-hTERT fusion protein to result in detectable telomerase activity, I 
performed a TRAP assay.  MRC-5 DD-hTERT cells were cultured with and 
without 700 nM Shield-1 for 7 days prior to harvesting and analysis by TRAP 
assay (Figure 3.2). Previous observations had indicated that telomerase 
activity measured by TRAP assay reached a plateau above this concentration 
(Katrina Gordon, Stancheva lab, unpublished), suggesting that 700 nM   
Shield-1 is sufficient to achieve maximal stabilisation. Wild-Type MRC-5 (WT) 
cells, which do not express telomerase, and MRC-5 hTERT cells, which 
constitutively overexpress hTERT, were used as negative and positive 
controls, respectively. Whole cell extracts from control cells and MRC-5 DD-
hTERT cells cultured with and without Shield-1 for 7 days were subjected to 
the TRAP assay and the resulting PCR products were analysed onto a 10% 
polyacrylamide gel (Figure 3.2.A). In agreement with absence of hTERT 
expression, WT cells showed no detectable TRAP ladder formation. On the 
other hand, MRC-5 hTERT showed strong TRAP ladder formation, as 
expected from high, constitutive overexpression. MRC-5 DD-hTERT cells 
cultured without Shield-1 showed a substantial reduction of telomerase activity 
to a level only detectable at the highest cell number used (2000 cells). In 
contrast, addition of 700 nM of Shield-1 resulted in a robust increase in 
telomerase activity, comparable to MRC-5 hTERT cells. To assess the rate of 
decrease in telomerase activity following removal of Shield-1, MRC-5 DD-
hTERT cells were cultured without Shield-1 and were harvested at 0, 2, 4- and 
8-days following Shield-1 removal (Figure 3.2.B). Removal of Shield-1 from 
the cell culture media showed progressive reduction in telomerase activity of 
MRC-5 DD-hTERT cells, which reached the lowest level on the eighth day. 
These data suggest (1) A negligible level of background expression of DD-
hTERT in absence of Shield-1; (2) A slow turnover of the fusion protein once 
Shield-1 is removed from the culture media. One week of culture is indeed 
required to achieve to the lowest level of telomerase activity upon Shield-1 
removal.  
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Figure 3.2 Telomerase activity can be modulated by Shield-1 treatment 
in MRC-5 DD-hTERT cells.  
Whole cell extracts obtained from the equivalent of 2000, 400 and 80 cells, 
were used for TRAP assay, from the indicated cell lines. Whole cell extracts 
equivalent to 2000 cells, heated for 10 minutes at 80 °C were used as heat-
inactivated controls “HI”, while buffer control “B” contains the entire reaction 
mix except the cell extract. 10 bp DNA ladder was used as a sizing marker and 
detected separately via EtBr staining. (A) MRC-5 DD-hTERT cells treated with 
Shield-1 for 7 days. (B) Telomerase activity measured in MRC-5 DD-hTERT 
cells following removal of Shield-1 for 2, 4 and 8 days. 
(A) 
(B) 
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To asses if prolonged period of culture could select for cells constitutively 
expressing  hTERT, either via removal of the DD-tag or reactivation of 
endogenous hTERT gene, MRC-5 DD-hTERT cells were cultured with and 
without Shield-1 and harvested at passage 13, 24 and 33. Whole cell extracts 
were subjected to TRAP assay to assess telomerase activity at three different 
passage numbers (Figure 3.3). MRC-5 DD-hTERT cells cultured continuously 
with Shield-1 showed consistent telomerase activity in the three different 
passages tested, comparable to the positive control. This was also the case 
with MRC-5 DD-hTERT cells cultured continuously without Shield-1, where 
telomerase activity is consistently low with increasing passage number 
compared to the positive control. This result suggests that endogenous 
reactivation of telomerase or DD-tag inactivation did not occur following 
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Figure 3.3 No selection for constitutive hTERT expression was observed 
in MRC-5 DD-hTERT cultured without Shield-1 following prolonged 
culture.  
Whole cell extracts of MRC-5 DD-hTERT cells equivalent to 2000, 400 and 80 
cells were used for TRAP assay. MRC-5 hTERT was used as positive control 
for telomerase activity. Heat-inactivated extract “HI” and lysis buffer only “B” 
were used as negative controls. Telomerase activity of MRC-5 DD-hTERT 
cells cultured with Shield-1 (A) and without Shield-1 (B) at passage 13, 24 and 
33 is showed here. 
(A) 
(B) 
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3.3 MRC-5 DD-hTERT cells undergo senescence due 
to shortening of the telomeres 
Although MRC-5 DD-hTERT cells continuously cultured without Shield-1 
(MRC-5 DD-hTERT -Shield-1) show very low telomerase activity compared to 
MRC-5 DD-hTERT cells continuously cultured with Shield-1 (MRC-5 DD-
hTERT +Shield-1), the TRAP assay detects persistent low-levels of hTERT 
activity in the former. As one of the aims of this project is to investigate whether 
telomerase reactivation could promote escape from cellular senescence, it 
was crucial to asses if the background level of DD-hTERT activity in absence 
of Shield-1 would be sufficient to prevent senesce. To investigate whether 
MRC-5 DD-hTERT -Shield-1 cells could undergo senescence, cumulative 
population doublings (CPD) was measured in MRC-5 DD-hTERT cells cultured 
with and without Shield-1 up to 190 days in three separate replicate cultures 
(Figure 3.4). MRC-5 DD-hTERT +Shield-1 cells showed a constant increase 
of CPD throughout the 190 days of culture, indicating that these cells do not 
undergo senescence. There is some variability in the rate of growth measured 
for the triplicate MRC-5 DD-hTERT cells + Shield-1 (Fig. 3.4).  One possible 
explanation is that prolonged culture could have led to selection of a mutated, 
faster growing sub-clone, at least in one case. However, these cells become 
contaminated by mycoplasma during the prolonged culture. I treated them at 
different time points with BM-Cyclin (Roche, Basel, Switzerland) to eliminate 
the contamination without interrupting the experiment. However, this has 
introduced a variable that could explain the differences in growth rate. The two 
cultures that have slower growth rate, suffered from persistent mycoplasma 
infection, which require longer treatment compared to the faster growing 
culture. More importantly, however, MRC-5 DD-hTERT -Shield-1 cells showed 
a decrease in the rate of CPD compared to MRC-5 DD-hTERT +Shield-1 at 
approximately 35 PD. Furthermore, the population doubling curve showed a 
gradual flattening from 40 - 47 PD (~100-190 days in culture) which suggests 
that these cells were ceasing cell division.  
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Figure 3.4 MRC-5 DD-hTERT cells cultured without Shield-1 undergo 
growth arrest at 40 - 47 PD.  
Calculated cumulative population doublings of three replicates of MRC-5 DD-
hTERT cells cultured with or without Shield-1 for 190 days. 
 
 
To confirm that the growth arrest was due to replicative senescence, telomere 
length and senescence were examined in these cells by TRF Southern blot 
and senescence-associated β-galactosidase (SA-β-gal) staining, respectively. 
MRC-5 DD-hTERT cells were continuously cultured with and without Shield-1, 
harvested at 5, 15, 25 and 35 PD and subjected to TRF Southern blot (Figure 
3.5). The results showed that +Shield-1 cells have a constant mean telomere 
size of 8 kb. In contrast, -Shield-1 cells showed decreasing mean telomere 
size, from 8 kb at 5 PD to 4.5 kb at 35 PD. MRC-5 hTERT control cells maintain 
a stable mean telomere length of 10 kb, while I could not measure telomere 
length in MRC-5 WT cells, presumably due to a very weak signal caused by 
high variability of telomere lengths. These results confirmed that telomere 
shortens with increasing population doublings in MRC-5 DD-hTERT cells 
cultured without Shield-1 but not in cells cultured with Shield-1, supporting the 
idea that growth arrest observed between 40 to 47 PD could be due to critically 
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short telomeres. From 25-35 PD, average size of telomeres of MRC-5            
DD-hTERT -Shield-1 seems to have plateaued at ~4.5 kb. Therefore, due to 
this observation and technical consideration involved in obtaining sufficient 
DNA for the fluorescent TRF southern blotting (30 µg) in non-dividing cells, 
telomeres at 40-47 PD were not measured. To further verify the hypothesis 
that MRC-5 DD-hTERT -Shield-1 cells undergo senescence at 40-47 PD, I 
have quantified the fraction of the population that has entered senescence in 
MRC-5 DD-hTERT +/- Shield-1 cells at 70 and 47 PD respectively. Both of the 
MRC-5 DD-hTERT +/-Shield-1 have been cultured in parallel from the start 
and by the time -Shield-1 cells were fully arrested, the +Shield-1 cells have 
reached 70 PD. By measuring senescence-associated β-galactosidase activity 
(SA-β-Gal), it appears that 75% of -Shield-1 cells at 47 PD and 9% of +Shield-
1at 70 PD have entered senescence (Figure 3.6). Together, telomere 
shortening and entry into senescence, suggest that growth arrest at ~40 PD of 
MRC-5 DD-hTERT cells -Shield-1 is due to the presence of enough critically 
short telomeres to trigger the DNA damage response and consequent growth 
arrest, consistent with previous reports (Bodnar et al., 1998; d’Adda di 
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Figure 3.5 Telomeres of MRC-5 DD-hTERT cells shorten with each 
population doubling in the absence of Shield-1.  
MRC-5 DD-hTERT cells cultured with or without Shield-1 were harvested at 5, 
15, 25 and 35 population doublings (PD) and subjected to TRF Southern blot. 
MRC-5 WT and MRC-5 hTERT cells were used as controls for short and long 
telomeres, respectively. 1 Kb DNA ladder was used as size marker (M) and 
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Figure 3.6 The majority of the cells in MRC-5 DD-hTERT -Shield-1 cultures 
have entered senescence by ~47 PD 
Senescence was assayed by SA-β-gal assay in MRC-5 DD-hTERT     +Shield-
1 (~70 PD) and -Shield-1 (~47 PD) cells. (A) Representative images.                
(B) Quantification of SA-β-gal positive cells (mean of 3 experiments). Error 




The results of the initial experiments presented above, aimed at characterising 
MRC-5 DD-hTERT cell line, support its suitability to investigate the role of 
telomerase in reversing entry into senescence. DD-hTERT fusion protein is 
fully functional, as indicated by the fact that MRC-5 DD-hTERT cells cultured 
with Shield-1 behaved similarly to MRC-5 hTERT, in that they are both capable 
of prolonged survival in culture, far surpassing the proliferation capability of 
MRC-5 WT cells. Moreover, fusing the DD domain to hTERT allows efficient 
control of hTERT levels, as shown by the fact that removal of Shield-1 from 
the culture media results progressive telomere shortening and cells 
undergoing senescence at 40-47 PD. Interestingly, the background levels of 
telomerase activity measured in MRC-5 DD-hTERT -Shield-1 cells could be 
similar to the low, basal levels of telomerase activity in some adult/ somatic 
***
(A) (B) 
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stem cells, which extend proliferation potential compared to somatic cells, but 
are insufficient to prevent cellular senescence (Kim et al., 1994; Hiyama et al., 
1996). To investigate this further, MRC-5 DD-hTERT cells could be treated 
with varying concentrations of Shield-1 to test the correlation of telomerase 
activity with Shield-1 concentration and compare this to telomerase activity in 
various stem cells. This could also assist in elucidating the hTERT or 
telomerase cellular levels that is required for immortality in stem cells and 
cancers. 
 
I have shown that 8 days of culture in the absence of Shield-1 is required to 
reach a low level of telomerase activity, comparable to the background. The 
slow kinetics of destabilisation of the fusion protein could be influenced by 
some Shield-1 remaining within the cell upon removal from the culture 
medium. Treating the cells with purified F36V DD protein would allow a more 
rapid removal of Shield-1 from the cells by competitive binding of Shield-1 
ligands to F36V DD protein (Egeler et al., 2011). Although this approach could 
improve the kinetics of destabilisation, it would not solve the issue of residual 
DD-hTERT remaining in absence of Shield-1. In the original experiment where 
a YFP reporter protein was fused to the FKBP L106P DD domain, basal levels 
of YFP expression at 1-2% of DD-YFP in the absence of Shield-1 (Banaszynski 
et al., 2006) were also detected, indicating that it is not possible to get a 
complete removal of a target protein using this system. Others have also 
confirmed this observation of residual protein levels in the absence Shield-1 
using the FKBP-based DD system (Maji et al., 2017; Qi et al., 2017). This could 
be a disadvantage when studying a protein which only require a small protein 
quantity in order to perform its cellular function. However, this does not appear 
to be the case for hTERT. There are other destabilising domains or degrons 
such as the ecDHFR DD (Iwamoto et al., 2010) and the Auxin-inducible 
Degron (AID) (Nishimura et al., 2009), which are based on engineered mutants 
of Escherichia coli dihydrofolate reductase and the Arabidopsis thaliana Auxin 
responsive protein IAA7 complemented with Oryza sativa TIR1 respectively,  
that could be used as an alternative to the FKBP-based DD system with 
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regards to the current protein and cell of interest. Latest improvements in these 
DD/Degron systems have made it possible to further minimise the basal 
protein levels in the absence of ligand (Shield-1 and Trimethoprim (TMP) for 
FKBP and ecDHFR DD respectively) (Kogenaru and Isalan, 2018) or the 
inefficient protein depletion in the presence of Auxin in the case with the AID 
system (Li et al., 2019). 
 
Finally, my experiments show that MRC-5 DD-hTERT -Shield-1 cells undergo 
growth arrest ~15 PD later than MRC-5 WT cells (Gordon et al., 2014). This 
discrepancy is potentially explained by the fact that MRC-5 DD-hTERT are 
cultured in the presence of Shield-1 for ~23 PD prior to the start of the extended 
culture experiments. As a consequence, the average telomere length of MRC-
5 DD-hTERT -Shield-1 at the start of the experiment would be longer than for 
MRC-5 WT cells. This hypothesis is confirmed by the TRF southern blot data 
(Figure 3.5) which showed that at 5 PD, the mean telomere length of MRC-5 
DD-hTERT -Shield-1 cells was approximately 8 kb, similar to MRC-5 DD-
hTERT +Shield-1 cells.  
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Chapter 4 Results - Reactivation of telomerase 
cannot induce escape from 
replicative senescence 
4.1 Introduction 
Critically short telomeres activate the senescence program as a consequence 
of the activation of the DNA damage response (DDR). The shortening of 
telomeric overhang and/or decreased quantity of TRF2 at telomeres can result 
in the loss of the T-loop protective structure, exposing telomere ends to be 
recognised as double strand breaks by the DDR (Li et al., 2003; Stewart et al., 
2003; Takai, Smogorzewska and De Lange, 2003; Cesare et al., 2009). 
Accordingly, ectopic expression of the human telomerase catalytic subunit 
hTERT in various non-transformed human cells has been shown to prevent 
replicative senescence and induce immortalisation (Bodnar et al., 1998; 
Counter et al., 1998; Vaziri and Benchimol, 1998). However, it is unclear 
whether expressing telomerase in senescent cells could force them out of 
proliferation arrest, by elongating critically short telomeres and thus switching 
off the DDR. I therefore set out to investigate whether telomerase reactivation 
in MRC-5 DD-hTERT cells is sufficient to force proliferation once senescence 
is established.  
 
4.2 Verification of reactivation of telomerase by 
Shield-1 treatment in senescent cells 
I have previously shown that MRC-5 DD-hTERT cells cultured without     
Shield-1 undergo senescence at 40 - 47 PD (Figure 3.4). Furthermore, I have 
demonstrated that telomerase activity can be modulated by removal/addition 
of Shield-1 to MRC-5 DD-hTERT (Figure 3.2). To verify whether DD-hTERT 
stabilisation in senescent cells would lead to restoration of telomerase activity, 
pre-senescent (~35 PD) and senescent (~42 PD) MRC-5 DD-hTERT -Shield-
1 cells were cultured with or without addition of Shield-1 for 7 days and 
telomerase activity was assessed by TRAP assay. MRC-5 DD-hTERT 
+Shield-1 (~35 and ~42 PD) and MRC-5 hTERT were used as positive controls 
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for telomerase activity. TRAP assay showed low telomerase activity in both 
pre-senescent and senescent MRC-5 DD-hTERT -Shield-1 cells compared to 
the positive controls (Figure 4.1). Furthermore, Shield-1 supplementation to 
both pre-senescent and senescent MRC-5 DD-hTERT -Shield-1 cells showed 
restoration of telomerase activity to both cells, comparable to the positive 
controls. This result confirmed that adding Shield-1 to senescent MRC-5 DD-
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Figure 4.1 Telomerase activity is comparably restored upon Shield-1-
mediated stabilisation of DD-hTERT in both pre- and senescent cells.  
Whole cell extracts from (A) pre-senescent and (B) senescent MRC-5 DD-
hTERT cells, equivalent to 2000, 400 and 80 cells, were subjected to TRAP 
assay and analysed as described previously. HI = heat-inactivated whole cell 
extracts. MRC-5 hTERT whole cell extract was used as a positive control.       
10 bp DNA ladder was used as a sizing marker and detected separately via 
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4.3 Senescent cells remain growth arrested following 
reactivation of telomerase by Shield-1 treatment 
To investigate whether telomerase could reverse senescence, pre-senescent 
(~35 PD) and senescent (~42 PD) MRC-5 DD-hTERT -Shield-1 cells were re-
supplemented with Shield-1 and cultured for 7 days. To assess senescence 
reversal, cell proliferation was measured by immunostaining for Ki-67, a 
proliferative marker (Gerdes et al., 1983; Bruno and Darzynkiewicz, 1992). 
MRC-5 DD-hTERT +Shield-1 cells, which were cultured continuously with 
Shield-1 and harvested at similar PD to the MRC-5 DD-hTERT -Shield-1, were 
used as a positive control for cellular proliferation. Quantification of Ki-67 
positive cells showed that 70% of MRC-5 DD-hTERT +Shield-1 cells were 
proliferating at ~35 PD (Figure 4.2). On the other hand, at similar PD 
(equivalent to pre-senescent cells), the percentage of proliferating cells in 
MRC-5 DD-hTERT -Shield-1 culture was reduced to 60%. This might suggest 
that a small proportion of the cell population had already undergone 
proliferative arrest, possibly due to replicative senescence. Re-
supplementation of Shield-1 to MRC-5 DD-hTERT -Shield-1 increased the 
proportion of proliferating cells to 64%. This suggest that reactivation of 
telomerase was able to prevent entry into senescence for a fraction of the pre-
senescent cell population. At ~42 PD, the proportion of the population of   
MRC-5 DD-hTERT +Shield-1 cells proliferating (67%) was very similar to 35 
PD (70%), indicating that continuous hTERT expression is sufficient to confer 
stable growth. On the contrary, only 3.4% of MRC-5 DD-hTERT -Shield-1 cells 
at ~42 PD were positive for Ki-67, irrespective of Shield-1 being added back 
to the culture medium or not (2.6%, Figure 4.2). This confirmed that the 
majority of cells cultured continuously without Shield-1 at ~42 PD were not 
dividing and possibly had entered senescence.  Reactivation of telomerase by 
adding Shield-1 for 7 days to MRC-5 DD-hTERT -Shield-1 cells at ~42 PD did 
not affect the fraction of Ki-67 positive cells in the population. This result 
suggest that once senescence is established, telomerase reactivation could 
not force cells out of the arrest and therefore could not reverse senescence. 
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Figure 4.2 Stabilisation of hTERT can avoid entry into senescence for 
some pre-senescent cells. 
(A) Representative images of Ki-67 immmunostaining (green) and DAPI (blue). 
Scale bar = 25 µm. (B) Mean number of Ki-67 positive cells. Error bars = SEM 
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Figure 4.3 No proliferation was observed in senescent cells following 
telomerase reactivation for 7 days.  
(A) Representative images of Ki-67 immmunostaining (green) and DAPI (blue). 
Scale bar = 25 µm. (B) Mean number of Ki-67 positive cells. Error bars = SEM 
(n = 3).  
(A) 
(B) 
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As an independent approach, I also quantified the number of proliferating cells 
in MRC-5 DD-hTERT cell population at ~35 and ~40 PD by flow cytometric 
analysis of EdU incorporation (Figure 4.4). EdU is a thymidine analogue 
incorporated into DNA during replication that can be labelled with Alexa Fluor 
647 fluorophore via Click chemistry. In agreement with the data obtained by 
Ki67 immunostaining, in the pre-senescent -Shield-1 cells, there was a 6% 
increase in EdU positive cells following telomerase reactivation. On the other 
hand, no increase was observed in the senescent -Shield-1 cells following 
telomerase reactivation. Overall, the result of the EdU proliferation assay was 
in agreement with the Ki-67 immunostaining, confirming that telomerase is 
















Figure 4.4 Senescent cells cannot be pushed back into proliferation by 
hTERT stabilization.  
Upon treatment with Shield-1 as in Fig. 4.3, cells were pulsed with 10 µM EdU 
for 24 hours and ethanol-fixed. EdU was stained with Alexa Fluor 647 azide 
via click chemistry and DNA counterstained by DAPI. EdU incorporation 
subsequently quantified by flow cytometry.   
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4.4 Prolonged culture of senescent cells in Shield-1 
did not affect proliferation  
To rule out the possibility that the failure to reverse senescence could be due 
to insufficient time in Shield-1, MRC-5 DD-hTERT +Shield-1 cells, -Shield-1 
cells and -Shield-1 cells re-supplemented with shield-1 (+S) were cultured for 
26 days instead of 7, from ~35 PD (Pre-senescent -Shield-1 cells) and from    
~42 PD (Senescent -Shield-1 cells). PD were tracked for both pre-senescent 
and senescent cells by determining the number of cells at seeding and at sub-
culturing and calculating the PD using the formula in chapter 2.2. Cells were 
seeded constantly at 750,000 cells for each passage and passaged/sub-
cultured at 90% confluency (every 3 – 5 days).  After 10-days of culture, pre-
senescent -Shield-1 cells showed a decline of PD rate as compared to 
immortal +Shield-1 cells, suggesting that a small proportion of the cell 
population entered growth arrest (Figure 4.5). Adding Shield-1 to reactivate 
telomerase in the pre-senescent cells was sufficient to avoid the decrease of 
PD rate (Figure 4.5). However, this was not the case when telomerase was 
reactivated in the senescent -Shield-1 cells. Similarly to what was observed for 
shorter culture, addition of Shield-1 and culture for 26 days were not sufficient 
to restore growth. These data suggest that pre-senescent but not senescent 
cells clearly responded to telomerase reactivation. Thus, I have confirmed that 
prolonged telomerase reactivation was unable to force cells to proliferate once 
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Figure 4.5 Prolonged culturing in presence of Shield-1 is not sufficient to 
restore proliferation of senescent cells.  
MRC-5 DD-hTERT +Shield-1 was used as a positive control for proliferating 
cells. MRC-DD-hTERT continuously cultured without Shield-1 (-Shield-1) were 
cultured without or with Shield-1 (+S) for 26 days and the calculated PD is 
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4.5 Effect of telomerase reactivation on pathways 
regulating senescence growth arrest 
Lack of senesce reversal upon telomerase re-expression could be explained 
in two different ways. Stabilised DD-hTERT could be able to elongate critically 
short telomeres and shut down the DDR, but the cells could have reached a 
stable arrest, independent of the DDR. Alternatively, stabilised DD-hTERT 
cannot elongate critically short telomeres and therefore is unable to switch off 
the DDR. To distinguish between these hypotheses, I have analysed the 
expression of DDR components responsible for the induction of cell cycle 
arrest in senescent cells treated for 7 days with Shield-1. In general, p53 
transcription factor and p16 cyclin dependent kinase inhibitor are associated 
with the activation and possibly maintenance of senescence.  Senescent cells 
showed slightly lower p53 levels compared to proliferating cells, in agreement 
with the reduced levels of p53 downstream target p21. On the other hand, p16 
levels were higher in senescent cells compared to proliferating cells. This 
suggests that proliferative arrest in MRC-5 DD-hTERT is mainly maintained by 
p16. In both proliferating and senescent cells, stabilisation of hTERT via 
Shield-1 treatment did not affect p53, p16 and p21 protein levels, suggesting 
that telomerase reactivation could not influence DDR signalling responsible for 
activation and maintenance of senescence. These data suggest that stabilised 
hTERT cannot elongate critically short telomeres in senescent cells or that 
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Figure 4.6 Telomerase reactivation does not affect p53, p21 and p16 
levels.  
Proliferating and senescent MRC-5 DD-hTERT cells cultured with and without 
Shield-1 were subjected to Western blot and probed with antibodies against 
p53 (53 kDa), p21 (16 kDa), p16 (16 kDa) and GAPDH (37 kDa). GAPDH was 
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4.6 Discussion 
One of the key hallmarks of cancer is cellular immortality. The importance  of 
telomerase reactivation to achieve the indefinite proliferative potential of 
cancer cells is well recognised (Kim et al., 1994; Hanahan and Weinberg, 
2011). Activation of telomerase has been shown to prevent replicative 
senescence and support proliferation of human endothelial and human primary 
colorectal carcinoma cells in vitro (Yang et al., 1999; Dalerba et al., 2005). 
Replicative senescence is defined as growth arrest resulting from DNA 
replication-induced telomere attrition. Therefore, telomerase should in theory 
be able to reverse replicative senescence by elongating telomeres. However, 
it has been previously reported that ectopic telomerase expression in 
replicatively senescent WI-38 and BJ fibroblasts is insufficient to rescue cell 
cycle arrest induced by the senescence program (Beauséjour et al., 2003). On 
the contrary, however, it has also been reported that telomerase expression 
could prevent oncogene induced senescence (OIS) in cells expressing 
oncogenic RAS and promotes reversal/escape from OIS (Suram et al., 2012; 
Patel et al., 2016). Although upregulation of telomerase was observed in cells 
that spontaneously escaped OIS, this does not prove that telomerase was 
responsible for bypassing the cell cycle arrest signalling associated with OIS.   
 
p53-p21 and p16-pRb pathways have been shown to link the DDR to the 
induction of senescence (Shay, Pereira-Smith and Wright, 1991; Beauséjour 
et al., 2003). In my experiments, the inability of telomerase expression in 
senescent cells to reverse the growth arrest indicates that probably the DDR 
is still active, suggesting that telomeres are not being elongated (Figure 4.6). 
Moreover, aside from its role in telomere lengthening, it has also been 
suggested that TERT could have non-canonical roles in regulating cellular 
proliferation via Wnt/β-catenin or NFκB signalling pathways (Choi et al., 2008; 
Park et al., 2009; Ghosh et al., 2012; Ding et al., 2013). The results shown in 
this chapter suggest that hTERT stabilised in senescent cells was either 
unable of performing these non-canonical roles or that these functions are 
insufficient to abrogate senescence and restore cell proliferation. 
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The action of telomerase at telomeres has been known to be restricted to the 
S-phase of the cell cycle (Wright et al., 1999; Tomlinson et al., 2006; Jády et 
al., 2006). This was thought to be caused by increased accessibility of 
telomeres at S - G2/M phase of the cell cycle and association of telomerase 
activity at telomeres with the replication machinery required for telomeric         
C-rich strand replication (Verdun et al., 2005; Jády et al., 2006). Recent 
progress in the field have also shown that this was possibly due to the 
requirement of TCAB1-mediated G1/S recruitment of the telomerase 
holoenzyme complex to Cajal body, prior to trafficking to telomeres (Venteicher 
et al., 2009; Vogan and Collins, 2015). TPP1, which is known to recruit 
telomerase to telomeres, has been also shown to undergo S - G2/M specific 
phosphorylation at S111, potentially explaining the S-phase restriction of 
telomerase action at telomeres (Wang et al., 2007; Xin et al., 2007; Zaug et 
al., 2010; Zhang et al., 2013). Senescent cells have been shown to undergo 
cell cycle arrest predominantly in G1. Due to S-phase specific action of 
telomerase at telomeres, G1 cell cycle arrest in senescent cells could prevent 
telomerase to gain access to telomeres. Unfortunately, due to the unavailability 
of markers/tags for specific detection of DD-hTERT, I was unable to confirm 
the subcellular localisation of telomerase holoenzyme complex. As the TRAP 
assay indicates that DD-hTERT re-expressed in senescent cells is active,  we 
can speculate that the telomerase complex is properly assembled, and is 
potentially localised in the nucleolus (Lee et al., 2014), as recruitment to Cajal 
bodies requires TCAB1 and is S-phase specific (Vogan and Collins, 2015). A 
TERT antibody (Abcam ab32020), which was successfully used for Western 
blots in this study could possibly be used to analyse DD-hTERT sub-cellular 
localisation. Alternatively, the TRAP assay results could be explained by the 
formation of an active telomerase complex in vitro, prior to assay. In vitro 
assembly of the telomerase holoenzyme has been previously reported 
(Weinrich et al., 1997; Masutomi et al., 2000), and lysing the cells may have 
abolished the distinct subnuclear localisation of hTR and hTERT, which 
prevent telomerase holoenzyme assembly in the senescent cells. 
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Chapter 5 Results - Pharmacological inhibition 
of p53 together with telomerase 
activation in senescent cells 
5.1 Introduction 
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor gene 
encoding for a transcription factor that acts as a crucial hub to control the 
activation of DDR, DNA repair, apoptosis (cell death) and senescence 
(permanent cell cycle arrest) genes. The DDR is a very complex molecular 
signalling cascade, initiated by sensor proteins detecting  damaged DNA, such 
as the MRN complex and KU70/80, ATM, ATR and DNA-PK kinases that 
generate a diffusible signal, amplified by intermediate transducers such as 
CHK1 and CHK2, and effector proteins such as p53 and/or p16. These 
effectors have the role of coordinating the type of cellular responses, inducing 
a temporary or permanent cell cycle arrest, depending on the severity of the 
damaged cells (Reviewed in (Jackson and Bartek, 2009; Ciccia and Elledge, 
2010)). A persistent activation of the DDR is required for the activation of 
cellular senescence and p53 plays an important role in senescence activation 
(Herbig et al., 2004; Fumagalli et al., 2012; Suram et al., 2012). p53 chronic 
activation leads to a persistent activation of the G1/S checkpoint, that blocks 
damaged cell from entry into S-phase. However, the role of p53 in 
maintenance of senescence is unclear. For example, inhibition of p53 using 
GSE-22 peptide is sufficient to abrogate senescence-associated cell cycle 
arrest and proliferation arrest in senescent BJ fibroblasts. However, WI38 
fibroblasts cannot escape senescence upon p53 inhibition (Beauséjour et al., 
2003). The differences in the response to p53 inhibition of these two cell lines 
is thought to be due to a cell-line intrinsic variability in the roles that the p53-
p21 or p16-pRb pathways play in response to senescence-inducing stimuli. 
Interestingly, in MEFs, although both CDK inhibitors p21 and p16 are 
expressed during senescence, shRNA mediated knockdown of p53 is 
sufficient to abrogate senescence growth arrest (Dirac and Bernards, 2003). 
These reports confirm that there are variations in senescence maintenance 
pathways in cells with different genetic backgrounds. In the previous results 
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chapter, I have shown that the addition of Shield-1 to senescent MRC-5 DD-
hTERT cells resulted in restoration of telomerase activity in these cells. 
However, this was insufficient to relief cell cycle arrest and reverse 
senescence. One of the reasons for this result could be that DD-hTERT cannot 
gain access to telomeres as cells do not enter S-phase due to persistent p53 
signalling. In order to test this hypothesis, I decided to transiently inhibit p53, 
just enough to allow entry into S-phase. In order to set up a tightly controllable 
p53 inhibition, I choose to employ a p53 inhibitor Pifithrin-α,  a compound 
initially discovered in a screening for inhibitors of p53-dependent 







Figure 5.1 Chemical structure of Pifithrin-α.  
Small molecule inhibitor of p53 [2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-
yl)-1-p-tolylethanone] or Pifithrin-α (Image taken from Komarov et al., 1999) 
 
 
5.2 Pifithrin-α downregulates p53 and its downstream 
target p21 
Pifithrin-α (PFT-α) is a small molecule inhibitor found to inhibit p53 and its 
downstream transcriptional target p21 (Komarov et al., 1999). To test PFT-α 
inhibition in MRC-5 WT and MRC-5 DD-hTERT, cells were cultured with          
10 µM of PFT-α for 1, 24 and 72 hours (Komarov et al., 1999). Treated cells 
were harvested, lysed in RIPA buffer and protein extracts were analysed for 
p53 and p21 levels. In MRC-5 WT cells, no noticeable decrease of p53 protein 
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levels was observed from 1 to 72 hours of treatment. On the other hand, there 
was a clear reduction in p21 protein levels particularly after 72 hours of 
treatment in the WT cells. Reduction in basal p53 were much more evident in 
MRC-5 DD-hTERT compared to MRC-5 WT cells. This was possibly due to 
higher basal p53 protein expression in MRC-5 DD-hTERT cells. Although p21 
is expected to decrease concomitant with decrease in p53 levels, it is unclear 
whether there is a decrease in p21 levels in MRC-5 DD-hTERT cells treated 
with PFT-α. Overall, these western blots showed that PFT-α was capable of 








Figure 5.2 p53 and p21 downregulation was observed upon treatment 
with PFT-α for 72 hours.  
MRC-5 WT and MRC-5 DD-hTERT cells were treated with 10 µM PFT-α and 
were subjected to Western blotting to detect p53, p21 and GAPDH (Loading 
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5.3 Senescent cells treated with Pifithrin-α remain 
growth arrested 
Having validated PFT-α as a p53 inhibitor in my cells, I proceeded to test if 
PFT-α mediated inhibition of p53 in combination with telomerase reactivation 
can abrogate proliferation arrest and reverse senescence. Proliferating and 
senescent MRC-5 DD-hTERT cells at similar PD (~42 PD) were cultured for 7 
days in the presence or absence of 10 µM PFT-α, in combination with 700 nM 
Shield-1. Media containing PFT-α plus Shield-1 or Shield-1 alone were 
replaced every 2 days to maintain the concentration of both chemicals in 
culture. SA-β-gal staining was used to assess the proportion of cells that have 
reversed senescence. In proliferating cells, no significant difference was 
observed in the small proportion (~ 1 %) of SA- β-gal positive stained cells in 
PFT-α treated compared to untreated cells (Figure 5.3). Similarly, treatment 
with PFT-α of senescent cells also did not affect the high proportion (~ 90%) 
of SA- β-gal positive stained cells in comparison with untreated cells.  In a 
parallel experiment, I independently assessed reversion of senescence arrest 
by monitoring cell proliferation by cell count. Cells were cultured for 7 days in 
the presence or absence of 10 µM PFT-α, in combination with 700 nM     
Shield-1. Cells were counted at seeding (day 0), at day 4 and at day 7 for 
proliferating cells and at seeding and day 7 for senescent cells. This is to 
account for the differences in proliferation between both cell types. As 
expected, both proliferating cells, with and without PFT- α, showed increasing 
cell number across the 7-day time point (Figure 5.4). There was a slight 
increase in the number of cells counted at day 7 in the treated fraction. 
However, as this experiment was only performed once, I could not confirm 
whether the slight difference observed in the proliferating cells at day 7 was 
due to PFT-α treatment. However, both assays show that treatment of 
senescent cells with PFT-α is not sufficient to reverse senescence, irrespective 
of DD-hTERT stabilisation. In conclusion, these data suggest that PFT-α 
mediated p53 inhibition in combination with telomerase was unable to 
abrogate growth arrest and senescence in senescent MRC-5 DD-hTERT cells. 
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Figure 5.3  PFT-α in combination with telomerase-reactivation was 
unable to reverse senescence.  
(A) Quantification of senescent cells in the population by SA-β-Gal staining. 
Representative images from brightfield microscopy are shown. (B) 
Quantification of SA-β-Gal positive MRC-5 DD-hTERT cells treated with and 
without 10 µM PFT-α in combination with 700 nM Shield-1 to re-activate 
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Figure 5.4  PFT-α in combination with telomerase-reactivation was 
unable to abrogate proliferation arrest of senescence MRC-5 DD-hTERT 
cells.  
Proliferating and senescent MRC-5 DD-hTERT cells were both cultured in 
media containing Shield-1, in the presence or absence of PFT-α for 7 days. 
Cells were counted with a haemocytometer at day 0, 4 and 7 for proliferating 
cells and at day 0 and 7 for senescent cells. 
 
 
5.4 Pifithrin-α was unable to inhibit p53 function in 
DNA damage response 
The conclusion that p53 inhibition is insufficient to reverse senescence, even 
upon DD-hTERT stabilisation relies on the efficacy of PFT-α mediated p53 
inhibition. However, a report from the same group that had discovered PFT-α 
has shown that PFT-α does not target p53 specifically (Komarova et al., 2003). 
As p53’s role during induction of senescence is related to its function within 
the DDR, it is important to verify if PFT-α is in fact able inhibit p53 function in 
the context of DDR. I therefore treated MRC-5 WT or DD-hTERT cells with 
mitomycin-C (MMC) in the presence/absence of PFT-α. MMC is a DNA 
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crosslinking agent which activates the p53 DDR response and upregulate p21. 
Treatment with MMC increased p53 and p21 levels particularly in DD-hTERT 
cells. However, PFT-α was unable to prevent damage-dependent p53 
upregulation, suggesting that PFT-α is does not efficiently inhibit p53 function 
during the DDR. This result suggests that PFT-α could inhibit p53 indirectly. 
Consequently, the inability of PFT-α treatment to reverse senescence in the 
experiments described in the previous paragraph is inconclusive, leaving open 










Figure 5.5  PFT-α was unable to inhibit p53 and p21 upregulation by the 
DDR pathway.  
Western blot for p53 and p21 in MRC-5 WT and MRC-5 DD-hTERT cells 
treated with 5 µM of Mitomycin C in combination with 10 µM PFT-α. Treatment 
was done for 6 hours and 24 hours for MRC-5 WT and MRC-5 DD-hTERT 
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5.5 Discussion 
The experiments described in this chapter were aimed at investigating whether 
restoring entry into S-phase in senescent cells could be sufficient to grant 
stabilised DD-hTERT access to critically short telomeres. Elongation and 
restoration of functional telomeres could have led to shutting down of the DDR 
responsible for the maintenance of growth arrest. In order to allow entry into 
S-phase, I inhibited p53, which controls one of the two key pathways leading 
to the establishment of growth arrest during senescence. The results 
presented show that inhibition of p53 using PFT-α, with or without of Shield-1, 
in senescent MRC-5 DD-hTERT cells was not able to reverse senescence.       
I proposed that there are at least three possible explanations for this result: (1) 
PFT-α does not effectively inhibit p53, (2) PFT-α does not specifically target 
p53, (3) Inhibition of p53 alone is not sufficient to abrogate the senescence 
activated cell cycle arrest. I have shown that PFT-α does decrease p53 levels 
in proliferating MRC-5 DD-hTERT cells, ruling out that the inhibitor is generally 
ineffective. However, I have also shown that PFT-α is unable to prevent DNA 
damage-dependent p53 upregulation and therefore, presumably, ineffective at 
preventing p53-dependent DDR. As a consequence, as p53 function in the 
induction of senescence is tightly coupled with the role in the DDR, my results 
could indicate that PFT-α is not the right tool to manipulate p53 function in this 
context. The molecular basis of PFT-α dependent p53 inhibition is largely 
unknown and there are contrasting data in the literature about its efficacy and 
specificity, for example in the context of heat shock response (Komarova et 
al., 2003; Murphy et al., 2004). It was also proposed that PFT-α can act as an 
aryl hydrocarbon receptor agonist, similar to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCCD) but with much lower efficacy compared to TCCD (Hoagland, 
Hoagland and Swanson, 2005). Overall, these data render the interpretation 
of my results very difficult. Alternatives to pharmacological inhibition of p53 
would be the inhibition of the upstream kinase ATM, using a well characterised, 
specific inhibitor, KU-55933 (Hickson et al., 2004), or p53 knockdown by 
shRNAs.  
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Chapter 6 Results - Transient knockdown of 
p53 or p16 and subsequent 
telomerase reactivation in senescent 
cells 
6.1 Introduction 
Several studies in human cells have shown that inhibition of both p53-p21 and 
p16-pRb pathways is required to bypass or prevent replicative senescence 
(Shay, Pereira-Smith and Wright, 1991; Smogorzewska and de Lange, 2002; 
Beauséjour et al., 2003). Although mouse cells do not undergo replicative 
senescence due to telomerase constitutive expression, they can be forced into 
senescence by expressing a dominant negative TRF2, that causes telomere 
uncapping and  DDR activation (Smogorzewska and de Lange, 2002). 
Interestingly, inhibition of p53 prior to TRF2 knockdown is sufficient to avoid 
entry into senescence in cells expressing dominant negative TRF2, 
highlighting the differences in senescence signalling between mice and 
humans in which mouse cells do not require the p16-pRb pathway for entry 
into senescence. Several studies have focused on the bypass of senescence, 
inhibiting p53-p21 and p16-pRb pathways by multiple means, such as 
expression of viral proteins SV40 LT or HPV E6 + E7, dominant negative 
version of the target protein or via RNAi. However, very few studies have 
addressed whether inhibiting these pathways is sufficient to abrogate 
senescence once it is established (senescence reversal). As in the previous 
chapter, I have shown that PFT-α mediated inhibition of p53 in the context of 
DDR was ineffective. I therefore set out to test an alternative means to achieve 
the same goal, namely using IPTG-inducible shRNA constructs directed 
against p53 mRNA. Using the same strategy, I also tested the effect of p16 
knock-down in combination with DD-hTERT stabilisation on senescence 
reversal. 
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6.2 p53 knockdown in MRC-5 DD-hTERT cells 
Four p53-targeting shRNAs, compiled from published reports (See Table 2.4 
for sequences and references) and the RNAi consortium database 
(http://www.broadinstitute.org/rnai/trc) were cloned into a pLKO-puro-IPTG-
3xLacO backbone for lentiviral transduction and IPTG-inducible shRNA 
expression. However, only for two shRNA constructs (shp53-1 and shp53-2) 
DNA sequencing confirmed successful cloning, while for the other two 
constructs repeated attempts to obtain sequences failed. shRNA genes are 
notoriously difficult to sequence due to the very stable secondary structures 
formed after denaturation. Therefore, only the two sequenced shRNA 
constructs were carried forward, to test their ability to induce p53 knockdown.  
To this end, MRC-5 DD-hTERT +Shield-1 cells were infected with lentiviruses 
carrying either control shRNAs directed against Luciferase mRNA (shLuc), or 
either one of two p53-directed shRNAs (shp53-1 or shp53-2). shRNA 
expression was then induced by treating infected cells with 1 mM IPTG for 48 
hours (Figure 6.1). The efficiency of knock-down was tested by analysing p53 
levels in infected cells by western blotting. As expected, MRC-5 DD-hTERT 
cells transduced with shLuc showed no difference in the levels of p53 and its 
downstream target p21, with or without IPTG-induction. In contrast, both 
shp53-1 and shp53-2 cells showed a reduction of p53 and p21 levels following 
IPTG-induction. shp53-1 was substantially more efficient in knocking down p53 
compared to shp53-2. The following experiments were therefore performed 
using shp53-1. I also verified that p53 knock-down did not affect the levels of 
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Figure 6.1 Knockdown of p53 by IPTG-inducible shRNAs in MRC-5 DD-
hTERT cells.  
Western blot quantification of p53 levels in MRC-5 DD-hTERT +Shield-1 cells 
lentivirally transduced with either shLuc, shp53-1 or shp53-2, with or without 
IPTG induction. The results obtained by using antibodies directed against p53, 
its downstream effector p21, p16 and GAPDH are shown. GAPDH was used 
as loading control. 
 
 
My previous experiment with PFT-α have shown its inability to inhibit DNA 
damage-induced p53. To assess whether shp53-1 mediated p53 knock-down 
is capable of inhibiting p53 function in the context of the DDR, MRC-5 DD-
hTERT +Shield-1 cells transduced with shp53-1 were cultured in the presence 
or absence of IPTG and exposed to 2 Gy of ionising radiation. The treatment 
was followed by 30 minutes EdU pulse at 1, 4, 8 and 24 hours prior to fixation 
with 4% formaldehyde. Fixed cells were analysed for EdU incorporation by 
Click-reaction mediated detection and fluorescence microscopy analysis. In 
response to ionising radiation induced double strand breaks, p53 triggers a 
sustained G1/S arrest, quantifiable as a decrease of the number of EdU-
incorporating cells in the culture. In agreement with this, control cells showed 
a substantial drop in the proportion of cycling cells, irrespective of the IPTG 
treatment, following ionising radiations. In the absence of IPTG, cells 
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transduced with shp53-1 also showed a decline in EdU incorporation that is 
comparable to the control cells. In contrast, IPTG-induction of shp53-1 
expression resulted in lack of sustained arrest in response to double strand 
break, measurable as an unchanged incorporation of EdU after irradiation. 
This response is typical of cells with defective G1/S checkpoint and is known 
as radio-resistant DNA synthesis (RDS). This result suggests that shp53-1 





















Figure 6.2 Knockdown of p53 by shp53-1 allowed cells to proliferate in 
the presence of ionising radiation-induced DNA damage.  
(A) Experimental plan. (B) Graph showing percentage of EdU positive (Edu+) 
cells through the time course of the experiment in non-transduced (NT) and 
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6.3 p53 knockdown alone could not abrogate 
senescence in MRC-5 DD-hTERT cells 
To assess whether shRNA-mediated inhibition of p53 is sufficient to abrogate 
proliferation arrest in senescent MRC-5 fibroblasts, shLuc and shp53-1 
transduced MRC-5 DD-hTERT cells were cultured with and without IPTG-
induction. Proliferating control cells were also cultured with Shield-1 while 
senescent cells were cultured either in the presence or absence of Shield-1. 
Cells were counted 12-days following treatment to understand whether 
senescent cells can proliferate when p53 is knocked down by shRNA and 
telomerase is stabilised/reactivated by addition of Shield-1 (Figure 6.3). 
Proliferating shLuc and shp53-1 cells showed increased number of cells 
following culture for 12-days with and without IPTG-induction, whereas 
senescent cells showed a decrease in cell number at assay endpoint in the 
presence or absence of IPTG-induction. This suggest that p53 knockdown was 
insufficient to abrogate cell cycle arrest and force senescent cells to proliferate. 
Introducing telomerase in combination with p53 knockdown led to similar 
results, confirming that the cell cycle arrest abrogation, required for telomerase 
to act on telomeres was not achieved. Interestingly, proliferating cells 
(senescence (-)) transduced with shp53-1 showed more cell growth than the 
corresponding shLuc control cells. This result could be explained by the loss 
of G1/S checkpoint induced by p53 knock-down, and the consequent increase 
of cell proliferation. Occurrence of similar observation in non IPTG-induced 
shp53-1 cells may suggest leaky expression of shp53-1. However, I have only 
performed this assay once, therefore, more experimental replicates need to be 
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Figure 6.3 Knockdown of p53 by shp53-1 was unable to abrogate 
senescence enforced growth arrest.  
(A) Experimental plan. (B) Quantification of cell proliferation by count at day 0 
and 12. The seeding density was maintained the same for all treatments, 7.5 
x 105 cells. Cells that reached 90% confluency were sub-cultured and re-
seeded at 7.5 x 105 cells. In this case, cumulative cell number at endpoint (day 
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Parallel to the cell counting experiment, I also analysed the proportion of the 
senescent population by SA-β-gal staining assay. Proliferating MRC-5 DD-
hTERT shLuc or shp53-1 transduced cells, cultured with Shield-1 were used 
as negative controls. These control cells showed no SA-β-gal staining, as 
expected. On the other hand, senescent MRC-5 DD-hTERT +/- Shield-1 cells, 
infected with shp53-1 and untreated or treated with IPTG showed a similar 
proportion of senescent population. Together with the previous results, these 
data suggest that p53 knockdown, with or without telomerase reactivation was 














Figure 6.4 Knockdown of p53 alone by shp53-1 was unable to reverse 
senescence.  
Brightfield microscopy images of SA-β-gal stained proliferating (left) and 
senescent (right) MRC-5 DD-hTERT transduced with IPTG-inducible shRNA 
to luciferase (shLuc) or p53 (shp53-1). IPTG induction was performed for 12 
days and topped up every 2 days with 1 mM IPTG. Shield-1 treatment was 
performed similarly to the IPTG treatment, with 700 nM Shield-1. 
 
Investigating the reversibility of senescence 
 Results - Transient knockdown of p53 or p16 and subsequent telomerase 
reactivation in senescent cells 
106   
6.4 Confirmation of p16 knockdown in MRC-5 DD-
hTERT cells 
The experiments above showed that knockdown of p53 alone is insufficient to 
abrogate senescence. It has been shown that cells that upregulate both p16 
and p53 during senescence require inhibition of both pathways in order to 
bypass senescence associated proliferation arrest (Shay, Pereira-Smith and 
Wright, 1991; Smogorzewska and de Lange, 2002). Therefore, I have 
compiled four shRNA sequences (Shp16-1, Shp16-2, shp16-3 and Shp16-4) 
from published reports (See Table 2.4 for sequences and references) and the 
RNAi consortium database (http://www.broadinstitute.org/rnai/trc) and cloned 
them into a pLKO-puro-IPTG-3XLacO backbone, similarly to the shRNAs 
directed against p53. Following lentiviral infection of MRC-5 DD-hTERT 
+Shield-1 cells and antibiotic selection with puromycin, cells were cultured with 
and without IPTG for 48 hours, trypsinised and subjected to western blotting 
to analyse p16 levels. Western blot showed that p16 is expressed in all cells 
prior to IPTG induction. Surprisingly, IPTG-induction did not result in a visible 
decrease of p16 levels in all four shRNAs tested, compared to the shLuc 
control. One possible explanation for this result is the level of shRNA 
expression obtained by IPTG-induction are not high enough to effectively 
knock-down p16 mRNA levels. To verify this hypothesis, the four selected 
shRNA against p16 were cloned into pLKO.1-hygro backbone. This plasmid 
uses the same U6 promoter as pLKO-puro-IPTG-3xLacO minus the lac operon 
and therefore allows constitutive expression of the shRNA. Although all four 
shRNAs sequenced have been cloned into pLKO.1-hygro backbone, I was 
only able to confirm successful cloning for two (shp16-2 and shp16-3) out of 
the four shRNAs. Lentiviral particles containing either shp16-2 or shp16-3 were 
used to infect proliferating and senescent MRC-5 DD-hTERT at maximum MOI 
(undiluted viral supernatant). Infected cells were selected with hygromycin for 
6 days and harvested for analysis of p16 levels by western blot. In both 
proliferating and senescent cells, shp16-2 but not shp16-3 showed substantial 
reduction of p16 protein levels compared to shLuc. It is interesting to note that 
senescent shLuc cells showed low levels of p21 and p53 compared to 
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proliferating cells which was also observed previously in MRC-5 DD-hTERT 
cells not lentivirally transduced with shRNA constructs (See chapter 4). 
Knockdown of p16 by Shp16-2 induced upregulation of p21 and p53, 
consistent with a previous observation in senescent WI-38 cells, where 
inhibition of p16 prior to senescence produced senescent cells which 
upregulates p21 (Beauséjour et al., 2003). Strangely, despite not showing a 
visible p16 knockdown, upregulation of p21 was also seen in senescent 
Shp16-3 cells. This upregulation of p21 was not observed in proliferating cells 
following p16 knockdown suggesting that this effect is specific to senescent 
cells and that this might correlate to p16 function during senescence. Shp16-





Figure 6.5 IPTG-inducible shRNA expression does not result in efficient 
knock-down of p16 levels.  
Following 48 hours of IPTG-induction, proliferating MRC-5 DD-hTERT cells 
transduced with 4 different IPTG-inducible shRNAs to p16 were subjected to 
Western blot analysis to assess p16 knockdown. HeLa and U2OS cell lysates 
were used as positive and negative control respectively, for the presence of 
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Figure 6.6 Constitutive Shp16-2 expression efficiently knocks down p16.  
Proliferating and senescent MRC-5 DD-hTERT cells infected with viruses 
carrying either ShLuc, Shp16-2 or Shp16-3 under the control of a constitutive 
U6 promoter, were tested for p16 levels by Western blot. p21 and p53 levels 




The aim of the work described in this chapter was to investigate potential 
routes to inhibit p53-p21 and p16-pRb pathways, to ultimately attempt 
reversing senescence in cells with stabilised telomerase. As briefly mentioned, 
both pathways are required for establishment and maintenance of senescence 
and inhibition of both of these pathways prior to senescence could prevent 
cells from entering senescence (senescence bypass) (Smogorzewska and de 
Lange, 2002). However, once senescence is established, abrogation of 
senescence (senescence reversal) have been reported to depend on the 
levels of p16 in the cells and that WI-38 fibroblasts expressing high levels of 
p16 at senescence cannot be forced to proliferate in spite of dual inhibition of 
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p53 and p16 (Beauséjour et al., 2003). However, in the same report, senescent 
cells that failed to proliferate following inhibition of p53 and p16 did undergo 
DNA replication. Therefore, this may suggest that there are factors preventing 
these cells to proceed to mitosis, possibly the DNA damage at telomeres which 
activates senescence in the first place. In this chapter, I have showed that 
knockdown of p53 alone was insufficient to abrogate growth arrest once 
senescence is established in my cells. Unfortunately, I have not been able to 
test whether dual knockdown of p53 and p16 can force cells to proceed to S-
phase. There is a possibility that the result in MRC-5 cells may replicate 
previous result in WI-38 as mentioned above. However, to my knowledge, the 
effect of introducing telomerase following abrogation of cell cycle arrest by dual 
p53 and p16 knockdown in senescent cells has not been investigated. 
Telomerase expression have been shown to affect stability of OIS via 
clearance of DNA damage at telomeres (Suram et al., 2012). Therefore, 
telomerase reactivation following abrogation of senescence could potentially 
result in reversal of senescence by means of eliminating the DDR signals at 
telomeres that maintain senescence.  
 
Although senescence is defined as a static proliferative arrest, it has been 
suggested that it is a more dynamic process than its definition suggest 
(Reviewed in (Van Deursen, 2014)). In human cells, p53 has been associated 
with the activation and maintenance of early or light senescence, while p16 is 
associated with late or deep senescence (Alcorta et al., 1996; Stein et al., 
1999; Chen and Ozanne, 2006). I have showed in chapter 4 that the senescent      
MRC-5 DD-hTERT cells have higher levels of p16 compared to proliferating 
cells at relatively similar population doublings (Figure 4.6). Furthermore, it 
seems that there is always a basal level of p16 expression in proliferating 
MRC-5 DD-hTERT cells. Although p16 expression is highly associated with 
senescence, expression of p16 have also been reported in cultured human 
cells under sub-optimal culture conditions (Ramirez et al., 2001). This may 
partially explain the expression of p16 in the proliferating MRC-5 DD-hTERT 
cells. Furthermore, p53 and p21 levels are lower in the senescent cells 
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compared to proliferating cells (Figure 4.6 and 6.6). Downregulation of p53 and 
p21 in senescent cells have been previously reported and was linked to 
SCFFBXO22 upregulation which can ubiquitylate methylated p53 for proteasomal 
degradation (Stein et al., 1999; Bakkenist et al., 2004; Chen and Ozanne, 
2006; Johmura et al., 2016).  
 
As mentioned above, the proliferating MRC-5 cells have relatively high basal 
levels of p16, which I proposed to be due to sub-optimal culture conditions. 
This includes media formulations and O2 levels in the cell culture incubator. 
Traditional CO2 incubators have atmospheric O2  levels which is approximately 
21% O2 partial pressure while in vivo physiological oxygen levels in tissues 
could range from 4 – 7.5% (McKeown, 2014). This suggest that the MRC-5 
cells used in the study were cultured in relatively hyperoxic conditions, which 
does not reflect its normal environment in vivo. Mitochondrial ROS production 
have been shown to increase linearly with increase in oxygen concentration 
(Grivennikova, Kareyeva and Vinogradov, 2018). This imply that culturing the 
MRC-5 cells at relatively hyperoxic condition may result in excess ROS 
production which could lead to increased oxidative stress and possibly 
senescence or senescence-like phenotype in certain situations. It has been 
shown that fibroblast live longer in vitro when cultured at 10% O2 compared to 
20% (Richter, Sanford and Evans, 1972; Packer and Fuehr, 1977). 
Furthermore, physiological O2 levels significantly delays cellular senescence 
and increase lifespan of MEFs compared to atmospheric O2 levels (Parrinello 
et al., 2003).  In addition, atmospheric O2 levels and excess ROS production 
has been implicated in upregulation of p16 (Jenkins et al., 2011; Sasaki et al., 
2014; Mas-Bargues et al., 2017; Lin et al., 2019). Hence, lowering O2 levels is 
a clear benefit for replicative lifespan of mammalian cells in vitro and could 
possibly lower p16 levels in culture. To allow for reduced O2  levels, a Tri-gas 
incubator can be used which allow injection of gaseous N2 in parallel with CO2  
injection. Gaseous N2 would displace O2  and reduce its concentration to tissue 
physiological levels. However, as cells require constant re-plating every 3-4 
days, it is very difficult to maintain O2  levels when cells were taken outside of 
                                                 Investigating the reversibility of senescence 
Results - Transient knockdown of p53 or p16 and subsequent telomerase 
reactivation in senescent cells   
111 
the incubator and this requires further observation to see the effect of this acute 
change in O2  levels when incubator O2  concentration have been set to in 
physiological levels. 
 
Non-specific antibody binding can also result in over representation of western 
blot data, which may explain the high basal p16 levels observed. The p16 
antibody used in this study is a monoclonal antibody (clone G175-1239) from 
BD biosciences and have been validated in the lab by western blot using whole 
cell lysates of U2OS cells (p16 negative) and HeLa cells (p16 positive), which 
showed positive band of ~16 kDa in size in the HeLa lane but not in the U2OS 
lane (Figure 6.5). Furthermore, it has also been frequently used for western 
blot in other senescence-related studies (Ramirez et al., 2003; Takaoka et al., 
2004; Zhang et al., 2009; Fischer et al., 2013). Thus, antibody specificity does 
not seem to be an issue in this case. Regarding other antibodies used in my 
western blot experiments, my p53 western blots may possibly benefit from 
adding p53 phosphorylation data, particularly p53 Ser15 phosphorylation 
which is the initial phosphorylation event required for p53 transactivation 
(Dumaz, 1999). It is known that following DDR-associated sequential 
phosphorylation of p53 at Ser15, Ser20 and Thr18 by upstream kinases ATM, 
Chk2 and CK1 respectively, MDM2 is dissociated from p53 leading to 
stabilisation of p53 protein (Jiang, Sheikh and Huang, 2010). This stabilisation 
can be observed as increased p53 protein levels in western blots. However, 
this increased p53 level is not a direct marker for p53 activity. Mutant p53 which 
have lost its transactivation capability is frequently showed to be constitutively 
highly expressed in cancer cells, when observed by western blot (Midgley and 
Lane, 1997). The inability of mutant p53 to transactivate its target genes 
resulted in the absence of  the p53 negative feedback loop with MDM2, leading 
to chronic stabilisation of p53 (Midgley and Lane, 1997).Therefore, this imply 
that p53 levels is insufficient to be a surrogate marker for its function, 
supporting the benefit of adding p53 phosphorylation data for characterisation 
of p53 function.  
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It was also reported that replicatively senescent BJ fibroblasts showed an 
active DDR, as detected via 53BP1 and γH2AX foci formation, that is 
maintained upon prolonged culture (Fumagalli et al., 2014). On the contrary, 
in the same report, DDR activation in senescent WI-38 and IMR-90 cells 
diminished upon prolonged culture, possibly due to loss by death of the cells 
carrying the highest DNA damage burden. Similarly to the observation in WI-
38 and IMR-90 cells, in my experiments senescent MRC-5 DD-hTERT cells 
showed a substantial reduction of cell numbers during serial passaging, 
suggesting the possible loss of cells with the highest DNA damage levels. 
Moreover, it is known that , like in the case of MRC-5 DD-hTERT cells, WI-38 
but not BJ cells express high levels of p16 (Beausejour et al., 2003).  
Knockdown of p16 in senescent cells resulted in upregulation of p53 and p21 
(Figure 6.6), suggesting a redundancy between p53-p21 and p16-pRb 
pathway in maintaining senescence, which was also previously reported (Stein 
and Dulic, 1998; Beauséjour et al., 2003). This might also explain the reliance 
of BJ fibroblasts on p53-p21 pathway for maintenance of senescence.  
 
As mentioned above senescent BJ cells but not WI-38 and IMR-90 cells 
maintain higher viability in culture. It is possible that loss of viability of 
senescent WI-38 and IMR-90 cells in culture is linked to the targeted 
degradation of p53 by SCFFBXO22. p21 has been implicated in maintenance of 
cell viability in senescent IMR90 fibroblasts induced by etoposide (Yosef et al., 
2017), hence, cells that downregulate p53 and its downstream target p21 
during senescence may not be able to maintain viability in culture. It would be 
interesting to test whether inhibition of p16, which upregulates p53 and p21 in 
RS-induced MRC-5 DD-hTERT cells could increase viability in culture. 
Together, these data suggest that in MRC-5 fibroblasts both pathways, p53 
and p16 are possibly activated sequentially during senescence and support 
the hypothesis that some type of cells progress from light to deep senescence 
by downregulating p53 and upregulating p16.  
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Chapter 7 Results - The effect of forced 
localisation of telomerase at 
telomeres by fusion of hPOT1 to 
hTERT in senescent cells 
7.1 Introduction 
As briefly discussed previously, my failure to force senescent MRC-5 cells 
back into proliferation is possibly explained by the fact that telomerase 
localisation to telomeres and the consequent telomere elongation are normally 
restricted to S-phase (Ten Hagen et al., 1990; Wright et al., 1999; Jády et al., 
2006; Tomlinson et al., 2006). I therefore reasoned that providing an S-phase 
independent mechanism to localise it to telomeres, could allow telomerase to 
inactivate DDR-dependent cell cycle arrest by elongating critically short 
telomeres. Currently, the molecular basis of the S-phase specific recruitment 
of telomerase to telomeres are only partially understood. However, it has been 
shown that mutations localised within hTERT Dissociates Activities of 
Telomerase (DAT) domain/region at the N-terminus result in loss of telomere 
elongation activity in vivo (in cells) but not in vitro (Armbruster et al., 2001; 
Banik et al., 2002; Armbruster et al., 2004). These data have been explained 
by the potential inability of DAT-mutant telomerase to localise to telomeres. To 
demonstrate this hypothesis, DAT-mutant hTERT was fused to POT1, a 
component of the shelterin complex which binds to the single-stranded 
telomeric overhang (Armbruster et al., 2004). Expression of the POT1-DAT 
mutant hTERT fusion protein was in fact able to rescue telomere elongation. It 
has been proposed that the signal to induce DDR-dependent replicative 
senescence is triggered by the depletion of shelterin components at critically 
short telomeres and by the shortening of the 3’-overhang, with the consequent 
loss the T-loop protective conformation (Li et al., 2003; Stewart et al., 2003; 
Takai, Smogorzewska and De Lange, 2003; Cesare et al., 2009). All these 
events effectively transform the end of the chromosome into a double strand 
break. I propose to use hPOT1-hTERT fusion to force hTERT localisation to 
telomeres in senescent MRC-5 cells. This could allow elongation of the 
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telomeric 3’-overhang, restore the T-loop conformation and reverse 
senescence by abolishing damage recognition at telomeres by the DDR. 
 
7.2 Lentiviral transduction of hPOT1-hTERT to MRC-5 
DD-hTERT cells  
MRC-5 DD-hTERT cells were infected with lentiviruses carrying hPOT1-
hTERT fusion. Following treatment with 5 µg/ml blasticidin to select a cell 
population carrying a stably integrated virus, genomic DNA (gDNA) was 
extracted and 1 µg of gDNA was subjected to PCR to confirm the presence of 
hPOT1-hTERT DNA sequence random integration into the MRC-5 DD-hTERT 
genome. PCR was performed using primers amplifying a 498 bp region 
spanning the 3’-end of hPOT1, the internal FLAG sequence and 4 bp into the 
5’-end of the hTERT sequence. As internal control, a primer pair designed to 
amplify a 381 bp of the internal region of the Blasticidin-S resistance gene (bsr) 
was also used for PCR. 1 pg and 10 pg of plasmids were used as controls for 
the presence or absence bsr and hPOT1-hTERT, respectively. The result 
showed that the controls were working as expected (Figure 7.1). Both MRC-5 
DD-hTERT transduced with vector only (pLENTI6/V5-DEST) and hPOT1-
hTERT showed a clear amplified band for bsr. On the other hand, only       
MRC-5 DD-hTERT cells transduced with pLENTI6-hPOT1-hTERT showed      
~500 bp band for hPOT1-hTERT. This result confirmed that MRC-5 DD-
hTERT vector only and hPOT1-hTERT cells had successfully integrated the 







                                                 Investigating the reversibility of senescence 
Results – The effect of forced localisation of telomerase at telomeres by 















Figure 7.1 Genotyping of hPOT1-hTERT in MRC-5 DD-hTERT following 
lentiviral transduction with pLENTI6-hPOT1-hTERT plasmid.  
PCR was performed for 30 and 35 cycles for bsr (381 bp) and hPOT1-hTERT 
(498 bp) respectively. M = Marker (GeneRuler Ladder Mix). Blasticidin S-
resistance gene (bsr). NTC = no template control. pDONR221 was used as 
negative and pLENTI6/V5-DEST as positive control for bsr amplification. 
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In order to verify whether hPOT1-hTERT fusion protein is expressed in      
MRC-5 DD-hTERT the transduced cells, I performed immunostaining using a 
monoclonal FLAG (M2) antibody to detect the fusion protein. Indeed, both 
hPOT1 and hTERT are FLAG-tagged. As a positive control for FLAG 
immunostaining, mouse embryonic stem cells (mESCs) stably expressing a 
FLAG-tagged KAP1 protein were used (Lynn Powell, unpublished). Despite a 
clear signal was detected for FLAG-KAP-1, hPOT1-hTERT fusion protein 
could not be detected in the MRC-5 DD-hTERT cells infected with the lentivirus 
encoding for hPOT1-hTERT fusion protein (Figure 7.2). To verify this further, 
the expression of the fusion protein was also assayed by western blot. In this 
case, mouse embryonic stem cells (mESCs) expressing a FLAG-Cas9 fusion 
protein were used as positive control for FLAG-immunodetection (Naiming 
Chen, unpublished). Accordingly, while the 150 kDa FLAG-Cas9 fusion protein 
was readily detected by probing the western blot with anti-FLAG antibody, 
hPOT1-hTERT fusion protein band, expected to run approximately around 
201kDa, could not be detected (Figure 7.3). Re-probing the same blot with 
mouse-anti-TERT antibody revealed strong bands at ~130 kDa which 
corresponds with stabilised DD-hTERT protein (139 kDa) in all samples except 
the FLAG-control cells and a very faint band only in which might be hPOT1-
hTERT. This suggest that expression of hPOT1-hTERT might be extremely 
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Figure 7.2 hPOT1-hTERT protein expression was not detected by 
immunostaining in MRC-5 DD-hTERT cells transduced with hPOT1-
hTERT.  
Images acquired at the fluorescence microscope, showing MRC-5 DD-hTERT 
cells infected with lentivirus carrying empty vector (vector only) or lentivirus 
encoding for hPOT1-hTERT. DNA was counterstained with DAPI. mESCs 
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Figure 7.3 hPOT1-hTERT protein expression in MRC-5 DD-hTERT 
+Shield-1 cells.  
Whole cell extracts of non-transduced MRC-5 DD-hTERT +Shield cells (DD+), 
transduced with vector only (DD+ Vector), with hPOT1-hTERT (DD+ hPOT1-
hTERT)  and of FLAG-control cells (mESCs FLAG-Cas9) were loaded onto 
6% SDS-PAGE gel at 100000 cells/well and transferred onto nitrocellulose 
membranes, subsequently probed with antibodies directed against (A) FLAG 
tag, (B) TERT and SMC-1 (loading control). The expected sizes for FLAG-
Cas9, DD-hTERT, hPOT1-hTERT and SMC-1 are 150 kDa, 139 kDa, 201 kDa 
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Since the hPOT1-hTERT transgene expression is constitutively driven by the 
CMV promoter present in the lentiviral vector, telomerase activity of MRC-5 
DD-hTERT cells expressing hPOT1-hTERT fusion protein should be high in 
the absence of Shield-1, compared to non-infected cells. Since, the fusion 
hPOT1-hTERT protein expression is not detectable by western blotting, I 
decided to try and detect it by taking advantage of the higher sensitivity of the 
TRAP assay, which measures telomerase enzymatic activity. MRC-5             
DD-hTERT cells infected with control lentivirus (vector only) or the virus 
encoding for hPOT1-hTERT were cultured for 7 days without Shield-1 to 
reduce DD-hTERT activity to background level (Figure 7.4). This was followed 
by culture with or without Shield-1 for 24 hours, in order to compare basal and 
Shield-1 stabilised telomerase activity in the absence or presence of hPOT1-
hTERT. Whole cell extract from these cells were subjected to TRAP assay. 
MRC-5 WT and hTERT were used as negative and positive controls for 
telomerase activity respectively. As expected, both vector control and hPOT1-
hTERT transduced MRC-5 DD-hTERT cultured with Shield-1 showed high 
telomerase activity. On the other hand, although both vector only and hPOT1-
hTERT transduced cells cultured without Shield-1 showed low telomerase 
activity if compared to cells cultured with Shield-1, hPOT1-hTERT cells -
Shield-1 showed a slightly higher telomerase activity in comparison to the 
vector transduced cells in the same condition. This is visible as an increased 
laddering at the top end of the gel in the 1000 cells lane and one extra band at 
the bottom end in the 100 cells lane compared to vector cells in the absence 
of Shield-1 (Fig. 7.4B). This result suggests that albeit at very low levels, 
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Figure 7.4 hPOT1-hTERT telomerase activity in MRC-5 DD-hTERT cells.  
(A) Experimental plan. (B) TRAP assay electropherogram. Whole cell lysate 
obtained from MRC-5 WT, hTERT, DD-hTERT (Vector) and DD-hTERT 
(hPOT1-hTERT) equivalent to 1000 and 100 cells were subjected to TRAP 
assay and loaded into a 0.5X TBE polyacrylamide gel. The extent of 6-bp DNA 
laddering is proportional to telomerase activity in the cell population. HI = heat 
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The very low levels of expression hPOT1-hTERT fusion protein observed 
could be due to CMV promoter silencing in MRC-5 cells. This problem has 
been reported for the CMV promoter in various cell types (Teschendorf et al., 
2002; Brooks et al., 2004; Meilinger et al., 2009; Qin et al., 2010). To verify this 
hypothesis, I tested whether higher expression levels of hPOT1-hTERT fusion 
protein could be obtained in a different cell type, namely 293T cells.  Cells were 
transfected with pLENTI6-hPOT1-hTERT using calcium phosphate method 
and harvested 2-days post-transfection for western blot analysis. pLENTI6-
hPOT1-hTERT transfected 293T cells showed a band at the expected size for 
hPOT1-hTERT (~201 kDa, Figure 7.5). No bands were observed at the same 
size in the lanes for vector-only and mock transfected cells. This suggests that 
hPOT1-hTERT expression driven by the CMV promoter is not silenced in 293T 
cells but possibly silenced or cannot drive high expression of hPOT1-hTERT 
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Figure 7.5 hPOT1-hTERT expression in 293T cells is detectable. 
Whole cell extracts obtained from HEK293T cells (293T) either mock 
transfected or transfected with pLENTI6/V5-DEST plasmid (Vector) or 
pLENTI6-hPOT1-hTERT plasmid (hPOT1-hTERT) were subjected to western 
blotting and probed with anti-FLAG antibody. Wild type mESCs (FLAG (-) Ctrl) 
or mESCs expressing FLAG-KAP1 (FLAG (+) Ctrl) were used as negative and 




The main aim of the work described in this chapter was to test whether 
artificially localising/tethering telomerase to telomeres via expression of 
hPOT1-hTERT fusion protein is sufficient to abrogate replicative senescence. 
I have successfully introduced hPOT1-hTERT into MRC-5 DD-hTERT cells as 
confirmed by genotyping PCR. However, I have not been able to obtain good 
levels of expression of the fusion protein using a lentiviral vector (pLENTI6/V5-
DEST). Due to this technical difficulty and time constraints, I was also unable 
to confirm localisation of hPOT1-hTERT to telomeres. However, by 
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troubleshooting, I found that the poor levels of expression of hPOT1-hTERT 
fusion proteins are due to the CMV promoter present in the lentivector, which 
is perhaps silenced or too weak to drive detectable expression of hPOT1-
hTERT in MRC-5 cells. A previous report testing five different gene promoters 
to drive expression of GFP in various human cell lines frequently used in 
laboratory experiments has demonstrated that chicken β-actin promoter 
coupled with cytomegalovirus early enhancer (CAG), human elongation factor 
1α promoter (EF1A) and Simian vacuolating virus 40 promoter (SV40) but not 
cytomegalovirus immediate early promoter (CMV), mouse phosphoglycerate 
kinase 1 promoter (PGK) and human ubiquitin C promoter (UBC) can drive 
high expression of GFP in MRC-5 cells (Qin et al., 2010). This is in agreement 
with my results showing that the same CMV promoter is insufficient to drive 
the expression of hPOT1-hTERT in MRC-5 cells but able to give good levels 
of expression in 293T cells. Treatment with 5-Aza-2’-deoxycytidine, has been 
shown to reverse CMV silencing and restore  expression of LacZ (β-
galactosidase) gene driven by a CMV promoter previously silenced 
(Radhakrishnan et al., 2008). By using this treatment on my cells, I could 
further verify my hypothesis. However, the most crucial part is to solve the low 
expression levels in MRC-5 DD-hTERT cells transduced with hPOT1-hTERT. 
To this end I am currently planning to replace the CMV with a CAG promoter. 
 
Alternatively, I could introduce a DD-tag to the N-terminus of hPOT1-hTERT 
and obtain stable cell lines using pre-senescent MRC-5 DD-hTERT -Shield-1 
cells. Since expression of DD-hPOT1-hTERT would not result in an active 
telomerase in the absence of Shield-1, MRC-5 DD-hTERT -Shield-1 cells 
encoding for DD-hPOT1-hTERT will senesce. Only in the presence of      
Shield-1 would these cells stabilise hPOT1-hTERT fusion protein, allowing 
hTERT localisation to telomeres in senescent cells. I have constructed the 
pLENTI6-DD-hPOT1-hTERT plasmid and have tried to transfect MRC-5 cells 
using Lipofectamine 3000. However, I encountered high level of cell death 
following transfection. Therefore, the transfection conditions require further 
optimisations. To validate the localisation of hPOT1-hTERT in senescent cells, 
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dual immunostaining with anti-FLAG and anti-TRF2 antibody will be 
performed, to detect hPOT1-hTERT and telomeres, respectively. Proliferation 
and senescence will be measured in hPOT1-expressing senescent cells by 
quantifying EdU incorporation and by SA-β-gal staining. In order to verify if 
reactivation and localisation of telomerase can switch off the DDR induced by 
critically short telomeres, it would also be interesting to measure the DDR at 
telomeres following hPOT1-hTERT expression by monitoring the 
presence/absence of ɣH2AX foci at telomeres. 
 
There are two of potential obstacles that could prevent hPOT1-hTERT fusion 
protein from localising to telomeres in the absence of proliferation. Although 
POT1 has a DNA binding domain (OB fold domain), it has been shown to be 
insufficient for its localisation at telomeres and requires TPP1 (ACD/PTOP) for 
its recruitment to telomeres (Liu et al., 2004). This indirect recruitment of POT1 
to telomeres is potentially the mechanism used by hPOT1-hTERT fusion 
protein to localise to telomeres. TPP1 and POT1 have been shown to exist in 
an approximately 1:1 ratio in the cell and this is possibly due to TPP1 
conferring stability to POT1 via formation of a heterodimer in the cell (Loayza 
and De Lange, 2003; Hockemeyer et al., 2007; Xin et al., 2007; Takai et al., 
2010). As TPP1 abundance in the cell is not in excess to POT1 and because 
POT1 requires TPP1 for stabilisation, the stability of hPOT1-hTERT may also 
be compromised due to this factor. Thus, the successful localisation of hPOT1-
hTERT in senescent cells hinges on TPP1’s abundance and ability to confer 
protein stabilisation to hPOT1-hTERT and its recruitment to telomeres in the 
absence of proliferation. 
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Chapter 8 Conclusion and future work 
Senescence is generally seen as a static cell cycle arrest resulting from cellular 
stress that could not be overcome by the cell. Unlike apoptosis, which is also 
a cellular response to irreparable cellular or DNA damage, senescent cells 
remain viable and can be maintained for months in culture, as this study have 
shown. However, it is proposed that senescence is a more dynamic process 
and that temporal epigenetic and transcriptional alterations occur in senescent 
cells maintained in culture. Although epigenetic studies suggest that senescent 
cells may be derived from the cells that have escaped senescence, very few 
studies have truly addressed whether these senescent cells can escape from 
or reverse senescence. In this study, I have attempted to test the possible 
ways that can be utilised to reverse senescence using RS-induced MRC-5 
fibroblasts. Using a different fibroblast cell line and telomerase activation 
method, I have currently confirmed a previous observation (Beauséjour et al., 
2003) that telomerase reactivation alone cannot induce the escape from RS. 
Using the DD-hTERT reversible telomerase activation system, I have also 
shown that low basal telomerase activity was insufficient to prevent telomere 
shortening and senescence. Further work is required to compare the 
telomerase activity of MRC-5 DD-hTERT cells and other telomerase-
expressing cells to understand how telomerase activity levels affect immortality 
in different human cells. A previous study in WI-38 fibroblasts, which are also 
derived from foetal lung fibroblasts similar to MRC-5 fibroblasts, showed that 
cellular division was not observed following a knockdown of p16 with shRNA 
and an inhibition of p53 via a p53 dominant negative peptide (Beauséjour et 
al., 2003). However, in that particular study, the role of telomerase was not 
tested following the inhibition of p53 and p16. Therefore, experimental 
evidence needs to be acquired to test whether knockdown of p53 and p16 with 
telomerase reactivation can reverse senescence.  
 
Studies using BJ cells showed that OIS and RS can be abrogated. BJ cells do 
not upregulate p16 and are thought to maintain senescence via p53. Inhibition 
of p53 but not telomerase expression is sufficient in overcoming the 
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proliferation arrest in the senescent BJ cells (Beauséjour et al., 2003). 
Furthermore, the BJ cells that escaped OIS upregulate telomerase and this 
was concomitant with diminished DDR foci at telomeres (Patel et al., 2016). 
The fact that telomerase was unable to abrogate RS but possibly abrogate OIS 
in the same type of cells can mean two things. Firstly, in the case with the 
spontaneous escape from OIS, p53 inhibition possibly precedes telomerase 
reactivation.  Secondly, the response to telomerase reactivation may be 
different in OIS compared to RS. Therefore, it would be interesting to test 
whether telomerase reactivation could result in senescence reversal of BJ cells 
undergoing OIS and RS. This might suggest that in cases where senescence 
is maintained by p53 only, telomerase reactivation may be sufficient to reverse 
the senescence in certain scenarios. It will also be interesting to pursue further 
the factors associated with the p16 dominance in proliferation arrest over p53 
in senescent cells. 
 
Due to technical difficulties encountered, I have not been able to test the 
potential of tethering of telomerase to telomeres using the hPOT1-hTERT 
fusion construct in the context of senescence. Therefore, further work is still 
required to test whether hPOT1-hTERT could force the localisation of 
telomerase to telomeres and elongate telomeres in senescent cells, in the 
absence of DNA replication. Further work is also required to study the tethering 
of telomerase to short telomeres, potentially by fusing TPP1 or TCAB1 to 
hTERT to complement the hPOT1-hTERT study. Overall, this work provides 
an insight into the understanding of how human cells can reverse senescence 
and the role of telomerase in the process of senescence reversal. 
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Appendix A Optimisation of Biotinylated-CxxC 
Affinity Purification (Bio-CAP) 
A.1 Introduction 
A.1.1 DNA methylation 
DNA methylation at the 5-carbon position of cytosine (5-mC) is a heritable 
epigenetic DNA modification, which occurs primarily at CpG dinucleotides in 
mammals (Holliday and Pugh, 1975; Riggs, 1975). An early discovery have 
identified DNA methylation at gene regulatory regions being associated with 
gene repression (Riggs, 1975). More recent studies have shown that DNA 
methylation is present not only at promoter regions but also at gene bodies 
and that its function changes depending on the location of the DNA methylation 
in the genome (Larsen, Solheim and Prydz, 1993; Robertson and Jones, 1998; 
Illingworth et al., 2010; Hahn et al., 2011; Laurent et al., 2010). Most CpG 
sequences in human DNA are methylated (70-80% of total CpGs) and the 
remaining unmethylated CpGs (20-30% of total CpGs) are mostly clustered 
together at short CpG rich regions called CpG Islands (CGIs), which are 
prevalent at the 5’-end regions of various genes (Bird, 1987; Saxonov, Berg 
and Brutlag, 2006). 
 
A.1.2 hTERT-immortalisation and DNA methylation 
Several groups have shown that ectopic hTERT expression is sufficient to 
immortalise several types of cells in in vitro culture (Bodnar et al., 1998; 
Counter et al., 1998; Vaziri and Benchimol, 1998). It is widely accepted that 
cellular immortality is a hallmark of cancer, which is achieved by re-activation 
of telomerase in 80% of cancers (Blasco, 2005; Hanahan and Weinberg, 
2011). However, hTERT-immortalised cells showed no cancer-associated 
phenotypes such as lack of contact-inhibition and anchorage-independent 
growth (Jiang et al., 1999; Morales et al., 1999). In addition, hTERT-
immortalised cells maintain a normal karyotype and long telomeres, which are 
advantageous properties for an in vitro model of normal cells. In contrast, more 
recent discoveries suggests that there are genetic and epigenetic changes 
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which could discriminate normal primary cells and their hTERT-immortalised 
counterparts (Gordon et al., 2014; Landan et al., 2012; Milyavsky et al., 2003). 
Furthermore, the DNA methylation patterns in hTERT-immortalised cells have 
been shown to mimic the patterns in pre-cancerous cells (Gordon et al., 2014) 
suggesting that telomerase might play a role in DNA methylation 
reprogramming during carcinogenesis.  Previously, published results from the 
Stancheva laboratory have showed that hTERT-immortalised MRC-5 
fibroblasts accumulate DNA methylation at gene promoters similar to MRC-5 
cells transformed with Simian Vacuolating Virus 40 T-Antigen (SV40 T-Ag) and 
oncogenic HRAS (Gordon et al., 2014). This suggests that oncogenes may not 
play a leading role in the formation of aberrant DNA methylation pattern 
present in pre-cancerous cells. However, it is also currently not known whether 
telomerase is required for this observed de novo DNA methylation events 
following the hTERT-induced immortalisation. On the other hand, cells 
undergoing senescence showed hypomethylation in late-replicating, normally 
heterochromatic areas of the genome, which is similar to cancers 
(Cruickshanks et al., 2013). Therefore, this brings into question whether the 
methylation profiles of senescent and immortalised cells are signs of pre-
malignancy and whether both cellular events have common players, which 
would be interesting to investigate further.  
 
A.1.3 Whole genome DNA methylation analysis by Bio-CAP 
sequencing. 
The advancement in high-throughput sequencing technology have made it 
possible to study genome-wide DNA methylation changes. The current gold 
standard technique to analyse whole genome DNA methylation is bisulphite 
conversion in combination with high throughput sequencing (Lister et al., 
2009).  This technique requires a treatment of genomic DNA with sodium 
bisulphite which converts non-methylated cytosines to uracils but leaves 
methylated cytosines unaltered, thereby allowing DNA methylation analysis at 
a single base-pair resolution (Hayatsu, Wataya and Kazushige, 1970; Shapiro, 
Servis and Welcher, 1970; Frommer et al., 1992). However, the bisulphite 
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conversion process is not error-free as non-methylated cytosines can fail to 
convert to uracil and cytosine can be incorrectly converted to thymine, which 
could give rise to an incorrect interpretation of the analysis (Genereux et al., 
2008). Furthermore, the whole genome bisulphite sequencing is prohibitively 
expensive due to the high sequencing costs associated with the required 
sequencing depths for the accurate sequencing analysis. With the current 
bioinformatics tools available, it is possible to cost-effectively acquire a whole 
genome DNA methylation profile using non-methylated or methylated DNA 
capture/enrichment methods, which would allow analysis of a smaller 
proportion of the genome to infer a whole genome DNA methylation profile (Li 
et al., 2010; Trimarchi et al., 2012; Xu et al., 2018). Some examples of these 
non-methylated/methylated DNA enrichment techniques include methylated 
DNA immunoprecipitation (MeDIP), methyl-CpG binding domain (MBD) 
protein capture, and CxxC Affinity Purification (CAP) (Weber et al., 2005; 
Illingworth et al., 2008; Serre, Lee and Ting, 2009). A development of the CAP 
technique called Biotinylated-CxxC Affinity Purification (Bio-CAP) was 
published in 2012   (Blackledge et al., 2012). It employs a non-methylated CpG 
binding CxxC zinc finger domain of the human KDM2B protein, fused to a His6-
tag containing six histidine residues at the N-terminus, an Avi-tag 
(GLNDIFEAQKIEWHE) at the C-terminus and a Tobacco Etch Virus (TEV) 
protease cleavage site (ELNYFQS) between the His6-tag and the CxxC 
domain (His6-CxxC-Avi). The His6-tag permits purification of the protein using 
immobilized metal affinity chromatography (IMAC) with Nickel-charged resins. 
The Avi-tag allows the CxxC protein to be immobilised to an Avidin-based 
support for further application in purifying non-methylated DNA, once the tag 
has been biotinylated by a recombinant E. coli BirA enzyme. Prior to the 
binding of the CxxC protein to the Avidin-based beads, the His-tag is removed 
by a TEV protease cleavage at the TEV site mentioned above. Removal of the 
His6-tag has been shown to increase binding capability of the CxxC domain 
protein to the non-methylated CpG (Blackledge et al., 2012). The full workflow 
of Bio-CxxC production, the biotinylated version of CxxC-Avi protein, is 
described in Figure A.1. During the first year of my PhD project, I established 
Investigating the reversibility of senescence 
Optimisation of Biotinylated-CxxC Affinity Purification (Bio-CAP) 
190               
 
and optimised the Bio-CAP technique while in the Stancheva laboratory. The 
following chapters describe the detailed optimisations and verifications 
necessary for the fully working order of the technique. Unfortunately, due to 
time constraints and changes in the direction of the project, the method was 
not utilised in any experiments detailed in the main text of my thesis and 








Figure A.1 Bio-CxxC protein production workflow required for the Bio-
CAP technique 
Purified His6-CxxC-Avi was cleaved with TEV protease to remove the His6-
tag and form CxxC-Avi. CxxC-Avi was further modified by in vitro enzymatic 
biotinylation at the Avi-tag using a purified His6-BirA enzyme, to form the final 
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A.2 Materials and Methods 
A.2.1 Protein expression and purification of His6-BirA and 
His6-CxxC-Avi proteins 
Plasmids for protein expression of His6-BirA (pET21a-BirA) and His6-CxxC-
Avi (pNIC28-hKdm2b-CxxC-PHD) were transformed into BL21 codon-plus RIL 
E. coli expression strain, in separate experiments and plated on LB (Luria-
Berthani) agar with ampicillin 100 µg/ml or kanamycin 50 µg/ml. Plates were 
incubated at 37 °C overnight. For the His6-BirA and His6-CxxC-Avi protein 
expression, one positive colony from a corresponding plate was inoculated into 
25 ml of LB broth supplemented with either 100 µg/ml ampicillin or 50 µg/ml 
kanamycin respectively and cultured overnight. 10 ml of an overnight culture 
was diluted into 4 x 1 L LB broth and grown to an OD600 of 0.4 – 0.6 at 37 °C 
with 200 RPM shaking. The culture was then transferred into a 25 °C shaking 
incubator and the expression was induced by the addition of 0.5 mM IPTG. 
After 5 hours of incubation, the culture was pelleted by centrifugation at      
6,000 RCF, 4 °C for 10 minutes. The supernatant was removed, and the pellet 
was resuspended in 1X PBS buffer, transferred into a clean 50 ml conical tube 
and pelleted again by centrifugation at 5,000 RCF, 4 °C for 10 minutes. Cell 
pellets were stored at -80 °C prior to protein extraction. Cells expressing His6-
BirA and His6-CxxC-Avi proteins were lysed using sonication and French 
press respectively. Soluble and insoluble protein fractions were separated by 
centrifugation at 20,000 RCF, 4 °C for 20 minutes.  Both His6-BirA and His6-
CxxC-Avi proteins were purified by IMAC using Novagen Ni-NTA His-Bind 
resin (Merck-Millipore, Burlington, MA, USA) in gravity-flow columns. His6-
tagged proteins bound to Ni-charged beads were washed sequentially with a 
low salt wash buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10 mM Imidazole, 
0.1% Triton-X100 and 1 mM PMSF) and a high salt wash buffer (50 mM Tris 
pH 8.0, 1000 mM NaCl and 1 mM PMSF) and eluted with the elution buffer (50 
mM Tris pH 8.0, 300 mM NaCl, 300 mM Imidazole and 1 mM PMSF). For His6-
BirA, only the low salt wash buffer was used for the washes and both wash 
and elution buffers were supplemented with 1 mM DTT. Peak elution fractions 
were pooled and dialysed overnight at 4 °C with the dialysis buffer containing 
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50 mM Tris pH 8.0, 300 mM NaCl and 0.5 mM PMSF to remove imidazole. 
Purified and dialysed His6-BirA protein sample was supplemented with 10% 
glycerol, aliquoted at 50 µl in 200 µl tubes, snap frozen in liquid N2 and stored 
at -80 °C until further use. Purified and dialysed His6-CxxC-Avi protein 
samples were concentrated using Amicon Ultra-15 centrifugal filter units 
(Merck-Millipore, Burlington, MA, USA) before the TEV protease cleavage 
performed overnight at 4 °C and in vitro biotinylation by His6-BirA. Prior to the 
in vitro biotinylation, the His6-CxxC-Avi samples were dialysed to a buffer 
containing 10 mM Tris, pH 8.0 and 250 mM potassium glutamate. The in vitro 
biotinylation was carried out by adding the His6-BirA enzyme supplemented 
with 10 mM ATP, 10 mM magnesium acetate and 50 µM D-biotin to the CxxC-
Avi proteins and incubating the reactions overnight on a tube rotator at 4 °C. 
The biotinylation reaction was re-applied to the Ni-NTA column to remove the 
His6-BirA enzyme and yield pure Bio-CxxC protein. Lastly, Bio-CxxC proteins 
were dialysed to 20 mM HEPES pH 7.0, 150 mM KCl, 0.5 mM DTT and 10% 
Glycerol. The dialysed Bio-CxxC protein samples were snap frozen in liquid N2 
and stored at -80 °C as 100 µl aliquots at the concentration of 1 mg/ml.          
 
A.2.2 Protein quantification and gel electrophoresis 
Sigma Bicinchoninic Acid (BCA) Assay kit (Merck-Millipore, Burlington, MA, 
USA) was used to quantify total protein concentration by following the 
manufacturer’s instructions. 15% SDS-PAGE gel in 1X SDS-PAGE running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) was utilised to assess the 
purified proteins by size. Specific concentration of proteins was also assessed 
by quantifying the signal of Coomassie blue (R-250) stained protein bands of 
SDS-PAGE gels on IR700 channel of Li-Cor Odyssey near-infrared imager (LI-
COR, Lincoln, NE, USA). The fluorescence intensity of bands of the proteins 
with an unknown concentration were interpolated to a standard curve plot 
based on the fluorescence intensity data of the BSA protein standards with 
known protein concentrations. 
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A.2.3 Optimisation of the His6-tag cleavage of His6-CxxC-Avi 
by TEV protease 
Optimisation of the His6-tag removal via the TEV protease cleavage was 
accomplished by incubating 150 µg of His6-CxxC-Avi with 0, 2 and 4 µg of 
TEV protease in the reaction buffer (50 mM Tris pH 8.0 and 300 mM NaCl), 
with or without 0.5 mM DTT. The reaction mix was applied to a gravity column 
loaded with Novagen Ni-NTA His Bind resin (Merck-Millipore, Burlington, MA, 
USA) to remove the His6-tag. Input, Flow-through and Eluate fractions were 
saved and the proteins were separated by size on a 15% SDS-PAGE gel, 
stained with Coomassie blue and scanned on a Li-Cor Odyssey near-infrared 
scanner using the IR700 channel. 
 
A.2.4 Optimisation of the enzymatic biotinylation of CxxC-Avi  
To assess the extent of biotinylation of the CxxC-Avi protein by His6-BirA, 
three biotinylation reactions containing 25 µg of the CxxC-Avi protein for each 
reaction were incubated overnight at 4 °C with 0, 0.5 and 1 µg of the His6-BirA 
protein respectively, in the biotinylating buffer (10 mM Tris pH 8.0 and 250 mM 
potassium glutamate) supplemented with 10 mM ATP, 10 mM magnesium 
acetate and 50 µM D-biotin. The three biotinylation reactions were purified 
from the excess of free biotin using a Microcon YM-10 mini centrifugal filter 
unit (Merck-Millipore, Burlington, MA, USA) and the purified biotinylation 
reactions were subsequently incubated with streptavidin agarose beads at 4 
°C for 1 hour (manufactured by Pierce, Thermo Fisher Scientific, Waltham, 
MA, USA), at 10 µl of resin per approximately 10 µg of the biotinylated protein. 
Following the binding reaction to streptavidin, the supernatant (flow-through) 
was collected centrifuged samples. Two subsequent washes of the resin with 
1X PBS were also collected. Total proteins from the untreated CxxC-Avi, Input, 
Flow-through, Wash and Beads fractions from the three biotinylation reactions 
were resolved on 15% SDS-PAGE gel, stained with Coomassie blue and 
scanned on a Li-Cor Odyssey near-infrared imager at IR800 channel for further 
analysis. 
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A.2.5 Electrophoretic Mobility Shift Assay (EMSA) 
EMSA was carried out using the EMSA buffer containing 6% glycerol, 20 mM 
HEPES, 150 mM KCl, 0.5 mM DTT, 25 ng/µl Poly dI-dC, 0.25% Tween-20 and 
DY-782 labelled methylated or unmethylated oligonucleotides. The 
oligonucleotides came as two complementary DNA sequences which were 
annealed together by heating a mixture of each pair to 95 °C and slowly cooling 
it down to room temperature. Two fluorescently labelled double-stranded 
oligonucleotides with the identical DNA sequence containing 3 non-methylated 
and 3 methylated CpGs respectively, at 1 µM concentration were mixed with 
0, 25, 50, 75 and 100 µM Bio-CxxC in EMSA buffer. Bio-CxxC was incubated 
with the labelled oligonucleotides in the EMSA buffer at room temperature for 
25 minutes before the samples were loaded onto a 10% non-denaturing 
polyacrylamide gel with the acrylamide to bis-acrylamide ratio of 19:1 in 1X 
TBE buffer containing 89 mM Tris-base, 89 mM Boric acid and 2 mM EDTA. 
The gels were pre-run at 150 V, 4 °C for 30 minutes before being loaded with 
samples. Loaded gels were run at 150 V, 4 °C for 2 hours. The gels were 
scanned on a Li-Cor Odyssey imager at IR800 channel.  










A.2.6 Cell Culture 
Mouse Embryonic Fibroblasts (MEFs) were cultured in DMEM (Sigma) 
supplemented with 10% Gibco Fetal Bovine Serum (FBS) (Thermo Fisher 
Scientific, Waltham, MA, USA) and 1X Gibso PSG (292 µg/ml L-glutamine, 
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100 U/ml Penicillin, 100 µg/ml Streptomycin) (Thermo Fisher Scientific, 
Waltham, MA, USA). MEFs were grown in a 37 °C incubator with 5.0% CO2. 
 
A.2.7 DNA extraction and purification 
Genomic DNA (gDNA) for the Bio-CAP experiments was isolated from MEFs. 
Cell pellets were dissolved in 1X TE buffer containing 0.1% SDS and 200 µg/ml 
proteinase K and incubated overnight at 55 °C. Phenol: chloroform: isoamyl 
alcohol (25: 24: 1) followed by 100% chloroform were used to extract genomic 
DNA. 1X volume of 100% isopropanol and 0.3 M sodium acetate pH 5.2 were 
used to precipitate the DNA at -20 °C for 1 hour. The DNA was pelleted by 
centrifugation at 17,000 RCF, 4 °C for 15 minutes. DNA pellets were washed 
with 70% ethanol and air dried for 10 minutes. The air-dried pellets were 
dissolved in 1X TE buffer containing 10 mM Tris (pH 8.0) and 1 mM EDTA. 
Any contaminating RNA was digested by incubating the samples with RNAse 
A for 30 minutes at 37°C.  
 
A.2.8 DNA Sonication 
Purified gDNA for the Bio-CAP experiments was sonicated using Diagenode 
Bioruptor Twin sonicator (Diagenode, Liège, Belgium). The DNA was diluted 
in 1xTE at 80 ng/µl and 0.1% SDS was added to the samples prior to the 
sonication.The gDNA samples were sonicated for 120 cycles of 30 seconds 
on and 30 seconds off at 4 °C.  
 
A.2.9 Bio-CAP 
50 µl of 0.5 µg/µl biotinylated-CxxC protein (Bio-CxxC) was added to 25 µl 
packed volume of magnetic Speedbeads Neutravidin beads (GE 
Healthsciences, Chicago, IL, USA) in a siliconised 1.5 ml microtube and 
incubated for 1 hour at 4 °C on a tube rotator to produce CxxC beads. 500 µl 
of sonicated gDNA at 17.5 ng/µl was incubated with the CxxC beads for 1 hour 
at 4 °C on a tube rotator. Beads were collected with an Invitrogen Dynamag-2 
magnetic tube rack (Thermo Fisher Scientific, Waltham, MA, USA) and the 
supernatant (flow-through) was saved for further analysis. The CxxC beads 
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were washed twice with the CAP100 buffer containing 20 mM HEPES-KOH 
pH 7.9, 0.1% Triton X-100, 12.5% Glycerol and 100 mM NaCl. gDNA was 
eluted from the CxxC beads using 2x 50 µl of a series of elution buffers 
containing 5 different NaCl concentrations: 300 mM, 500 mM, 700 mM and 
1,000 mM of NaCl, for CAP300, CAP500, CAP700 and CAP1000 elution 
buffers respectively. 100 µl of input, flow-through, CAP300, CAP500, CAP700 
and CAP1000 fractions were purified using Invitrogen Purelink PCR 
purification kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the 
manufacturer’s instructions. 
 
A.2.10 PCR-amplification of the DNA pulled down in the Bio-
CAP experiments 
PCR reactions using Bio-CAP fractions as templates were carried out using 1 
U of in-house made Taq polymerase, 0.2 mM dNTPs, 1X PCR Buffer, 3 mM 
MgCl2, 10 nM forward and reverse primers, 1 µl purified Bio-CAP fractions in 
25 µl reactions. Input and flow-through fractions were diluted 1:10 with dH2O, 
while elution fractions were used undiluted. The PCR conditions used are as 
follow: Initial denaturation for 5 minutes at 95 °C followed by 35 cycles of 
denaturation for 30 seconds at 95 °C, annealing for 30 seconds at 58 or 60 °C 
(depending on primers used) and extension for 30 seconds at 72 °C and then 
followed by a final extension step at 72 °C for 10 minutes. The PCR products 
were separated by size using DNA electrophoresis in a 2% agarose gel made 
with 1X TAE buffer containing 40 mM Tris pH 8.0, 20 mM acetic acid and 1 
mM EDTA and run at 14 V/cm for 30 minutes. 
 
A.2.11 Bio-CAP PCR Primers 
Mouse gene promoters can be divided into three groups based on the 
observed/expected CpG ratio (CpG o/e) calculated in 500 bp windows: Low 
CpG density promoters (LCP) or non-CGI promoters (CpG o/e <0.45), 
Intermediate CpG density promoters (ICP) or weak CGI promoters (CpG o/e 
0.4-0.6) and High CpG density promoters HCP or strong CGI promoters (CpG 
o/e >0.6; High density) (Mohn et al., 2008). Based on this gene promoter 
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classification and the previous promoter DNA methylation data generated in 
the Stancheva laboratory for mouse embryonic fibroblasts (MEFs) (Myant et 
al., 2011), primers for the PCR were designed to test the efficacy of Bio-CAP 
in capturing non-methylated DNA corresponding to specific promoters. In 
addition, primers for Actb (β-actin) and Rhox6 gene promoter regions were 
also included as controls for unmethylated and methylated promoters, 
respectively. I have also designed primers to amplify the imprinting control 
regions (ICR) which are differentially methylated regions located near 
imprinted genes and known to regulate their transcription in cis (Reviewed in 
(Bartolomei and Ferguson-Smith, 2011)). Sequences of primers used for PCR 
of DNA from purified Bio-CAP fractions are as follow: 
Primer name Target Sequence 
GEN-FABP7-Pr-F Fabp7 promoter 5'-ATTGGCTTTTTGCCCGCTTC 
GEN-FABP7-Pr-R Fabp7 promoter 5'-AACTGGAGGAACTCGGGTCT 
GEN-UTS2-Pr-F Uts2 promoter 5'-AAGTTCTCCAGAGCAGACGC 
GEN-UTS2-Pr-R Uts2 promoter 5'-GTCACCTCACCTGGAAGCTG 
GEN-MSN-Pr-F Msn promoter 5'-GGGGTTTGTAAAGTCGTGGC 
GEN-MSN-Pr-R Msn promoter 5'-TTTGGCTGGAAACTGTCGGG 
GEN-USP44-Pr-F Usp44 promoter 5'-CGAAAGCCTAGCAGACGGTA 
GEN-USP44-Pr-R Usp44 promoter 5'-CCCTCATCAGCGGATTCTCC 
Actb-DIP-F Actb promoter 5'-ATGAAGAGTTTTGGCGATGG 
Actb-DIP-R Actb promoter 5'-GATGCTGACCCTCATCCACT 
ChIP-Rhox6-F2 Rhox6 promoter 5'-CCATGTTGCTCAGGTCTTTATCTC 
ChIP-Rhox6-R2 Rhox6 promoter 5'-GAGCGAGCCAGTTCAGTACAAG 
Zac1 qPCR F Zac1 ICR 5'-GCATCTGCGATTTGTCACTC 
Zac1 qPCR R Zac1 ICR 5'-CTTGCTCTCCAGTCCCGATA 
Snrpn qPCR F Snrpn ICR 5'-CAGGACATTCCGGTCAGAG 
Snrpn qPCR R Snrpn ICR 5'-TACTAGAATCCACAAGCCCAG 
Nespas qPCR F Nespas ICR 5'-CCGGACACTTTGAACTTTGG 
Nespas qPCR R Nespas ICR 5'-GCATCCTTGATTGGCGTGAC 
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A.3 Results 
A.3.1 Expression and purification of His6-BirA and His6-CxxC-
Avi proteins for establishment of Bio-CAP technique 
Both bacterial expression plasmids (pET21a and pNIC28) used to express 
His6-CxxC-Avi and His6-BirA proteins requires IPTG, a non-hydrolysable 
allolactose analogue, to induce expression of the cloned target genes under 
the control of T7 promoter. IPTG relieves binding of lac repressor to the lac 
operator, which is located between the T7 promoter and the target gene in the 
bacterial expression plasmid, to allow transcription of target genes by T7 RNA 
polymerase. 0.5 and 0.4 mM IPTG were used to induce expression of His6-
CxxC-Avi and His6-BirA respectively in E. coli strain BL21-CodonPlus-RIL. 
Induction was done at 25 °C for 6 hours and 4 hours for His6-CxxC-Avi and 
His6-BirA respectively. To check for recombinant protein expression, 15 µl of 
bacterial culture (uninduced and IPTG-induced) were mixed with 5 µl 4X SDS-
PAGE sample buffer, boiled at 100 °C for 15 minutes and subjected to SDS-
PAGE.  Coomassie blue stained SDS-PAGE gels showed good expression of 
His6-CxxC-Avi (19 kDa) and His6-BirA (36 kDa) proteins in E. coli strain BL21-
CodonPlus-RIL following induction with 0.5 and 0.4 mM IPTG respectively 







Figure A.2 Expression of His6-BirA and His6-CxxC-Avi proteins 
Coomassie blue staining of SDS-PAGE gels showed expression of (A) His6-
BirA and (B) His6-CxxC-Avi recombinant proteins in E. coli strain BL21-
CodonPlus-RIL following IPTG induction.  
 
(A) (B) 
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Figure A.3 His6-BirA and His6-CxxC-Avi protein extraction from E. coli 
strain BL21-Codonplus-RIL.  
(A) His6-BirA and (B) His6-CxxC-Avi proteins were extracted from E. coli and 
soluble fraction (supernatant) was separated from insoluble fraction (pellet) by 
centrifugation and both fractions were analysed by SDS-PAGE and 
Coomassie blue staining.  
 
 
Following protein induction, proteins were extracted from cells using methods 
mentioned in the materials and methods section. Coomassie blue stained 
SDS-PAGE gels of soluble and insoluble fractions showed that a large 
proportion of proteins, including target recombinant proteins, were found in the 
soluble fraction, which suggests a good level of protein extraction using the 
chosen methods (Figure A.3). To purify His6-BirA and His6-CxxC-Avi, soluble 
fractions were applied to IMAC columns. SDS-PAGE analysis of the collected 
IMAC fractions showed that both proteins bind to the nickel-charged resin and 
that 300 mM imidazole was sufficient to elute both proteins (Figure A.4). 
Elution fractions containing the highest amount of target proteins were pooled 
(Elution fractions 2-4 for His6-BirA and 2-3 for His6-CxxC-Avi) and dialysed to 
suitable buffers for storage (His6-BirA) and further downstream processing 
(His6-CxxC-Avi). The IMAC purification yields 6 mg of His6-BirA protein from 
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Figure A.4 Purification of His6-BirA and His6-CxxC-Avi protein by IMAC 
(A) His6-BirA and (B) His6-CxxC-Avi soluble fractions were loaded into Ni-
charged IMAC gravity column, washed with wash buffer containing 10 mM 
imidazole and eluted with elution buffer containing 300 mM imidazole. Input, 
Flow-through, Wash and Eluate fractions were collected and 15 µl of each 
fractions were analysed by SDS-PAGE and the SDS-PAGE gel was stained 
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As briefly mentioned in the introduction section, removal of the His6-tag can 
increase the efficiency of CxxC domain binding to non-methylated CpG. 
Between the His6-tag and the N-terminus of the CxxC domain there is a TEV 
protease-recognition site. Incubation of His6-CxxC with TEV protease can 
therefore free the CxxC domain from the His6-tag. To optimise this procedure, 
2 and 4 µg of His6-TEV protease (Simon Varzandeh, Richardson Laboratory, 
University of Edinburgh) were added to 150 µg His6-CxxC-Avi in separate 
reactions, with or without 0.5 mM DTT and incubated overnight at 4 °C. The 
reaction mix was applied to an IMAC column to bind the cleaved His6-tag. 
IMAC collected fractions were analysed by SDS-PAGE to observe the 
efficiency of His6-tag cleavage. The result showed that both 2 and 4 µg of TEV 
protease exhibit similar activity as shown from the intensity of the smaller 
CxxC-Avi band (18.9 kDa) in the flow-through fractions (Figure A.5). 
Furthermore, His6-CxxC-Avi (21.4 kDa) band was not detected in the flow-
through fractions of both 2 and 4 µg TEV protease reactions supplemented 
with 0.5 mM DTT, suggesting that the addition of DTT resulted in complete 
digestion of the His6-tag from His6-CxxC-Avi protein. Therefore, it can be 
concluded that 1 µg His6-TEV protease is sufficient to efficiently cleave His6-
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Figure A.5 Optimisation of His6-tag removal from His6-CxxC-Avi by TEV 
protease 
Coomassie blue stained SDS-PAGE gel of IMAC fractions of His6-CxxC-Avi 
protein cleaved by TEV protease with or without 0.5 mM DTT. His6-TEV 
protease size is 28 kDa.        
 
 
A.3.2 Biotinylation of CxxC-Avi protein by His6-BirA 
In order to be able to pool down CxxC-Avi protein and associated DNA with 
streptavidin beads, CxxC-Avi protein was biotinylated in-vitro at the C-terminus 
on the Avi-tag, using His6-BirA enzyme. To assess the extent of biotinylation 
of the CxxC-Avi protein by His6-BirA enzyme, three biotinylation reactions 
containing 25 µg CxxC-Avi protein each were incubated with 0, 0.5 and 1 µg 
His6-BirA enzyme, respectively. Subsequently, CxxC-Avi proteins were mixed 
with streptavidin beads and input, flow-through, wash and beads fractions 
were collected and analysed by SDS-PAGE. Analysis of Coomassie blue 
stained SDS-PAGE gel showed that CxxC-Avi treated with 1 µg His6-BirA 
enzyme displayed the highest fraction of protein binding to streptavidin beads, 
as indicated by the band intensity of the beads fraction (Figure A.6). In 
agreement with this, CxxC-Avi treated with 1 µg His6-BirA showed the lowest 
protein loss in the flow-through compared to 0 and 0.5 µg His6-BirA. Increasing 
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Hi6-BirA enzyme quantity to 1.5 µg for 25 µg CxxC-Avi protein did not increase 
the amount of biotinylated CxxC-Avi bound to the beads (data not shown). 
These results suggest that 1 µg His6-BirA for 25 µg CxxC-Avi is the most 









Figure A.6 Optimisation of CxxC-Avi protein biotinylation by His6-BirA 
CxxC-Avi protein treated with 0, 0.5 and 1 µg His6-BirA biotinylating enzyme 
was incubated with streptavidin beads. Input, biotinylated protein bound to the 
beads (beads) and protein not bound to the beads (flowthrough) were 
analysed by SDS-PAGE. CxxC-Avi treated with 1 µg His6-BirA showed the 
highest amount of CxxC-Avi protein binding to beads. 
 
 
A.3.3 Bio-CxxC protein preferentially binds to non-methylated 
DNA 
To assess the ability and specificity of Bio-CxxC protein (the biotinylated 
version of CxxC-Avi protein) binding to non-methylated CpG DNA, I carried out 
an electrophoretic mobility shift assay (EMSA) (Figure A.7). The results 
showed that Bio-CxxC has a much higher affinity for non-methylated CpG, 
showing an efficient band shift already at at 1:50 DNA:Protein molar ratio. Only 
at the highest DNA:protein ratio used Bio-CxxC protein showed some binding 
to methylated DNA. This suggests that Bio-CxxC preferentially binds to DNA 
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containing unmethylated CpGs and that non-specific binding occurs minimally 
and only at very high protein concentration. These results are in agreement 
with the data showing that KDM2B/FBXL10, from which the CxxC domain of 
Bio-CxxC protein was derived, binds specifically to non-methylated CpGs 









Figure A.7 Bio-CxxC protein showed preferential binding to non-
methylated DNA 
Two fluorescently labelled double-stranded oligonucleotides with identical 
DNA sequence containing 3 non-methylated and 3 methylated CpGs, 
respectively, at 1 µM concentration, were mixed with 0, 25, 50, 75 and 100 µM 
Bio-CxxC in EMSA buffer and loaded to a non-denaturing polyacrylamide in 
increasing DNA:Protein ratio for EMSA analysis.  
 
 
A.3.4 Optimisation of Bio-CAP PCR 
Bio-CAP can be carried out using avidin conjugated to agarose or magnetic 
beads. Magnetic beads were selected over agarose due to lower unspecific 
DNA binding and ease of handling (no centrifugation required). DNA polled 
down by Bio-CAP was purified over spin-columns and analysed by PCR using 
specific primers, designed to amplify candidate promoters of known CG 
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content and methylation status (Table A.1). Ideally, we would have liked to test 
Bio-CAP on known and well characterised CGIs. However, presumably due to 
the high GC content, these region could not be PCR-amplified. Addition of 
DMSO or GC-rich specific PCR reagents and the use of Phusion polymerase 
(NEB, Ipswich, MA, USA) did not solve the problem (data not shown). 
Therefore, the primers for CGI promoters (Cog8 and Smarca5) were excluded 
from the analysis. PCR-analysis of DNA purified by Bio-CAP showed 
enrichment of unmethylated promoters (Fabp7, Msn, Actb) (Figure A.8.). 
Fabp7 promoter was amplified in the low salt (CAP300) fraction, while Msn 
and Actb promoters were amplified in the high salt fractions (CAP 700 and 
CAP1000), suggesting that CpG density affects the strength of CxxC protein 
binding to unmethylated DNA. On the other hand, none of the primers 
detecting methylated promoters (Uts2, Usp44 and Rhox6) were able to amplify 
DNA, in either low or high salt Bio-CAP purified fractions. The results were 
consistent across three different concentrations of input DNA, suggesting that 
Bio-CAP can be carried out with amount of input DNA as low as 350 ng, without 
significantly losing specificity.  
 
Analysis of mouse imprinting control regions (ICRs) by Bio-CAP would be very 
interesting. Each ICR is present in each cell in two states, where one allele is 
methylated while the other is not, depending on the parent-of-origin. I decided 
to take advantage of this feature to investigate if Bio-CAP is sensitive enough 
to discriminate the two co-existing alleles. To this end, I designed PCR primers 
against three different ICRs, Zac1, Snrpn and Nespas, known to be methylated 
only on the maternal allele (Zhang et al., 2016). While Zac1, and Nespas, 
showed exclusively enrichment in CAP700 and CAP1000 fractions (Figure 
A.9.), Snrpn showed also a slight enrichment in CAP300 fraction. Previously, 
Bio-CAP qPCR analysis of imprinted Gnas promoter of murine V6.5 embryonic 
stem (ES) cells also showed enrichment in both low salt (300 & 500 nM) and 
high salt (700 and 1000 nM) fractions (Blackledge et al., 2012). Bisulphite 
sequencing analysis has confirmed in this case that the methylated allele of 
Gnas was specifically eluted in the CAP300 fraction, while the unmethylated 
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allele was eluted with the CAP500, CAP700 and CAP1000 fractions 
(Blackledge et al., 2012). Therefore, my analysis of ICRs suggests that Bio-
CAP was able to either exclusively isolate the unmethylated allele or, at least, 
to separate the two alleles in different fractions.  
 
Table A.1. Promoter regions with known CpG density and methylation 















Non CGI Promoter                                 
(Low CpG density) 
Fabp7 Uts2 
Weak CGI Promoter 
(Intermediate CpG density) 
Msn Usp44 
Strong CGI Promoter           
(High CpG density) 
Cog8 Smarca5 
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Figure A.8 Bio-CAP captures unmethylated promoters but not 
methylated promoters 
Bio-CAP was carried out using 0.35, 1.75 and 8.75 µg input sonicated gDNA.  
Bio-CAP isolated DNA was analysed by PCR amplification, carried out with 
primers designed to the indicated target promoters. The products were 
analysed by agarose DNA electrophoresis. Parallel analysis of known 
methylated and un-methylated promoter regions showed that Bio-CAP can 
specifically enriched un-methylated DNA. 
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Figure A.9. Bio-CAP can discriminate between the methylated and 
unmethylated alleles of ICRs.  
Bio-CAP was carried out using 0.35, 1.75 and 8.75 µg input sonicated gDNA. 
ICR PCR products of Bio-CAP fractions were analysed by agarose DNA 
electrophoresis to assess DNA enrichment of ICRs. 
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A.4 Discussion 
Previously, methylated CpG capture techniques, such as methylated DNA 
immunoprecipitation (MeDIP) and methylated DNA affinity purification (MAP), 
have been utilised in combination with either microarrays or high throughput 
sequencing techniques to generate genome-wide methylation profile as an 
alternative or supplementary to whole-genome bisulphite sequencing 
(Reviewed in (Laird, 2010)). However, approximately 98% of CpGs which are 
sparsely spaced in the genome, are predominantly methylated and around 2% 
are concentrated in CpG Islands which are mostly unmethylated (Bird, 2002). 
Furthermore, around 70% of promoter regions contain CpG islands (Saxonov, 
Berg and Brutlag, 2006). Therefore, due to the smaller proportion of analysed 
DNA, unmethylated DNA enrichment technique such as CxxC Affinity 
Purification (CAP) can offer the advantages of low sequencing depth 
requirement, increased sensitivity of CGI detection and increased cost-
effectiveness in comparison to methylated DNA enrichment techniques 
(Blackledge et al., 2012; Illingworth et al., 2008).  Bio-CAP is a modified CxxC 
Affinity Purification (CAP) technique, previously developed to purify CpG 
islands, which were predominantly unmethylated (Illingworth et al., 2008). The 
modification allowed the use of lower amount of input gDNA, lower amount of 
CxxC protein and made liquid chromatography, used in the original CAP 
method, dispensable (Blackledge et al., 2012; Illingworth et al., 2008). 
Motivated by these advantages, I planned to utilise this method for analysing 
DNA methylation changes on promoters of hTERT-immortalised cells, 
following prolonged culture with and without telomerase.  As previously 
mentioned, hTERT-immortalised cells exhibit increased DNA methylation at 
gene promoters (Gordon et al., 2014). Bio-CAP-sequencing, in combination 
with a system designed to switch telomerase activity on and off, would have 
allowed me to assess whether telomerase was required for the induction 
and/or maintenance of DNA methylation on promoters. 
 
In this chapter, I have optimised the production of His6-BirA and His6-CxxC-
Avi proteins, which were the two most important component to create Bio-
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CxxC protein used in the Bio-CAP technique. My results showed that the Bio-
CAP technique is capable of specific enrichment of promoter regions 
containing non-methylated CpGs with DNA input as low as 350 ng, particularly 
in the high salt fractions (CAP700 and CAP1000). Furthermore, it is also 
capable of capturing unmethylated alleles of ICRs. However, non-methylated, 
CGI-poor promoter such as Fabp7 promoter was enriched in the low salt 
fractions (CAP300), suggesting that CpG density affects the binding of Bio-
CxxC to unmethylated DNA. Therefore, further optimisations are required to 
identify the salt concentration threshold that specifically discriminates between 




Primary and Immortalised MEFs used for optimisation of Bio-CAP were 
acquired from Natalia Torrea. MRC-5 hTERT, DD-hTERT and DD-hTERT ΔPT 
cell lines were generated by Katrina Gordon. Plasmids for expression of His6-
BirA and His6-CxxC-Avi proteins were acquired from Rob Klose. Simon 
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